



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Cognitive-behavioural therapy for clozapine-resistant schizophrenia

Citation for published version:

Morrison, AP, Pyle, M, Gumley, A, Schwannauer, M, Turkington, D, MacLennan, G, Norrie, J, Hudson, J, Bowe, S, French, P, Hutton, P, Byrne, R, Syrett, S, Dudley, R, Dudley, R, Griffiths, H, Barnes, TRE, Davies, L, Shields, G, Buck, D, Tully, S & Kingdon, D 2019, 'Cognitive-behavioural therapy for clozapine-resistant schizophrenia: The FOCUS RCT', *Health Technology Assessment*, vol. 23, no. 7, pp. 1-143.
<https://doi.org/10.3310/hta23070>

Digital Object Identifier (DOI):

[10.3310/hta23070](https://doi.org/10.3310/hta23070)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Health Technology Assessment

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT

Anthony P Morrison, Melissa Pyle, Andrew Gumley, Matthias Schwannauer, Douglas Turkington, Graeme MacLennan, John Norrie, Jemma Hudson, Samantha Bowe, Paul French, Paul Hutton, Rory Byrne, Suzy Syrett, Robert Dudley, Hamish J McLeod, Helen Griffiths, Thomas RE Barnes, Linda Davies, Gemma Shields, Deborah Buck, Sarah Tully and David Kingdon



**National Institute for
Health Research**

Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT

Anthony P Morrison,^{1,2*†} Melissa Pyle,^{1,2†}
Andrew Gumley,³ Matthias Schwannauer,⁴
Douglas Turkington,⁵ Graeme MacLennan,⁶
John Norrie,⁷ Jemma Hudson,⁶ Samantha Bowe,¹
Paul French,^{1,8} Paul Hutton,⁹ Rory Byrne,^{1,2}
Suzy Syrett,³ Robert Dudley,¹⁰ Hamish J McLeod,³
Helen Griffiths,⁴ Thomas RE Barnes,¹¹ Linda Davies,¹²
Gemma Shields,¹² Deborah Buck,¹² Sarah Tully^{1,2}
and David Kingdon¹³

¹Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, Prestwich, UK

²Division of Psychology and Mental Health, University of Manchester, Manchester, UK

³Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

⁴Department of Clinical Psychology, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK

⁵Academic Psychiatry, Northumberland, Tyne and Wear NHS Foundation Trust, Centre for Ageing and Vitality, Newcastle General Hospital, Newcastle upon Tyne, UK

⁶Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, Aberdeen, UK

⁷Clinical Trials Unit, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK

⁸Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK

⁹School of Health and Social Care, Edinburgh Napier University, Edinburgh, UK

¹⁰School of Psychology, Newcastle University, Newcastle upon Tyne, UK

¹¹Centre for Mental Health, Imperial College London, London, UK

¹²Division of Population Health, University of Manchester, Manchester, UK

¹³Department of Psychiatry, University of Southampton, Academic Centre, Southampton, UK

*Corresponding author

†First author

Declared competing interests of authors: Anthony P Morrison reports personal fees from the provision of training workshops in cognitive–behavioural therapy (CBT) for psychosis and royalties from books on the topic, outside the submitted work. Andrew Gumley reports grants from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (grant number 13/15/04) outside the submitted work. Douglas Turkington reports personal fees from Insight–CBT partnership (Insight Healthcare, Newcastle upon Tyne), outside the submitted work. Gemma Shields reports grants from NIHR during the conduct of the study. Graeme MacLennan reports grants from the NIHR HTA programme during the conduct of the study. Hamish J MacLeod reports that he occasionally provides CBT for psychosis workshops and receives fees for this work. John Norrie reports personal fees from the NIHR Editors Board and grants from NIHR HTA General Board Deputy Chairperson, outside the submitted work, and has membership of the HTA Funding Boards Policy Group and Pre-Exposure Prophylaxis Impact Review Panel. Linda Davies reports grants from the NIHR HTA programme during the conduct of the study. Paul French has membership of the HTA prioritisation Panel. Paul Hutton reports that he sits on an Expert Steering Group for Professor Jill Stavert’s Centre for Mental Health and Incapacity Law Rights and Policy at Edinburgh Napier University, and that he is a member of a committee developing National Institute for Health and Care Excellence (NICE) guidelines on supporting decision-making for people who may lack mental capacity. Robert Dudley reports receiving a NIHR Comprehensive Local Research Network Greenshoots award to fund time to support his contribution to the FOCUS (Focusing on Clozapine Unresponsive Symptoms) trial, royalties from Guilford Press and personal fees from Trinity College Dublin, outside the submitted work. Samantha Bowe reports personal fees from Pennine Care NHS Foundation Trust and personal fees from Cheshire & Wirral Partnership NHS Foundation Trust, outside the submitted work. Thomas RE Barnes reports personal fees from Sunovion (Marlborough, MA, USA) and Otsuka (Tokyo, Japan)/Lundbeck (Copenhagen, Denmark), outside the submitted work.

Published February 2019

DOI: 10.3310/hta23070

This report should be referenced as follows:

Morrison AP, Pyle M, Gumley A, Schwannauer M, Turkington D, MacLennan G, *et al*. Cognitive–behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. *Health Technol Assess* 2019;**23**(7).

Health Technology Assessment is indexed and abstracted in *Index Medicus*/MEDLINE, *Excerpta Medica*/EMBASE, *Science Citation Index Expanded* (SciSearch®) and *Current Contents®*/Clinical Medicine.

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.513

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/hta>

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 10/101/02. The contractual start date was in December 2012. The final report began editorial review in August 2017 and was accepted for publication in February 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2019. This work was produced by Morrison *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk

Abstract

Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT

Anthony P Morrison,^{1,2*†} Melissa Pyle,^{1,2†} Andrew Gumley,³ Matthias Schwannauer,⁴ Douglas Turkington,⁵ Graeme MacLennan,⁶ John Norrie,⁷ Jemma Hudson,⁶ Samantha Bowe,¹ Paul French,^{1,8} Paul Hutton,⁹ Rory Byrne,^{1,2} Suzy Syrett,³ Robert Dudley,¹⁰ Hamish J McLeod,³ Helen Griffiths,⁴ Thomas RE Barnes,¹¹ Linda Davies,¹² Gemma Shields,¹² Deborah Buck,¹² Sarah Tully^{1,2} and David Kingdon¹³

¹Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, Prestwich, UK

²Division of Psychology and Mental Health, University of Manchester, Manchester, UK

³Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

⁴Department of Clinical Psychology, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK

⁵Academic Psychiatry, Northumberland, Tyne and Wear NHS Foundation Trust, Centre for Ageing and Vitality, Newcastle General Hospital, Newcastle upon Tyne, UK

⁶Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, Aberdeen, UK

⁷Clinical Trials Unit, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK

⁸Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK

⁹School of Health and Social Care, Edinburgh Napier University, Edinburgh, UK

¹⁰School of Psychology, Newcastle University, Newcastle upon Tyne, UK

¹¹Centre for Mental Health, Imperial College London, London, UK

¹²Division of Population Health, University of Manchester, Manchester, UK

¹³Department of Psychiatry, University of Southampton, Academic Centre, Southampton, UK

*Corresponding author tony.morrison@manchester.ac.uk

†First author

Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people with schizophrenia who have a poor response to standard antipsychotic medication. However, a significant number of patients who trial clozapine have an inadequate response and experience persistent symptoms, called clozapine-resistant schizophrenia (CRS). There is little evidence regarding the clinical effectiveness of pharmacological or psychological interventions for this population.

Objectives: To evaluate the clinical effectiveness and cost-effectiveness of cognitive-behavioural therapy (CBT) for people with CRS and to identify factors predicting outcome.

Design: The Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial was a parallel-group, randomised, outcome-blinded evaluation trial. Randomisation was undertaken using permuted blocks of random size via a web-based platform. Data were analysed on an intention-to-treat (ITT) basis, using random-effects regression adjusted for site, age, sex and baseline symptoms. Cost-effectiveness analyses

were carried out to determine whether or not CBT was associated with a greater number of quality-adjusted life-years (QALYs) and higher costs than treatment as usual (TAU).

Setting: Secondary care mental health services in five cities in the UK.

Participants: People with CRS aged ≥ 16 years, with an *International Classification of Diseases*, Tenth Revision (ICD-10) schizophrenia spectrum diagnoses and who are experiencing psychotic symptoms.

Interventions: Individual CBT included up to 30 hours of therapy delivered over 9 months. The comparator was TAU, which included care co-ordination from secondary care mental health services.

Main outcome measures: The primary outcome was the Positive and Negative Syndrome Scale (PANSS) total score at 21 months and the primary secondary outcome was PANSS total score at the end of treatment (9 months post randomisation). The health benefit measure for the economic evaluation was the QALY, estimated from the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), health status measure. Service use was measured to estimate costs.

Results: Participants were allocated to CBT ($n = 242$) or TAU ($n = 245$). There was no significant difference between groups on the prespecified primary outcome [PANSS total score at 21 months was 0.89 points lower in the CBT arm than in the TAU arm, 95% confidence interval (CI) -3.32 to 1.55 points; $p = 0.475$], although PANSS total score at the end of treatment (9 months) was significantly lower in the CBT arm (-2.40 points, 95% CI -4.79 to -0.02 points; $p = 0.049$). CBT was associated with a net cost of £5378 (95% CI $-\text{£}13,010$ to $\text{£}23,766$) and a net QALY gain of 0.052 (95% CI 0.003 to 0.103 QALYs) compared with TAU. The cost-effectiveness acceptability analysis indicated a low likelihood that CBT was cost-effective, in the primary and sensitivity analyses (probability $< 50\%$). In the CBT arm, 107 participants reported at least one adverse event (AE), whereas 104 participants in the TAU arm reported at least one AE (odds ratio 1.09, 95% CI 0.81 to 1.46; $p = 0.58$).

Conclusions: Cognitive-behavioural therapy for CRS was not superior to TAU on the primary outcome of total PANSS symptoms at 21 months, but was superior on total PANSS symptoms at 9 months (end of treatment). CBT was not found to be cost-effective in comparison with TAU. There was no suggestion that the addition of CBT to TAU caused adverse effects. Future work could investigate whether or not specific therapeutic techniques of CBT have value for some CRS individuals, how to identify those who may benefit and how to ensure that effects on symptoms can be sustained.

Trial registration: Current Controlled Trials ISRCTN99672552.

Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 23, No. 7. See the NIHR Journals Library website for further project information.

Contents

List of tables	xi
List of figures	xv
List of abbreviations	xvii
Plain English summary	xix
Scientific summary	xxi
Chapter 1 Introduction	1
Psychosis and schizophrenia	1
Prevalence rates and the personal, social and economic impact of schizophrenia	2
Treatment options for people with a schizophrenia diagnosis	2
<i>Antipsychotic medication</i>	3
<i>Treatment-resistant schizophrenia</i>	3
<i>Clozapine-resistant schizophrenia</i>	5
<i>Psychological interventions</i>	6
Summary	11
Rationale for the research/trial aims and objectives	12
Chapter 2 Methods	13
Trial design	13
Role of funding source	13
Approval	13
Trial sites	13
Participants	13
<i>Inclusion and exclusion criteria</i>	13
Data collection	14
Outcome measures	15
<i>Primary outcome</i>	15
<i>Secondary outcomes</i>	15
<i>Measurement of adverse events and effects</i>	16
<i>Other measures including psychological processes</i>	17
Economic assessment	19
<i>Health economics</i>	19
Trial interventions	19
<i>Fidelity to the treatment manual</i>	19
<i>Research assistant training and supervision</i>	20
<i>Randomisation and blinding</i>	21
<i>Patient and public involvement</i>	21
<i>Change to the protocol</i>	21
<i>Statistical methods and trial analysis</i>	21
<i>Economic evaluation methods</i>	24

Chapter 3 Baseline results	29
Reliability of outcome measures	29
Participant baseline characteristics	30
<i>Trial recruitment</i>	30
<i>Participant flow</i>	31
<i>Baseline characteristics</i>	32
Chapter 4 Outcome and results	35
Primary outcome	35
Secondary outcomes	38
Compliance with treatment	41
Subgroup analyses	44
Adverse events and potential unwanted side effects of trial participation	49
Internalised stigma of mental illness	51
Chapter 5 Economic evaluation results	57
Chapter overview	57
Missing cost and utility data	57
Baseline clinical and demographic characteristics	58
Descriptive analysis of health status, utility, quality-adjusted life-years and cost for participants with complete cost and quality-adjusted life-year data	59
<i>Health status, utility and quality-adjusted life-years</i>	59
<i>Costs</i>	61
Descriptive analysis of utility, quality-adjusted life-years and cost for all participants, using multiple imputation data	63
<i>Costs</i>	64
Primary analysis of incremental costs, quality-adjusted life-years and incremental cost-effectiveness ratio	65
Sensitivity analyses of incremental costs, quality-adjusted life-years and incremental cost-effectiveness ratio	67
Chapter 6 Discussion	69
Summary	69
Findings in context	69
Strengths and limitations	73
Implications for public health/treatment services	76
Implications for future research	77
Conclusions	78
Acknowledgements	79
References	83
Appendix 1 Recruitment information	95
Appendix 2 Additional analyses	97
Appendix 3 Economic analyses	133

List of tables

TABLE 1 Details of the protocol amendments approved by NRES Committee North West – Lancaster	22
TABLE 2 Variables assessed in the sensitivity analysis	27
TABLE 3 Reliability alpha	29
TABLE 4 Recruitment by centre	30
TABLE 5 Baseline characteristics	32
TABLE 6 Baseline medication	34
TABLE 7 The PANSS outcome	35
TABLE 8 The PANSS total scores excluding participants for whom a blind break had occurred	38
TABLE 9 Improvement in PANSS total scores	38
TABLE 10 The PANSS total effect of time	38
TABLE 11 The PSYRATS outcomes	39
TABLE 12 Other secondary outcomes	40
TABLE 13 Employment status	41
TABLE 14 Number of sessions attended for those randomised to CBT	41
TABLE 15 Complier-average causal effect analysis of the actual number of sessions at 9 months	42
TABLE 16 Complier-average causal effect analysis of the actual number of sessions at 21 months	42
TABLE 17 Therapy data	43
TABLE 18 Fidelity ratings	43
TABLE 19 Adverse events and effects	50
TABLE 20 Levels of ISMI reported in the group at baseline	51
TABLE 21 The ISMI outcomes	53
TABLE 22 Available cost and utility data at different assessments	57

TABLE 23 Baseline demographic and clinical characteristics associated with costs or utility	58
TABLE 24 Regression analyses of baseline utility and demographic and clinical characteristics	59
TABLE 25 People with no problem on EQ-5D domains for participants with complete cost and QALY data	59
TABLE 26 The EQ-5D-5L utility scores and EQ VAS scores at each assessment for participants with complete cost and QALY data	60
TABLE 27 Days of follow-up and QALYs for participants with complete cost and QALY data: new utility value set	60
TABLE 28 Mean number of health and social care visits/admissions for participants with complete cost and QALY data	61
TABLE 29 Costs of health and social care, excluding costs of CBT intervention, for participants with complete cost and QALY data	62
TABLE 30 Mean use, length and costs of CBT intervention	63
TABLE 31 Total costs of health and social care, including costs of CBT intervention for participants with complete cost and QALY data	63
TABLE 32 Utility and QALYs for all participants, using MI data	64
TABLE 33 Costs of health and social care from the MI data	64
TABLE 34 Net costs and QALYs of CBT vs. TAU: primary and sensitivity analyses	65
TABLE 35 Cost-effectiveness of CBT when compared with usual care: primary and sensitivity analyses	67
TABLE 36 Utility values, population norms (EQ-5D-3L and Time Trade Off values) and FOCUS trial participants (EQ-5D-5L and crosswalk values)	72
TABLE 37 Referral pathway of participants randomised	95
TABLE 38 Ineligible reasons	96
TABLE 39 The PANSS outcome using MI	97
TABLE 40 Complier-average causal effect analysis estimates, using a minimum of six sessions of CBT attendance at 9 months	98
TABLE 41 Complier-average causal effect analysis estimates, using a minimum of six sessions of CBT attendance at 21 months	99
TABLE 42 Questionnaire about the Process of Recovery: age, age at onset and sex	100
TABLE 43 Questionnaire about the Process of Recovery: DI, DUP and clozapine	101

TABLE 44 Positive and Negative Syndrome Scale: difficulty with abstract thinking, conceptual disorganisation and LNS	103
TABLE 45 Questionnaire about the Process of Recovery: childhood trauma	104
TABLE 46 Questionnaire about the Process of Recovery: AUDIT, DAST and PAM-SR attachment avoidance	106
TABLE 47 Questionnaire about the Process of Recovery: BCSS	107
TABLE 48 Questionnaire about the Process of Recovery: psychosis	109
TABLE 49 Personal and Social Performance: age, age at onset and sex	110
TABLE 50 Personal and Social Performance: DI, DUP and clozapine	111
TABLE 51 Personal and Social Performance: difficulty with abstract thinking, conceptual disorganisation and LN	113
TABLE 52 Personal and Social Performance: childhood trauma	114
TABLE 53 Personal and Social Performance: AUDIT, DAST and PAM-SR attachment avoidance	116
TABLE 54 Personal and Social Performance: BCSS	117
TABLE 55 Personal and Social Performance: psychosis	119
TABLE 56 Psychotic Symptom Rating Scale – auditory hallucinations: age, age at onset and sex	120
TABLE 57 Psychotic Symptom Rating Scale – auditory hallucinations: DI, DUP and clozapine	121
TABLE 58 Psychotic Symptom Rating Scale – auditory hallucinations: difficulty with abstract thinking, conceptual disorganisation and LN	123
TABLE 59 Psychotic Symptom Rating Scale – auditory hallucinations: childhood trauma	124
TABLE 60 Psychotic Symptom Rating Scale – auditory hallucinations: AUDIT, DAST and PAM-SR attachment avoidance	126
TABLE 61 Psychotic Symptom Rating Scale – auditory hallucinations: BCSS	127
TABLE 62 Psychotic Symptom Rating Scale – auditory hallucinations: psychosis	129
TABLE 63 Sensitivity analysis of LN subgroup	130
TABLE 64 Participants responding ‘quite a lot’ or ‘very much’ to each of the items by whole trial and by treatment group	132

TABLE 65 Baseline EQ-5D domain responses for participants with complete cost and QALY data	133
TABLE 66 The EQ-5D domain responses at 9 months for participants with complete cost and QALY data	134
TABLE 67 The EQ-5D domain responses at 21 months for participants with complete cost and QALY data	135
TABLE 68 Unit costs of health and social care services	136
TABLE 69 Mean costs of health and social care for participants with complete cost and QALY data, by cost category and assessment	139
TABLE 70 Total cost of health and social care at each follow-up assessment for participants with complete cost and QALY data	140
TABLE 71 Mean cost of health and social care, by cost category and assessment point: MI data	141
TABLE 72 Net costs of CBT intervention, generalised linear regression, gamma (log) distribution: MI data, baseline to 21 months	142
TABLE 73 Net QALYs of CBT intervention, linear regression: MI data, baseline to 21 months	142
TABLE 74 Net costs and QALYs of CBT vs. TAU for participants with complete cost and QALY data	143

List of figures

FIGURE 1 Recruitment over time	30
FIGURE 2 The CONSORT flow diagram	31
FIGURE 3 Profile of PANSS total scores	36
FIGURE 4 Site differences for PANSS total scores	36
FIGURE 5 Comparison of CBT and TAU by subgroups	44
FIGURE 6 Comparison of CBT and TAU by psychosis subgroup	48
FIGURE 7 Profile of ISMI subscales	51
FIGURE 8 The PANSS total subgroups	54
FIGURE 9 Cost-effectiveness plane of 10,000 pairs of net costs and QALYs: bootstrapped MI data	66
FIGURE 10 Cost-effectiveness acceptability curve: primary analysis	67
FIGURE 11 Cost-effectiveness acceptability curve: sensitivity analysis 1	68
FIGURE 12 Cost-effectiveness acceptability curve: sensitivity analysis 2	68

List of abbreviations

AE	adverse event	GP	general practitioner
AnTI	Anxious Thoughts Inventory	HRA	Health Research Authority
AUDIT	Alcohol Use Disorders Identification Test	ICC	interclass correlation coefficient
BCSS	Brief Core Schema Scale	ICD-10	<i>International Classification of Diseases, Tenth Revision</i>
BPRS	Brief Psychiatric Rating Scale	ICER	incremental cost-effectiveness ratio
CACE	complier-average causal effect	IQR	interquartile range
CBT	cognitive-behavioural therapy	ISMI	Internalised Stigma of Mental Illness
CDSS	Calgary Depression Scale for Schizophrenia	ISRCTN	International Standard Randomised Controlled Trial Number
CGI	Clinical Global Impression	ITT	intention to treat
CI	confidence interval	IVI	Interpretation of Voices Inventory
CMHT	community mental health team	LNS	letter-number span
CONSORT	Consolidated Standards of Reporting Trials	MI	multiple imputation
CRS	clozapine-resistant schizophrenia	NICE	National Institute for Health and Care Excellence
CTQ	Childhood Trauma Questionnaire	NIHR	National Institute for Health Research
CTS-R	Cognitive Therapy Scale – Revised	NNT	number needed to treat
CTU	Clinical Trials Unit	NRES	National Research Ethics Service
CVD	cardiovascular disease	PAM-SR	Psychosis Attachment Measure self-report
DAST	Drug Abuse Screening Test	PANSS	Positive and Negative Syndrome Scale
DI	duration of illness	PICO	population, intervention, comparator and outcome
DMEC	Data Monitoring and Ethics Committee	PIS	participant information sheet
DUP	duration of untreated psychosis	PPI	patient and public involvement
EIP	Early Intervention in Psychosis	PSP	Personal and Social Performance
EQ-5D	EuroQol-5 Dimensions	PSSRU	Personal Social Services Research Unit
EQ-5D-5L	EuroQol-5 Dimensions, five-level version	PSYRATS	Psychotic Symptom Rating Scale
EQ VAS	EuroQol Visual Analogue Scale	QALY	quality-adjusted life-year
ES	effect size	QPR	Questionnaire about the Process of Recovery
FGA	first-generation antipsychotic		
FI	family intervention		
FOCUS	Focusing on Clozapine Unresponsive Symptoms		

LIST OF ABBREVIATIONS

RA	research assistant	SGA	second-generation antipsychotic
RCT	randomised controlled trial	SP	supportive psychotherapy
REC	Research Ethics Committee	SURG	Service User Reference Group
SAE	serious adverse event	TAU	treatment as usual
SAP	statistical analysis plan	TRRIP	Treatment Response and Resistance in Psychosis
SCIPS	semistructured clinical interview for psychosis subgroups	TRS	treatment-resistant schizophrenia
SD	standard deviation	TSC	Trial Steering Committee
SE	standard error	WTPT	willingness-to-pay threshold

Plain English summary

People who experience schizophrenia are usually prescribed antipsychotic medication. Some who take an antipsychotic continue to experience distressing and persistent symptoms; for these people the antipsychotic clozapine has been shown to be effective in reducing symptoms. About 30–40% of people who try clozapine experience persistent symptoms and there is little research to indicate what treatments are effective if clozapine has a poor impact. The Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial was designed to test whether or not a talking treatment called cognitive–behavioural therapy (CBT) is clinically effective in reducing the symptoms of schizophrenia, and whether or not CBT is cost-effective. A total of 487 participants who met the criteria for a schizophrenia diagnosis and who had tried clozapine but experienced a poor response were recruited. Participants were randomly allocated to receive CBT plus treatment as usual (TAU) or TAU alone. CBT lasted for 9 months, and participants could have up to 30 hours of CBT. Participants were followed up at 9 and 21 months and it was found that those who had CBT experienced some small improvements in symptoms of schizophrenia at 9 months, but this did not last to 21 months. The data suggest that CBT was not cost-effective compared with TAU. Some benefits of CBT were evident at 21 months, such as feeling less emotional distress, a better understanding of ‘delusional’ beliefs and better self-rated recovery. The small benefit of CBT at 9 months is the same level of benefit people get from taking a second antipsychotic medication, but without the medication side effects. Although CBT cannot be recommended routinely for all people who have a poor response to clozapine, it may be helpful for some.

The results cannot answer questions about how helpful CBT is for people who have received a diagnosis of schizophrenia who have not tried clozapine. Better ways to help this population needed to be developed.

Scientific summary

Background

For around one-third of the people who meet the criteria for a schizophrenia diagnosis, treatment with antipsychotic medication will result in little change in symptoms and, commonly, the symptoms become progressively more unresponsive to medication, with subsequent relapses. For people who experience a poor response to treatment with standard antipsychotic medication, the antipsychotic clozapine is currently considered the mainstay of treatment for those who meet the criteria for treatment-resistant schizophrenia (TRS). However, a significant proportion of people will experience persistent symptoms after an adequate trial of clozapine. For this group of people, who meet the criteria for clozapine-resistant schizophrenia (CRS), the evidence base for treatments is limited; augmentation strategies with a second antipsychotic are a common clinical practice, but meta-analyses demonstrate small effects for this treatment strategy. There is a clear indication from cognitive-behavioural therapy (CBT) trials that people who meet the criteria for both TRS and CRS can be engaged in CBT. There is emerging evidence to suggest that, for this population, CBT can have small to moderate effects on overall symptoms and may be particularly beneficial for auditory hallucinations. However, the field has lacked a large high-quality trial of CBT for people with CRS.

Objectives

The objectives of the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial were to provide evidence of the clinical effectiveness and cost-effectiveness of CBT for people who meet the criteria for CRS and to utilise baseline data from this randomised controlled trial (RCT) to develop a risk model that identifies factors that predict a good outcome from CBT. Our objectives were to test the following hypotheses:

- In people with a diagnosis of a schizophrenia spectrum disorder, who have an inadequate response to or are unable to tolerate clozapine, CBT plus treatment as usual (TAU) will lead to an improvement in psychotic symptoms, measured using a psychiatric interview [Positive and Negative Syndrome Scale (PANSS)] over a 21-month follow-up period, compared with TAU alone.
- Cognitive-behavioural therapy plus TAU will lead to an improved quality of life and user-defined recovery compared with TAU alone.
- Cognitive-behavioural therapy plus TAU will lead to a reduction in affective symptoms and negative symptoms compared with TAU alone.
- Cognitive-behavioural therapy plus TAU will be cost-effective compared with TAU alone.

Methods

The FOCUS trial was a parallel-group, randomised, outcome-blinded evaluation (PROBE) trial, conducted to evaluate the addition of a standardised CBT intervention to TAU for individuals who are unable to tolerate or have had an inadequate response to clozapine. The comparison group received TAU only. CBT was delivered over a 9-month treatment window and participants received up to 30 hours of CBT.

The FOCUS trial was conducted over a 4-year period across five sites in the UK. Recruitment for the trial commenced on 1 January 2013 and ended on 1 June 2015. The follow-up phase of the trial ended in February 2017. Participants were recruited from a number of NHS mental health services, including community mental health teams (CMHTs), early intervention teams, recovery teams and inpatient services. People were eligible to take part in the FOCUS trial if they were considered to have had an inadequate

response to a trial of clozapine treatment. This was defined as treatment with clozapine at a stable dose of ≥ 400 mg (unless limited by tolerability) for ≥ 12 weeks, or, if currently augmented with a second antipsychotic, for ≥ 12 weeks, without remission of psychotic symptoms. Alternatively, potential participants could have discontinued clozapine in the preceding 2 years because of side effects, lack of efficacy or a problem identified during routine blood monitoring appointments. Potential participants were also required to meet the following inclusion criteria: have an *International Classification of Diseases*, Tenth Revision (ICD-10), diagnosis on the schizophrenia spectrum or meet the criteria for an Early Intervention in Psychosis (EIP) service; have a minimum total PANSS score of 58 points at baseline assessment; score ≥ 4 points on items for delusions or hallucinations or ≥ 5 points for items on suspiciousness or grandiosity on the PANSS; be aged ≥ 16 years; have an identified care co-ordinator or consultant psychiatrist; and be competent and willing to provide written informed consent to take part. Participants were excluded based on the following criteria: a primary diagnosis of substance or alcohol dependence when this could be the cause of the psychotic experiences; diagnosis of developmental disability; organic impairment; non-English speaking (in cases in which this would prevent engagement in assessment and CBT); and currently receiving or had received structured CBT for psychosis from a qualified psychological therapist within the previous 12 months.

The primary outcome was the total PANSS score at 21 months (i.e. at the 12-month follow-up). Secondary outcomes were the total PANSS score at 9 months (end of treatment), PANSS subscales, self-rated recovery, social and occupational functioning, Clinical Global Impression (CGI), depression, anxiety, adverse effects and substance use. Other measures, including measures of psychological processes, included appraisals of voices and paranoia, beliefs about self and others, working memory, attachment, childhood trauma and stigma. Health benefit data were collected using the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), and data on the resources used for each participant were collected using the Economic Patient Questionnaire (EPQ). All measures were collected at baseline, 9 months and 21 months, except for the EPQ score, which was also collected at 3, 6, 13 and 17 months.

The primary outcome, total PANSS score at 21 months, was analysed using an intention-to-treat (ITT) linear model with adjustment for prespecified baseline covariates of sex, age and baseline PANSS score. The treatment effects over time were explored using repeated-measures mixed-effects models. The secondary outcomes were analysed in a similar way using an ITT linear model adjusted for prespecified baseline covariates.

Results

A total of 487 participants were recruited to the trial; of these, 242 were allocated to CBT and 245 to TAU. The median number of CBT sessions attended was 23, and 88% of participants attended at least six sessions of CBT, which was the minimum number of sessions needed to be classified as having received CBT.

At 9 months, the total PANSS score was 2.4 points lower in the CBT group (95% CI -4.79 to -0.02 points; $p = 0.049$) than in the TAU group. At 21 months, the total PANSS score was 0.89 points lower in the CBT arm, but this difference was not statistically significant (95% CI -3.32 to 1.55 points; $p = 0.475$).

Analysis of secondary outcomes at 9 months showed that the following outcomes were significantly lower in the CBT arm than in the TAU arm: PANSS positive 1.56 points lower (95% CI -4.79 to -0.02 points; $p = 0.049$), PANSS emotional distress 1.08 points lower (95% CI -2.02 to -0.13 points; $p = 0.025$) and Psychotic Symptom Rating Scale (PSYRATS) auditory hallucinations 2.56 points lower (95% CI -4.87 to -0.26 points; $p = 0.029$). At 21 months, PSYRATS delusions emotional distress was 0.53 points lower in the CBT arm (95% CI -1.05 to -0.00 points; $p = 0.049$), CGI was 0.33 points lower in the CBT arm (95% CI -0.54 to -0.11 points; $p = 0.013$) and self-rated recovery was 2.03 points higher in the CBT arm (95% CI 0.04 to 4.01 points; $p = 0.045$). Risk modelling did not reveal any subgroups of people who had a good response to CBT. There was no evidence that the treatment effect was moderated by any of the prespecified

subgroups. The number of reportable serious adverse events was two in the CBT arm and one in the TAU arm. There were 107 people with one or more adverse events in the CBT arm and 104 in the TAU arm ($p = 0.58$). However, there were no significant differences between the CBT and TAU arms on other prespecified outcomes for potential unwanted side effects of trial participation including suicidal crisis, severe symptomatic exacerbation or PANSS deterioration. CBT was associated with a net cost of £5378 (95% CI –£13,010 to £23,766) and net quality-adjusted life-year (QALY) gain of 0.052 (95% CI 0.003 to 0.103 QALYs) compared with TAU. The probability that CBT was cost-effective was 0.13.

Conclusions

The FOCUS trial is the first study to provide high-quality evidence with a low risk of bias regarding the clinical effectiveness and cost-effectiveness of CBT for people who meet the criteria for CRS. CBT for CRS was not superior to TAU on the primary outcome of total PANSS score at 21 months, but was superior on total PANSS score at 9 months (end of treatment). CBT was not found to be cost-effective compared with TAU, despite producing a net gain in overall health measured by QALYs. However, self-rated recovery did differ between the groups at 21 months (i.e. at the 12-month follow-up).

Trial registration

This trial is registered as ISRCTN99672552.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Chapter 1 Introduction

Psychosis and schizophrenia

The term psychosis is used to refer to a mental health problem that can involve changes to a person's perceptions and/or to their thoughts. A person who has experience of psychosis may report perceptual changes such as hearing a voice that another person cannot hear, or seeing something that another person cannot see. Perceptual changes may also occur to a person's taste, smell and/or bodily sensations. Such perceptual changes are typically referred to as hallucinations. A person experiencing psychosis may also report beliefs that others around them consider unusual, that are out of keeping with their social or cultural background and that are lacking rational grounds (often referred to as delusions). Common delusional beliefs include feelings of being persecuted, ideas of reference and feelings of importance.¹ Persecutory beliefs are thought to be the most commonly occurring of the range of delusional beliefs.² Experiences of hallucinations and delusions can be distressing and confusing and can have a negative impact on functioning. In addition, a person with experience of psychosis may report changes in their ability to concentrate or may communicate in a manner that is hard for other people to understand, which is commonly referred to as thought disorder. In both clinical practice and research, delusions, hallucinations and thought disorder are typically referred to as positive symptoms of psychosis. In addition, people who experience psychosis may report flat affect (blunted affect), a decrease in verbal output and verbal expressiveness, loss of motivation (including social withdrawal) and loss of enjoyment.³ These experiences are often referred to as negative symptoms. This term was originally proposed because these changes refer to the loss or absence of usually present functions or characteristics.^{4–6} Estimates suggest that 15–20% of people who receive a schizophrenia diagnosis will experience persistent negative symptoms.^{7,8}

Psychosis is considered to exist on a continuum,⁹ from the occasional occurrence of psychotic phenomena in the general population^{9–12} to persistent and frequent psychotic symptoms resulting in distress and, in many cases, the need for care from a mental health service. Someone who experiences psychosis and presents to mental health services for care may receive a schizophrenia spectrum diagnosis. Experiences of psychosis are often categorised using a diagnostic classification system, namely the *International Classification of Diseases*, Tenth Revision (ICD-10),¹³ or the *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition (DSM-V).¹⁴ Schizophrenia spectrum diagnoses include schizophrenia, schizoaffective disorder, delusional disorder and schizophreniform disorder. However, there has been considerable debate over the use of such diagnostic terms and classification systems.¹⁵ One argument is that these classification systems suggest that psychosis difficulties are dichotomous rather than continuum based.⁹ In addition, concerns have been raised regarding the reliability of the diagnostic classification systems used.¹⁶ The diagnostic label of schizophrenia has become stigmatising, with intrinsic negative associations about prognosis¹⁷ leading some countries to drop the term schizophrenia.¹⁸ The use of diagnostic terminology has, therefore, been contentious and Murray,¹⁹ in 2017, highlighted the burgeoning evidence that schizophrenia is not a dichotomous condition, but rather the severe end of a continuum. Murray¹⁹ expects to see the end of the concept of schizophrenia in the future. However, diagnosis and diagnostic terminology is commonly utilised throughout both clinical practice and research. For the purpose of this report, we wish to acknowledge this debate and, throughout, we will adopt respectful terminology. When reviewing the literature relevant to the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial, we use the terms psychosis and schizophrenia, depending on the sample of participants recruited to the studies being referred to. In relation to the sample of participants included in the FOCUS trial, we refer to the population as people who meet the criteria for a schizophrenia spectrum diagnosis or people who meet the criteria for clozapine-resistant schizophrenia (CRS).

Prevalence rates and the personal, social and economic impact of schizophrenia

A first episode of psychosis typically occurs in young adults; a review of the literature on the age at onset of mental health disorders by Kessler *et al.*²⁰ found that, for those with a schizophrenia diagnosis, the age at onset is usually between 15 and 35 years of age. Reports of the lifetime prevalence in the literature vary from 0.12 to 1.6 per 100 persons.²¹ In the UK, a systematic review²² commissioned by the Department of Health and Social Care reported that the incidence rate for all clinically relevant psychosis diagnoses is 31.72 per 100,000 persons per year, and for schizophrenia is 15 per 100,000 persons per year; the incidence of the latter being the same as the international incidence rate for schizophrenia reported by McGrath *et al.*²³

Although the prevalence of schizophrenia is relatively low, the personal, social and economic costs are considerable and the management of schizophrenia is among one of the largest health challenges globally as well as for the UK NHS. For example, Kirkbride *et al.*²² report that, in 2009, the estimated economic costs for services and society attributable to broadly defined schizophrenia amounted to £8.8B. The majority of the costs were attributable to lost employment (47%) and service costs (40%). Using disability-adjusted life-years lost as a measure of the overall number of years lost as a result of ill health, disability or early death, schizophrenia was ranked eighth among mental health diagnoses and brain disorders in Europe in 2010.²⁴

Considerable health inequalities are reported for people who have a schizophrenia diagnosis, with increased risk of serious diseases, such as diabetes mellitus, cardiovascular disease (CVD), a human immunodeficiency virus (HIV) infection and respiratory problems.²⁵ The prevalence of CVD among those with a schizophrenia diagnosis is estimated to be 75%, compared with an estimated 50% in the general population.²⁶ Of great concern is the mortality risk associated with schizophrenia. A recent systematic review and meta-analysis²⁷ of the literature on potential life lost and life expectancy in schizophrenia found that, on average, people with a diagnosis of schizophrenia die 14.5 years earlier than those in the general population. The same authors²⁷ report that the average life expectancy for people with a schizophrenia diagnosis is 64.7 years (for men and women combined); among men only, the average life expectancy is 8 years shorter than in the general population. The estimated risk of suicide in the general population is 1%, in comparison with 10% in those with a schizophrenia diagnosis.²⁶ In addition to the health inequalities outlined above, people with a schizophrenia diagnosis face widespread public stigma and discrimination, representing further inequalities and a major challenge to recovery. The incidence of anticipated, experienced and internalised stigma is high among people with psychosis.^{28,29} A large-scale survey of people with schizophrenia diagnoses across 27 different countries found that nearly half of the respondents felt at a disadvantage as a result of having a diagnosis of schizophrenia, because of stigma.²⁹ Nearly half of the sample reported interpersonal/social difficulties with making or keeping friends and around one-quarter identified feeling at a disadvantage in terms of finding and keeping work and in relation to their personal safety.²⁹

Given the significant personal, societal and economic costs associated with schizophrenia, the treatment and care provided for people who meet the criteria for schizophrenia spectrum diagnoses should be a priority for policy-makers, commissioners and service providers.

Treatment options for people with a schizophrenia diagnosis

In this section of the report, we will consider the evidence base for treatments for people with a schizophrenia diagnosis considering both pharmacological and psychological interventions. We will begin the section with a consideration of the efficacy of antipsychotic medication, with a particular emphasis on treatment options for people with a schizophrenia diagnosis who have a poor response to antipsychotic medication. We will outline the psychological interventions recommended by the National Institute for Health and Care Excellence (NICE), with a specific emphasis on cognitive-behavioural therapy (CBT),

given that this is the intervention evaluated by the FOCUS trial. We will consider the efficacy of CBT in conjunction with antipsychotic medication with a particular emphasis on efficacy for CRS.

Antipsychotic medication

The NICE guideline³⁰ for psychosis and schizophrenia in adults recommends, for people with a first episode of psychosis, an acute exacerbation or recurrence of psychosis or schizophrenia, that oral antipsychotic medication be offered. The NICE guideline³⁰ does not make a specific recommendation for the type of antipsychotic offered, that is first-generation antipsychotics (FGAs) or atypical/second-generation antipsychotics (SGAs). The range of antipsychotic medications in both of these classes differ in their psychopharmacological properties, efficacy and adverse effect profiles.³¹ A recent systematic review and meta-analysis³² of placebo-controlled antipsychotic medication trials identified a total of 167 double-blind randomised controlled trials (RCTs) with a total sample of 28,102 people with a schizophrenia diagnosis. Meta-analysis of the data found a small to medium effect size (ES) for overall efficacy of 0.47, but this reduced to a small ES of 0.38 when looking at rigorous trials. Leucht *et al.*³² reported that 23% of the participants who received antipsychotic medication had a 'good' response (defined as $\geq 50\%$ change on the primary outcome), compared with 14% in the placebo group, with an absolute difference of 9%. Although the percentage is greater for those who receive antipsychotic medication, the authors³² conclude that this is still only a minority of participants who have a good response. With regard to the superiority of FGAs versus SGAs, a meta-analysis³¹ of studies comparing FGAs and SGAs found that four SGAs demonstrated superiority over FGAs in reducing overall symptoms for people with a schizophrenia diagnosis, with small to moderate ESs; specifically, these were amisulpride (ES = 0.31), clozapine (ES = 0.52), olanzapine (ES = 0.28) and risperidone (Risperdal, McGregor Cory Ltd) (ES = 0.13). However, direct comparisons of FGAs with SGAs in large, rigorously conducted, publicly funded RCTs^{33,34} have found no differences in efficacy, leading some to conclude that the class of 'atypical' antipsychotics has been fabricated for marketing purposes and has no basis in science or clinical practice.³⁵

Antipsychotic medication is the mainstay of treatment for people who meet the criteria for a schizophrenia diagnosis; however, it has been argued that evidence from meta-analyses demonstrates that the superiority of antipsychotic medication over placebo has been overestimated.³⁶ In addition, antipsychotics have a wide range of side effects, such as metabolic effects (including weight gain), cardiovascular effects, hyperprolactinaemia, antimuscarinic side effects (dry mouth, blurred vision and cognitive impairment), sexual dysfunction and movement disorders.³⁷ The adverse effects of antipsychotic medication are associated with increased stigma, physical morbidity and mortality, poor adherence and reduced quality of life.³⁷ A systematic review³⁸ of the effects of antipsychotic drugs on brain volume concluded that some of the structural brain changes found in people with a schizophrenia diagnosis may be the result of antipsychotic medication. The headline result from the largest study³⁴ to date to compare FGAs with SGAs was that 74% of participants discontinued their study medication before 18 months, which indicates issues of tolerability and adherence to antipsychotic medication.

Morrison *et al.*³⁶ argue that the adverse effects of antipsychotic medication have been underestimated, and authors of a recent review³⁹ of antipsychotic medication as a treatment for people with a schizophrenia diagnosis concluded that 'we still remain a long way from being able to recommend with precision, specific treatments for individual patients, in terms of the clinical response and lack of adverse events' (Lally and MacCabe³⁹).

A choice of treatments for people with experience of psychosis or with a schizophrenia diagnosis and an evidence base for these treatments is, therefore, imperative.

Treatment-resistant schizophrenia

It is common for the symptoms experienced by someone with a diagnosis of schizophrenia to become progressively more unresponsive to medication with subsequent relapses.⁴⁰ Findings from a recent systematic review conducted by Kennedy *et al.*⁴¹ indicate a 60% failure rate to achieve a response to treatment with standard antipsychotic medication after 23 weeks. The persistence of symptoms after adequate treatment with antipsychotic medication is commonly referred to in the literature and clinical

practice as ‘treatment-resistant’ schizophrenia (TRS); for comparison with the literature, we will utilise the terminology ‘people with experience of TRS’ throughout this report. Global estimates of the prevalence of TRS would suggest that 7.8 million people worldwide are experiencing TRS.⁴² As outlined in *Prevalence rates and the personal, social and economic impact of schizophrenia*, people with a schizophrenia diagnosis frequently experience health inequalities; for the TRS group, these health inequalities are inflated. The mean quality of life score for those who meet TRS criteria is 20% lower than for people with a diagnosis of schizophrenia whose symptoms are considered to be in remission.⁴¹ Moreover, in comparison with other mental health diagnoses that are considered to be ‘severe and enduring’, those with TRS have worse outcomes in terms of both symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS), and social/functional outcomes, with TRS being a predictor for poor community functioning.⁴³ For the person experiencing TRS, the continued presence of symptoms represents a barrier to recovery and improvements in quality of life, and increased personal social/economic costs.⁴¹ In sum, the importance of identifying effective treatments for this group cannot be overstated.

In defining criteria for TRS, many researchers and clinicians have referred to the following conceptualisation of TRS, outlined by Kane *et al.*:⁴⁴ two periods of treatment with different antipsychotics at an adequate dose for ≥ 4 weeks without a $\geq 20\%$ reduction in symptoms. Since the publication of the Kane *et al.*⁴⁴ study, there have been numerous investigations of treatments for people with TRS; however, these studies often use different definitions of TRS. A systematic review⁴⁵ of the TRS literature highlights the fact that the definition of TRS has been inconsistent across numerous clinical trials for TRS, and it is argued that the lack of clarity regarding the definition of TRS is a limiting factor for translating the research findings into clinical practice. It also increases heterogeneity across the studies and, therefore, reduces the conclusions that can be drawn from meta-analyses.⁴⁵ Furthermore, the international guidelines utilised by clinicians working in the field use varying definitions of TRS (e.g. NICE guidelines³⁰). In the UK, NICE does not specify a duration of treatment of an episode that it deems adequate, unlike the American Psychiatric Association, which specifies a duration of ≥ 6 weeks. In response, the Treatment Response and Resistance in Psychosis (TRRIP) working group was convened to develop criteria for treatment resistance in schizophrenia. This work represents an important development in research and practice in the field of TRS. Howes *et al.*⁴⁵ note that, of the 42 studies identified as eligible for their systematic review, only two, from the same research group, used identical TRS criteria. Based on the systematic review conducted by Howes *et al.*,⁴⁵ an online survey of the TRRIP group members (identifying agreements and disagreements) and meetings of the TRRIP group members, the following criteria for TRS have been recommended: (1) current symptoms of a minimum duration and severity determined by a standardised rating scale that includes both positive and negative symptoms, that is, the Brief Psychiatric Rating Scale (BPRS) or PANSS; (2) moderate or worse functional impairment; (3) prior treatment of at least two different antipsychotics, each for a minimum duration and dosage; (4) systematic monitoring of adherence and meeting of minimum adherence criteria; (5) at least one prospective treatment trial; and (6) criteria that clearly separate responsive from treatment-resistant patients.⁴⁵

The NICE guideline³⁰ treatment recommendation for people diagnosed with TRS is to review diagnosis and adherence to medication, ensure that the medication prescription is at an adequate dose for the correct period of time, consider possible causes of non-response, such as substance misuse and physical health problems, and offer psychological intervention [CBT and family intervention (FI)]. For those who experience persistent symptoms of schizophrenia following adequate treatment with at least two different antipsychotic drugs (at least one of which should be a non-clozapine SGA), a trial of clozapine should be offered.³⁰ Clozapine is a SGA and it is currently considered to be the treatment of choice for people with TRS,⁴⁶ as demonstrated by the NICE guideline recommendation.³⁰ However, clozapine has a number of adverse effects and, in comparison with FGAs, clozapine is associated with more frequent haematological problems, drowsiness, hypersalivation and temperature increases.⁴⁷ The most dangerous adverse effect associated with clozapine is agranulocytosis, which is a haematological disorder of the white blood cells that help fight infection. The unwanted side effects of clozapine can prevent the optimal dose of clozapine being reached or tolerated over time, and data from a cohort study in the UK showed that 45% of people discontinued treatment with clozapine within the first 2 years of the drug being initiated.⁴⁸ Results of the same study also suggest that tolerability and adverse drug reactions play a key role in patient-led decisions

to discontinue clozapine: in just over half of cases, the reason given for discontinuation was adverse drug reactions, with sedation being the most frequently reported.⁴⁸

The use of clozapine as a treatment for TRS grew in popularity following the highly influential double-blind study of clozapine versus chlorpromazine conducted by Kane *et al.*⁴⁴ Since this study, there has been an increased number of RCTs comparing clozapine with FGAs, paving the way for subsequent meta-analyses of these trials. Essali *et al.*⁴⁷ conducted a systematic review and meta-analysis of trials comparing clozapine with FGAs, identifying a total of 42 eligible trials with 3950 participants. Although there was no difference in mortality or employment status between those on clozapine and those receiving FGAs, clozapine was superior in relation to clinical improvements, reduced relapse rates and greater reduction in BPRS scores. Although the meta-analysis conducted by Essali *et al.*⁴⁷ suggests superiority of clozapine over FGA, the authors note problems of heterogeneity with the data and the high risk of bias across the studies.⁴⁷

There has been some debate regarding the efficacy of clozapine in comparison with other antipsychotic medications. Two meta-analyses^{49,50} of clozapine versus treatment with standard antipsychotic medication were published in 2016. Both meta-analyses found that clozapine was no more effective in the long term for total psychotic symptoms than other antipsychotic medications. However, Siskind *et al.*⁴⁹ report that for positive symptoms clozapine is superior to other antipsychotic medications in both the short and the long term. Given the absence of superiority over other antipsychotic medications for total symptoms in the long term, Siskind *et al.*⁴⁹ recommend that, for patients who do not respond to clozapine by 6 months, other antipsychotic medications with lower side effect profiles should be considered. The network meta-analysis by Samara *et al.*,⁵⁰ which integrated all published and unpublished single- and double-blind RCTs of all antipsychotic medications for TRS, found that there was little evidence of efficacy of antipsychotic medications other than clozapine, haloperidol, olanzapine and risperidone. The authors⁵⁰ concluded that there is, however, insufficient evidence to determine which of these medications are most effective for people with TRS, commenting that 'The most surprising finding was that clozapine was not significantly more efficacious than most other drugs' (Samara *et al.*⁵⁰) and arguing that there is a need for blinded studies of antipsychotic medication for TRS.⁵⁰ Howes *et al.*⁴⁵ note that the conclusions that can be drawn from the network meta-analysis by Samara *et al.*⁵⁰ may be limited by the heterogeneity across the studies included in the review. Clearly, it is challenging when two meta-analyses with similar research questions are published within the same year, making it difficult for clinicians, researchers and commissioners to interpret the data; however, clozapine remains the mainstay of treatment for TRS.

Clozapine-resistant schizophrenia

Around 30–40% of people who trial clozapine will experience a poor response to this medication.⁵¹ Moreover, the range of adverse effects from clozapine means that the optimal dose may not always be reached or clozapine may not be tolerated long term. In both the research literature and clinical practice, a person who experiences a poor response to clozapine is typically said to have 'clozapine-resistant schizophrenia' (CRS) and, for this reason, we use that term in this report. CRS is defined as the persistence of symptoms after treatment with clozapine for ≥ 12 weeks at a stable dose of ≥ 400 mg per day, unless the dose was limited by side effects.⁵²

The most frequent approach to the treatment of CRS is to augment clozapine with another antipsychotic medication.^{53,54} This is an approach taken frequently in clinical practice.^{53,54} Clozapine has low antidopaminergic properties and, therefore, is often combined with an antipsychotic medication that has dopaminergic properties.⁵³ There is some evidence of small but significant benefits of clozapine augmentation with a second antipsychotic,^{54,55} but studies are scarce.⁵⁶ There is some indication that augmentation with risperidone may have adverse effects, as evidence from the Cochrane review⁵⁷ comparing risperidone with placebo suggests that adding risperidone to clozapine treatment leads to reduced functioning. Not only are antipsychotic augmentation studies infrequent, but their results are highly heterogeneous, which limits the conclusions that can be drawn from meta-analyses.⁵⁴ Many of the studies to date are subject to detection bias, with concealment of allocation unclear in eight of the studies included in the meta-analysis of antipsychotic augmentation conducted by Taylor *et al.*⁵⁵ With this representing just over 50% of the studies

included in the review, findings may be compromised by the risk of detection bias. Moreover, several of the studies included in the systematic review conducted by Porcelli *et al.*⁵⁴ were rated as being of low quality, with the mean quality assessment score across the 24 studies being 5.43 points (SD 1.88 points, range 3–8 points), with 0 points being the minimum score and 9 points being the maximum score.

A systematic review and meta-analysis conducted by Taylor *et al.*⁵⁵ identified 14 RCTs, with a total sample of 734 participants, that compared clozapine plus a second antipsychotic with clozapine plus placebo for ≥ 6 weeks' duration. Augmentation with a second antipsychotic was found to have a small but significant effect over placebo, with an ES of 0.239. The long-term adverse effects of clozapine augmentation with a second antipsychotic are unclear from the Taylor *et al.*⁵⁵ review because 11 of the 14 trials followed up participants for only ≤ 10 weeks. Potential long-term adverse effects include hyperprolactinaemia and increased striatal dopamine blockade.⁵⁵ There is scarce evidence to answer the question of which combination strategy of clozapine and another antipsychotic medication is more effective. Sommer *et al.*⁵⁶ conducted a systematic review of 29 randomised, double-blind, placebo-controlled trials of clozapine augmentation with a second drug, including augmentation with drugs from a different class (i.e. not an antipsychotic). Of these, 10 trials evaluated the efficacy of augmentation with another antipsychotic and included amisulpride, aripiprazole, haloperidol, risperidone and sulpiride. Only clozapine augmented with sulpiride proved superior to placebo in reducing symptom severity, and this finding was from one small trial (with a sample size of $n = 28$).

The most recent review of clozapine augmentation with another antipsychotic medication was carried out by Barber *et al.*⁵⁸ The aim was to evaluate the efficacy and tolerability (in terms of side effects) of clozapine combined with various antipsychotic medications. The search yielded a limited number of studies, which were of low quality and high heterogeneity. In total, five studies met the inclusion criteria, yielding a total of 309 participants. Findings from the review demonstrated that there are a very limited number of studies that can indicate the superiority of one clozapine combination strategy over another, and the evidence that is available is of low quality. The current evidence does not allow a specific clozapine augmentation strategy to be recommended; individual pragmatic trials may be indicated, but, given the increased risk of adverse effects from polypharmacy, augmentation with a second antipsychotic should be discontinued if the benefits do not outweigh the risks.

An alternative strategy that has been evaluated is augmenting clozapine with another medication of a different class, namely benzodiazepines or antidepressants. In a review, Dold and Leucht⁵³ argued that there is currently insufficient evidence for this approach, although they do recognise that targeted use of augmentation may be indicated in specific cases, such as the use of medication to target agitation.

In summary, the literature regarding the efficacy of treatments for TRS indicates that a significant proportion of people will experience CRS and continue to experience persistent difficulties. The evidence base for treatments for CRS is sparse⁵⁹ and augmentation strategies with a second antipsychotic demonstrate small effects.⁵⁵

Psychological interventions

Psychological therapies for people with psychosis have been extensively evaluated in recent years. Clinical trials and subsequent meta-analyses have evaluated individual and group treatments (including CBT, supportive counselling, befriending, narrative therapies and psychodynamic approaches), FIs (individual or multifamily) and art therapies (including music therapies, dance therapy and art therapy). After thoroughly reviewing the evidence base, the NICE guideline³⁰ currently recommends that all people with experience of psychosis or with a schizophrenia diagnosis should be offered CBT and FI, and for those who experience TRS or CRS it is recommended that the care team review the person's engagement with and use of both of these psychological treatments.³⁰

Cognitive-behavioural therapy

The generic cognitive model⁶⁰ has been applied to our understanding and treatment of schizophrenia. This cognitive model suggests that the way in which we interpret events has consequences for how we feel and behave, and that such interpretations are often maintained by unhelpful thinking biases and behavioural responses. Cognitive models of psychosis and psychotic experiences suggest that it is the way in which people interpret and respond to psychotic phenomena that accounts for distress and disability, rather than the psychotic experiences themselves.^{61–63}

Key elements of CBT include a shared, individualised formulation of the problem, which can include consideration of life events that may contribute to the development and/or maintenance of psychosis, such as trauma and deprivation; evaluating unhelpful thoughts; and conducting behavioural experiments.⁶⁴ Morrison *et al.*⁶⁴ place emphasis on the importance of CBT being conducted via a strong therapeutic relationship for people who experience psychosis and schizophrenia, the use of normalising information, collaboration between the client and the therapists, and therapy being based on a client's problem list and idiosyncratic goals.

The importance of delivering CBT in an empowering and recovery-orientated manner has been highlighted in a 2016 article by Brabban *et al.*,⁶⁵ who suggest 10 key considerations to ensure that CBT is delivered ethically, in a manner that is recovery orientated and promotes therapeutic relationships: (1) collaboration, (2) use of everyday language, (3) acknowledging the historical and developmental context of the client's difficulties, namely adverse life experiences, so as not to minimise the impact of these, (4) evaluating rather than challenging beliefs, (5) applying caution with use of the stress vulnerability model of psychosis and schizophrenia, (6) validating the client's experience using a cognitive formulation, (7) delivering hope to the client, (8) offering informed choice about engaging with CBT, (9) ensuring that CBT training is extensive and specialist and (10) ensuring that there is access to continued supervision.

Cognitive-behavioural therapy has been shown to have small to moderate effects when delivered in combination with antipsychotic medication, with several meta-analyses showing support for this approach.^{66–68} The most conservative ES estimate for total symptoms is 0.33, demonstrating small but significant effects of CBT for psychosis over treatment as usual (TAU); however, the ES for total symptoms reduces to 0.15 for studies with a low risk of bias from masking.⁶⁹ The same meta-analysis⁶⁹ reports small ESs for positive symptoms (ES = 0.25) and negative symptoms (ES = 0.13). A 2014 meta-analysis conducted by Turner *et al.*,⁷⁰ which compared CBT for psychosis with other psychological therapies, found that, across the 48 included studies, CBT was more efficacious in improving overall and positive symptoms of psychosis than in improving other psychological therapies. van der Gaag *et al.*⁷¹ note that there has been a focus on positive and negative symptoms in meta-analyses of CBT; however, CBT is a formulation-based approach that aims not necessarily to reduce the frequency or severity of positive and negative symptoms, but rather to help service users make sense of distressing hallucinatory experiences and delusional beliefs, with the aim of reducing distress and increasing coping. In a meta-analysis of treatment effects of individually tailored case-formulation CBT on auditory hallucinations and delusions, van der Gaag *et al.*⁷¹ found modest and significant ESs for auditory hallucinations at the end of treatment (ES = 0.44), and this increased when contrasted with active treatment (ES = 0.49) and for blinded studies (ES = 0.46). Although modest significant ESs were found for delusions at the end of treatment (ES = 0.36), these ESs lost significance when (1) contrasted with active treatment and (2) the ES was reduced for blinded studies (ES = 0.24). Findings from the meta-analysis conducted by van der Gaag *et al.*⁷¹ suggest that CBT can be effective in treating auditory hallucinations, but that the evidence for treating delusions is less robust.

Although meta-analyses suggest small to moderate ESs for CBT, in comparison with other psychological approaches, there remains debate in the literature about CBT's value for psychosis and schizophrenia.^{69,72} In particular, McKenna,⁷² in the 2014 Maudsley Debate, suggest that the meta-analysis carried out by NICE in 2009 for the schizophrenia guideline was methodologically flawed, leading to an increased chance of type I error and the probability that any positive findings were as a result of chance. In addition, Jauhar *et al.*⁶⁹ suggest that the conclusions regarding efficacy of CBT are mistaken, because the most large, well-conducted

trials have failed to demonstrate a significant effect at the end of treatment, and the supportive meta-analyses overestimate the effects from smaller, low-quality trials. They also argue that their finding of 'non-significant effects on positive symptoms in a relatively large set of 21 masked studies also suggests that claims that CBT is effective against these symptoms of the disorder are no longer tenable'.⁶⁹

Cognitive-behavioural therapy for treatment-resistant schizophrenia

In relation to TRS, the efficacy of CBT has been evaluated in a number of RCTs with some encouraging evidence; key details of these studies are presented below. Tarrier *et al.*⁷³ conducted one of the earliest trials of CBT for TRS using a three-arm RCT design in which participants were randomly allocated to CBT, supportive counselling or TAU. In total, 87 eligible participants were randomised, and those who received CBT exhibited significantly greater improvements in positive symptoms at the 3-month assessment than those who received supportive counselling or TAU. Because the authors did not provide further definition of 'stable medication', it is difficult to establish whether or not this group would meet strict TRS criteria. Augmenting clozapine with CBT was first evaluated by Pinto *et al.*⁷⁴ In their RCT⁷⁴ of CBT with social skills training compared with supportive therapy as an adjunct to clozapine, 41 treatment-resistant participants who had recently started taking clozapine were recruited. Treatment resistance was defined as non-response to at least two antipsychotic medication trials, each ≥ 6 weeks in duration, at a dose of > 600 mg per day of chlorpromazine equivalents. At the end of treatment, both the CBT plus social skills training and supportive counselling groups showed statistically significant improvement in total BPRS score and positive and negative symptom ratings. However, comparisons between the groups showed that, post intervention, participants who had received CBT plus social skills training had lower total BPRS score and lower negative symptoms scores than participants who had received supportive therapy.⁷⁴ This study⁷⁴ provided preliminary evidence for augmenting clozapine with a psychological intervention; however, as this study is non-blind there is a risk of bias that limits the conclusions that be drawn from the findings. In another RCT of CBT for TRS, Kuipers *et al.*⁷⁵ found that the CBT group had a significant improvement on the BPRS, as defined by a 25% reduction in the BPRS score; however, significant differences were not observed between the CBT and control groups on any of the other clinical outcomes. Findings from the study⁷⁵ also suggested that CBT was considered an acceptable treatment, because participants had a low drop-out rate from therapy (11%), and 80% of those who received CBT expressed high levels of satisfaction with the intervention. Sensky *et al.*⁷⁶ recruited 90 participants to a RCT comparing CBT with befriending for people with TRS. For this study, treatment resistance was defined as the persistence of symptoms resulting in distress or dysfunction for ≥ 6 months despite an adequate trial of antipsychotic medication.⁷⁶ Analysis of the data demonstrated no significant difference between the groups at the end of treatment, but an effect was observed at follow-up for positive and negative symptom ratings and depression for the CBT group. A 5-year follow-up study⁷⁷ of these participants indicated some evidence for the medium-range effectiveness of CBT: participants who received CBT had significantly lower overall symptom severity scores than those in the befriending group. A three-arm RCT⁷⁸ of CBT versus supportive psychotherapy (SP) versus TAU, for people with a schizophrenia diagnosis who experienced persistent delusions and/or hallucinations after treatment with antipsychotic medication for 6 months, found greater improvement in PANSS total score among those allocated to CBT. In addition, the results of the study demonstrated that those in the psychological intervention arms (CBT or SP) experienced a greater reduction in the severity of delusions and that more people in the CBT arm than in the SP and TAU arms achieved a $\geq 25\%$ reduction in PANSS scores.⁷⁸ Although the study indicates promise for the acceptability of CBT for this group, and promise for the effects of CBT on total PANSS score and delusion severity, this was a small study with between 19 and 23 participants in each arm. Valmaggia *et al.*⁷⁹ carried out a small RCT of manualised CBT for psychosis versus a time-matched control intervention of supportive counselling for people with TRS, matching the Kane *et al.*⁴⁴ definition. Sixty-two participants were randomised and the between-group analyses at the end of treatment demonstrated no significant difference between the CBT and supportive counselling groups on positive, negative or general subscale of the PANSS, or the delusion subscale of the Psychotic Symptom Rating Scale (PSYRATS). There was however, a significant improvement in the CBT group on two items of the PSYRATS voices subscale (the physical characteristics and interpretation of voices). These differences were not sustained at follow-up, indicating some short-term effects of CBT on voices for the TRS group.

To date, there have been no published meta-analyses of CBT specifically for TRS. However, a meta-analysis of CBT and FIs for people with a diagnosis of schizophrenia reported that the majority of the studies included in the review included participants who would appear to meet TRS criteria, that is, they were prescribed an antipsychotic medication and had a long duration of illness (DI), and concluded that CBT may be useful for those with TRS.⁶⁶ A more recent systematic review⁸⁰ of the literature on interventions for TRS found 13 studies investigating CBT for TRS. This review included any paper in which the authors had considered the participants to be experiencing TRS, and so did not follow a strictly defined definition of TRS, with the result that the samples included are likely to be highly heterogeneous; this raises the question of whether or not the studies included are reflective of intervention studies for the TRS group. In addition, closer inspection of the CBT studies included in the review⁸⁰ reveals that the CBT intervention usually targeted specific symptoms of psychosis (i.e. command hallucinations⁸¹ and auditory hallucinations⁸²) or was aimed at improving outcomes that were not directly related to symptoms, such as therapeutic alliance.⁸³

Cognitive-behavioural therapy for clozapine-resistant schizophrenia

To date, only one study has examined the efficacy of CBT for CRS.⁸⁴ In this controlled trial, treatment resistance was evaluated using Kane *et al.*'s⁴⁴ criteria and, to meet trial inclusion criteria, participants were required to have taken clozapine for ≥ 6 months without improvement of symptoms of psychosis. Twenty-two participants who met the inclusion criteria were allocated to either CBT ($n = 10$) or befriending ($n = 12$). CBT was found to be significantly more effective in reducing BPRS total score, PANSS total score and PANSS general psychopathology subscale score at the end of treatment and at the 6-month follow-up. However, an effect was not found for the reduction of positive symptoms. Although the result of the study by Barretto *et al.*⁸⁴ is encouraging, there are significant methodological limitations. The sample size was very small, limiting the power of the study to detect an effect of CBT for positive symptoms. Moreover, the study design is limited by the absence of randomisation.

Predictors of response to cognitive-behavioural therapy

In addition to understanding the overall efficacy of CBT relative to standard treatment, a further important research consideration is determining predictors of response to CBT, to better understand who will benefit from CBT. In determining who will have a good response to CBT, secondary analyses of CBT trials have indicated that patient characteristics including sex, ethnicity and baseline symptom severity may moderate the outcomes of CBT for people with a schizophrenia diagnosis.^{85–88} More specifically in relation to TRS, studies of CBT in this group have indicated that fewer recent hospital admissions,⁸⁹ greater cognitive flexibility concerning delusions⁸⁹ and less severe symptoms on allocation⁷³ are associated with a better response to CBT. The DI has been shown to be associated with response to CBT,^{90–92} and this has also been demonstrated in TRS groups.⁷³ Similarly, insight at baseline has been shown to be associated with good outcomes in CBT for psychosis.⁹³

It is likely that the way in which events are appraised will be dependent on the experiences a person has had in life and the way in which they view themselves and other people.⁶³ Experience of traumatic life events, such as abuse, could lead to the development of a view that other people are threatening, causing later experiences to be interpreted in this light.^{62,63} Research in the general population that has found an association between negative life events and unusual beliefs or perceptual experiences has provided support for this view.⁹⁴ There is increasing evidence of a link between abuse and psychosis⁹⁵ as well as other types of traumatic or difficult life experiences and psychosis, for example being held hostage,⁹⁶ living in highly urbanised areas,⁹⁷ refugee migrant status,⁹⁸ low social capital⁹⁹ and racial discrimination.¹⁰⁰ A 2012 meta-analysis¹⁰¹ of 41 studies found a significant relationship between adversity in childhood and risk of psychosis later in life. The types of traumatic childhood experience that were included in the review¹⁰¹ were emotional, physical and sexual abuse; neglect; bullying; and death of a parent. It was found that, apart from parental death, each of these factors was significantly related to psychosis. Loss of a parent was also found to be significantly related to psychosis when the data from one paper with outlying results were removed from the analysis. This review,¹⁰¹ therefore, concluded that the experience of trauma in childhood

is strongly related to an increased risk of psychosis. Specific types of traumatic experience have also been found to relate to specific psychotic experiences. It has been found that sexual abuse is related to voice-hearing, whereas growing up in care is related to experience of paranoia.¹⁰² A longitudinal study¹⁰³ found that experience of psychosis in children aged 12 years was particularly associated with traumatic events, characterised by intention to harm. This suggests that it could be the perception of threat that is of significance to the development of psychotic experiences.¹⁰³ Experiences, such as those described above, could lead to beliefs that others are dangerous, and increase the likelihood that future experiences will be interpreted as threatening.² Use of a longitudinal formulation within CBT can, therefore, provide validation of the experiences that an individual has suffered and make sense of current experiences in the context of a traumatic history.¹⁰⁴ This process can also foster hope of recovery by identifying specific areas in which change strategies could be applied.¹⁰⁴

Cognitive difficulties, that is, difficulties with attention, memory and working memory, are frequently experienced by people with a schizophrenia diagnosis.^{105,106} Working memory has been described as a system for temporarily storing information while using it to complete tasks involving cognitive function, such as problem-solving.¹⁰⁷ A large meta-analysis investigating working memory in schizophrenia consistently found that participants with a diagnosis of schizophrenia performed worse than control groups on a range of tests of working memory.¹⁰⁸ Furthermore, it has been found that those individuals with a longer-term diagnosis and receiving antipsychotic medication are likely to be the most seriously affected. For example, it has been shown that participants with a greater DI demonstrate the poorest performance on working memory tasks.¹⁰⁸ In relation to spatial working memory, it was found that participants' performances significantly worsened after receiving clozapine for just 17 weeks.¹⁰⁹ It has previously been demonstrated that anticholinergic drugs, including clozapine, affect memory performance.¹¹⁰

It has been proposed that neurocognitive deficits in people with a diagnosis of depression are likely to predict outcome from CBT.¹¹¹ The same is likely to be true for people with a schizophrenia diagnosis, given that CBT relies on skills, such as memory and generating alternative hypotheses.¹¹² Neurocognition is also known to be associated with functional outcomes, such as social skills and ability to perform daily activities.¹¹³ Neuropsychological impairment has been found to be predictive of poorer outcome among participants receiving Cognitive Behavioural Social Skills Training.¹¹² It was hypothesised that neuropsychological impairment could be related to poorer attendance and reduced engagement with homework in this group. Memory difficulties could make engaging with homework tasks, a factor thought to improve outcome, more problematic.¹¹⁴ However, few studies have formally evaluated the impact of neurocognitive variables on outcome with CBT, and a clear relationship has not been identified.¹¹⁵

Although some researchers have endeavoured to identify who has a good response to CBT, the current evidence for predictors of a good response to CBT is limited and the findings are often unreliable because of insufficient statistical power, with very few findings surviving replication. There is a clear benefit to understanding how best to target CBT at those who are most likely to respond, and further research is required.

Important outcomes for trials

A further criticism of these studies is the absent or limited focus on outcome measures that service users consider meaningful and important to their recovery. A review¹¹⁶ of 24 measures commonly used to evaluate psychosis and mood disorders found that service user preference was for measures that were patient rated rather than clinician rated and that evaluated side effects of both pharmacological and psychological interventions; interestingly, measures of social functioning were rated particularly low because of the assumptions made about 'good' social functioning. However, it is interesting to note that the PANSS, a commonly used outcome measure, was rated as the most acceptable of the psychosis outcome measures.¹¹⁶ Although this suggests that measuring these symptom-based domains is important

to service users, there is also clear evidence that recovery-orientated outcomes are a priority.¹¹⁷ A recovery-orientated model of care engenders values of hope, independence and control over one's life following a mental health problem, connection with a self-identity and having meaning to life and being able to take responsibility for one's recovery.¹¹⁷ The emphasis is not on the remission or absence of symptoms.¹¹⁸ A qualitative study¹¹⁹ investigating how service users with experience of psychosis or schizophrenia diagnoses defined recovery identified three key themes: (1) rebuilding self, (2) rebuilding life and (3) hope for a better future. Within these key themes, processes of recovery included understanding oneself, empowerment, participation in life activities and social support, understanding a personal process for change and a personal desire for change. Importantly, Pitt *et al.*¹¹⁹ emphasised that recovery is a journey, not a linear process with a clear end point. A 2011 systematic review¹²⁰ of the literature on personal recovery from a mental health problem identified a total of 97 papers; synthesis of the findings from these papers resulted in five key processes of recovery: (1) connectedness, (2) hope and optimism for the future, (3) identity, (4) meaning and (5) empowerment.

It has also been argued, especially in relation to the evaluation of psychological therapies for people with psychosis, that affective processes or emotional distress or dysfunction should be the outcomes that are evaluated in trials. For example, CBT for psychosis trials have been criticised as inappropriately conceiving CBT as a quasi-neuroleptic on the basis of adopting methodologies designed to evaluate antipsychotic medication, including use of psychiatric symptoms as the primary outcome rather than affective dysfunction.¹²¹

The importance of recovery-orientated services and treatments for people with experience of psychosis or for people with a schizophrenia diagnosis is in the NICE guideline,³⁰ which emphasises the importance of recovery-orientated values in the treatment of psychosis and schizophrenia. The Schizophrenia Commission report¹²² makes a call for all mental health services working with people with experience of psychosis and schizophrenia to work in a person-centered approach that embraces the interests and opinions, as well as the strengths and aspirations of the person with psychosis.

Arguably, the lack of specific focus on outcome measures that evaluate these domains, which are important to service users, limits any conclusions that can be drawn from previous treatment studies, both psychological and pharmacological. Similarly, trials that use symptom-focused measures, such as the PANSS, often fail to demonstrate clinically significant change, even if treatments demonstrate statistical superiority. This has led to attempts to define clinically significant response,¹²³ and meta-analyses of trials often use a > 50% improvement on the PANSS as an operational definition of a good outcome.³²

Summary

To summarise, there is clear evidence from the CBT trials that people with TRS and CRS can be engaged in CBT, and that CBT can have small to moderate effects on overall symptoms and may be particularly beneficial for auditory hallucinations. However, it has been highlighted in a 2014 meta-analysis⁶⁹ that the large and methodologically robust trials of CBT for psychosis have not demonstrated a significant advantage of CBT for either symptoms or relapse, and to date there have been no large high-quality trials of CBT for people with CRS. Moreover, CBT trials have been criticised for poor reporting of adverse effects,¹²⁴ and future trials should report adverse effects as an outcome. Klingberg *et al.*^{125,126} have provided a useful template for assessing adverse effects that includes death caused by suicide, suicide attempt, suicidal crisis [as defined in the Calgary Depression Rating Scale for Schizophrenia (CDSS), item 8, rating 2] and severe symptomatic exacerbation, defined by the Clinical Global Impression (CGI) scale, which includes ratings of illness severity, changes in overall clinical status, and therapeutic effects. In addition, further research is needed to identify factors that predict a good outcome from CBT.

Rationale for the research/trial aims and objectives

The objectives of this RCT were to provide evidence of the clinical effectiveness and cost-effectiveness of CBT for people with CRS and to utilise baseline data from the RCT to develop a risk model that identifies factors that predict good outcome from CBT. Using the patient-level data available from the trial, the objectives for the economic evaluation were to:

- estimate the costs of health and social care in the intervention and TAU groups, and assess whether or not there were differences between the groups
- estimate the quality-adjusted life-years (QALYs) of participants in the intervention and TAU groups, and assess whether or not there were differences between groups
- assess whether or not any additional benefit is worth any additional cost.

The research objectives of this RCT were to test the following hypotheses:

- In people with a diagnosis of a schizophrenia spectrum disorder who have an inadequate response to or are unable to tolerate clozapine, CBT plus TAU will lead to improvement in psychotic symptoms, measured using a psychiatric interview (PANSS) over a 21-month follow-up period compared with TAU alone.
- Cognitive-behavioural therapy plus TAU will lead to improved quality of life and user-defined recovery compared with TAU alone.
- Cognitive-behavioural therapy plus TAU will lead to a reduction in affective symptoms and negative symptoms compared with TAU alone.
- Cognitive-behavioural therapy plus TAU will be cost-effective compared with TAU alone.

Chapter 2 Methods

Trial design

The FOCUS trial was a parallel-group, randomised, outcome-blinded evaluation (PROBE) to evaluate the addition of a standardised CBT intervention to TAU for individuals who are unable to tolerate or have had an inadequate response to clozapine. The comparison group received TAU only. The trial was intended to be a definitive, pragmatic clinical effectiveness and cost-effectiveness trial. It was conducted over 4 years across five sites within the UK, with recruitment commencing on 1 January 2013 and ending on 1 June 2015. The follow-up phase for the trial ended in February 2017. A copy of the full ethics-approved trial protocol can be found on the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/1010102#/. In addition, the study protocol has been published in a peer-reviewed journal.¹²⁷

Role of funding source

The FOCUS trial was funded as a result of a National Institute for Health Research (NIHR) Health Technology Assessment-commissioned call. The call specified the design in PICO (population, intervention, comparator and outcome) terms, requiring that the population be patients with schizophrenia who had not responded to an adequate dose of clozapine or were unable to tolerate it, the intervention was CBT, the comparator was TAU and the outcome was psychiatric symptoms.

Approval

The National Research Ethics Service (NRES) Committee North West – Lancaster (reference 12/NW/0520) approved the FOCUS trial. Ethics approval was granted on 13 August 2012. The trial was also registered on the International Standard Randomised Controlled Trial Number (ISRCTN) clinical trial registry (reference ISRCTN99672552). The trial was registered on 29 November 2012, before recruitment was started in January 2013.

Trial sites

The study was conducted in secondary care mental health services (community mental health, residential rehabilitation and inpatient settings) at five UK centres. These were (1) Manchester, (2) Edinburgh, (3) Glasgow, (4) Newcastle upon Tyne and (5) Southampton.

Participants

A total of 487 participants were recruited across the five sites between 1 January 2013 and 1 June 2015. The Manchester site recruited 108 of the total participants, Southampton recruited 105, Edinburgh recruited 94, Newcastle upon Tyne recruited 92 and Glasgow recruited 88. Participants were recruited from a range of services and settings including community mental health teams (CMHTs), early intervention teams, recovery teams and inpatient services.

Inclusion and exclusion criteria

Participants were eligible to take part in the FOCUS trial if they were considered to have had an inadequate response to a trial of clozapine treatment, specifically treatment with clozapine at a stable dose of ≥ 400 mg

(unless limited by tolerability) for ≥ 12 weeks, or, if currently augmented with a second antipsychotic, for ≥ 12 weeks, without remission of psychotic symptoms. This criterion was selected as a review of medication trials found 400 mg to be the minimum dose necessary for effective treatment with clozapine.¹²⁸ Other clinical trials looking at CRS have employed the same criteria.⁵² Alternatively, participants were eligible for the trial if they had discontinued clozapine in the preceding 2 years because of side effects, lack of efficacy or a problem identified during routine blood monitoring appointments.

Participants were also required to have been given an ICD-10 diagnosis on the schizophrenia spectrum, or to meet criteria for an Early Intervention in Psychosis (EIP) service.

To be included, participants were also required to achieve a minimum total score on the PANSS of 58 (equivalent to a CGI scale of at least mild difficulties),¹²⁹ as well as a score of ≥ 4 on items for delusions or hallucinations, or of ≥ 5 for items on suspiciousness or grandiosity, to ensure that symptoms of psychosis had not remitted. The research assistant (RA) assessed this at baseline. Participants had to be aged ≥ 16 years and have an identified care co-ordinator or consultant psychiatrist. In addition, participants were required to be competent and willing to provide written informed consent to take part.

Exclusion criteria were having a primary diagnosis of substance or alcohol dependence if this could be the cause of the psychotic experiences, having a diagnosis of developmental disability or organic impairment and being non-English-speaking. Individuals who were currently receiving or had received structured CBT from a qualified psychological therapist within the preceding 12 months were also excluded from the trial. This was operationalised as CBT delivered in line with the NICE guidelines³⁰ for the treatment of psychosis and schizophrenia as ≥ 16 sessions of CBT that is delivered in line with a CBT treatment manual.³⁰

Data collection

In accordance with the approved protocol, potential participants were initially informed about the study by a member of their care team and, if they expressed interest, were asked to consent to being contacted by the FOCUS trial research team. If they did so, a member of the research team briefly described the study and sent the participant information sheet (PIS) by post. The individual was then given a minimum of 24 hours to consider the information. Following this, the RA arranged to meet the participant at a place of their choosing; in the majority of cases this was the participant's own home. Some preferred to meet within a mental health service or, if there were any possible risk issues, a meeting at a NHS site would be arranged. Participants who were current inpatients were visited on the ward. The RA talked through the PIS with the individual and ensured that the information was understood by asking the participant to reflect it back to them. When both the RA and the participant were satisfied that all the information about the trial had been provided and understood, the participant was asked to sign the consent form. The RA then read through each point and the participant initialled the boxes provided if they agreed to the information. Both the RA and the participant signed their names underneath.

The RA would then commence the baseline assessment. In the majority of cases, this was conducted across two visits, but this was at the participant's preference. On average, to complete all assessment measures in full would take approximately 2 hours. The assessment would begin with the PANSS interview and then move on to the self-report measures (outlined below). Each participant was also provided with a personalised crisis card at the baseline assessment. This included contact details for their care team and general practitioner (GP) as well as other helpline numbers, such as the Samaritans. Finally, participants were compensated with £10 for their time and contribution to the research process.

Face-to-face follow-up assessments were completed at 9 and 21 months. The participant was contacted by telephone and an appointment was arranged. Ongoing consent was confirmed with participants at each follow-up. The RA conducted a PANSS interview and asked the participant to complete the self-report measures

at each of these time points. Participants were compensated £10 for their time and contribution to the research process at these time points.

Follow-up assessments were completed by telephone at 3, 6, 13 and 17 months. These telephone assessments focused only on obtaining health economics data – no clinical outcome data were collected. The participants were sent £5 gift vouchers in the post on completion of these follow-ups. 'Keeping in touch' cards were also posted to the participant on two occasions between these telephone calls.

Outcome measures

Primary outcome

Although there is considerable debate regarding the most appropriate or important outcome measures (e.g. whether to focus on specific psychiatric symptoms or broader recovery and quality of life), the FOCUS trial was funded as a result of a commissioned call that specified the PICO. The commissioned call specified the important outcome as psychiatric symptoms and, therefore, PANSS,¹³⁰ a reliable and valid, semistructured interview to assess the severity of symptoms associated with psychosis, was chosen as the primary outcome. It is widely used as the primary outcome measure in studies of treatments for people with a schizophrenia diagnosis and research indicates that a 15-point change on the total PANSS score translates to minimal clinical improvement.¹²³ This allows comparison with other published trials and inclusion of these results in any future systematic reviews and meta-analyses of treatment evidence. PANSS has 30 items that are scored between 1 (absent) and 7 (extreme), and includes seven items that map on to the positive symptoms (such as hallucinations and delusions), seven items relating to negative symptoms (such as blunted affect and emotional withdrawal) and 16 items assessing general psychopathology (such as anxiety and depression). This three-factor model of PANSS was originally proposed by Kay *et al.*¹³⁰ However, multiple-factor structures have been suggested for PANSS, including the original three-factor model, a four-factor model and, more commonly, a five-factor model.¹³¹ Using confirmatory factor analysis on a large data set ($n = 5769$), van der Gaag *et al.*¹³¹ tested the fit of 25 published five-factor models; the results indicated that it was not possible to find a fit of these models. Further analysis of the same data set using a 10-fold cross-validation identified a five-factor model with the following subscales: (1) positive, (2) negative, (3) agitation–excitement, (4) depression–anxiety and (5) cognitive.¹³² This model of PANSS was used for the FOCUS trial. As the PANSS has a 1 (absent) to 7 (severe) rating scale, each participant is allocated a minimum score of 30 even if they have no symptomology. As noted by Leucht *et al.*,¹³³ this poses a significant challenge to understanding percentage change on PANSS, as percentage change is underestimated if 30 minimum points are not subtracted from the total score before calculating percentage change. Therefore, for the analysis of PANSS percentage change for the FOCUS trial, we rescaled the PANSS as recommended by Leucht *et al.*¹³³ The commissioned call specified that the minimum duration of follow-up should be 12 months. The primary outcome was therefore specified as PANSS total score at 12-month follow-up from the end of the 9-month treatment window.

Secondary outcomes

Positive and negative symptoms

These were measured by PANSS as described in the preceding section.

Hallucinations and delusions

The PSYRATS¹³⁴ is a semistructured interview consisting of 12 items assessing aspects of voice-hearing, such as frequency, volume, distress and disruption caused, and six items assessing aspects of unusual beliefs, such as preoccupation, distress and disruption. All items are scored from 0 to 4, with higher scores indicating greater severity. Both sections include cognitive and emotional subscales, and the voices section also includes a physical subscale.

Recovery

The Process of Recovery Questionnaire (QPR) was developed in collaboration with service users to assess recovery from psychosis.¹³⁵ A shortened 15-item version was used here.¹³⁶ Participants respond using a five-point scale ranging from 'disagree strongly' to 'agree strongly'. Items include 'I feel better about myself' and relate to the preceding 7 days.

Social and occupational function

The Personal and Social Performance (PSP) scale¹³⁷ assesses functioning in four key areas: (1) socially useful activities, (2) personal and social relations, (3) self-care and (4) disturbing and aggressive behaviour. A score is allocated out of 100, with higher scores indicating better functioning.

Depression

The CDSS¹³⁸ is a structured interview measure with nine items. The items include assessment of hopelessness, feelings of guilt and suicidal ideation. For each section, the assessor can score the client between a score of zero (absent) and three (severe). Therefore, possible scores range from 0 to 27. The measure was incorporated into the PANSS interview during the assessment of depression.

Anxiety

The Anxious Thoughts Inventory (AnTI)¹³⁹ is a 22-item, self-report questionnaire designed to measure aspects of worry. Each question is scored from one (almost never) to four (almost always). The measure has a three-factor structure comprising (1) social worry, (2) health worry and (3) meta-worry. The seven-item meta-worry scale only was included in the FOCUS trial. This subscale includes statements, such as 'I worry that I cannot control my thoughts as well as I would like to'.

Substance use

The Alcohol Use Disorders Identification Test (AUDIT) was developed by the World Health Organization (WHO). It consists of 10 questions relating to alcohol use, with cut-off scores to identify hazardous drinking levels. Scores range from 0 to 4 on each item, with total AUDIT scores ranging from 0 to 40.¹⁴⁰ The higher the score, the more severe the alcohol use-related problems. AUDIT has been found to be reliable when used with participants with first-episode psychosis.¹⁴⁰

The Drug Abuse Screening Test (DAST)¹⁴¹ consists of 10 items relating to recent drug use. Participants are asked to provide a dichotomous yes/no response to such questions as 'Are you always able to stop using drugs when you want to?'. DAST has been found to reliably identify substance abuse issues in participants with first-episode psychosis.¹⁴⁰

Clinical Global Impression

The CGI consists of three items, each scored on a seven-point scale. The RA was required to rate the severity of the participant's current difficulties from one (not at all ill) to seven (extremely ill). This was completed at all time points. At 9 and 21 months only, the RA also rated change in the participant's presentation since baseline. This was rated from one (very much improved) to seven (very much worse). In addition, at each time point, the participant was asked to rate the perceived severity of their own difficulties from one (no mental health problems) to seven (very severe mental health problems).

Measurement of adverse events and effects

To ensure a thorough review of adverse events (AEs) and effects, we used a number of methods to identify and report AEs including Health Research Authority (HRA) standard operating procedure (SOP), guidance from our Trial Steering Committee (TSC) and Data Monitoring and Ethics Committee (DMEC) and guidance recommended by Klingberg *et al.*¹²⁶ and a bespoke patient-rated adverse effects measure, developed for the FOCUS trial. Each will be outlined in more detail.

The HRA requires all non-Clinical Trials of an Investigational Medicinal Product (CTIMPs) to report the following AEs, when the chief investigator considers the event related and unexpected: death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, consists of a congenital anomaly or birth defect and is otherwise considered medically significant by the investigator. In addition to this list of AEs, our DMEC and TSC advised that self-harm and harm to others also be included. All such events were reported by RAs and therapists to the chief investigator. As per HRA policy, serious adverse events (SAEs) were reported to the Research Ethics Committee (REC) if they were deemed by the chief investigator to be related to trial proceedings and unexpected. To minimise the potential for bias, all AEs were also reviewed by an independent clinician who was a member of the independent DMEC. If the independent clinician considered the event both related and unexpected, then it was reported to the REC.

In addition to the above, for the purpose of the trial, we also defined adverse effects in the trial protocol in line with Klingberg *et al.*^{125,126} as:

1. death caused by suicide
2. suicide attempt
3. suicidal crisis (explicit plan for serious suicidal activity without suicide attempt) as defined in CDSS, item 8, rating 2)
4. severe symptomatic exacerbation, defined by the CGI, which includes ratings of illness severity, changes in overall clinical status, and therapeutic effects. A rating of CGI 2 as six or more and CGI 1 as six or more would be regarded as a severe AE.

In order to better evaluate the adverse effects of trial participation, the adverse effects measure was developed for the FOCUS trial. Participants rated 27 statements on a five-point scale from 'not at all' to 'very much'. Statements included 'taking part took up too much time' and 'I did not like or feel I could trust the FOCUS team members'. A free-text box was also provided for participants to record any additional details about their experience of taking part in the FOCUS trial. This measure was either provided following the final assessment, or at the point of withdrawal for participants who left the trial early. The measure was completed anonymously and was optional.

Other measures including psychological processes

Appraisals of voices

The Interpretation of Voices Inventory (IVI)¹⁴² is a 26-item measure consisting of cognitive and metacognitive appraisals of voice-hearing. The IVI has three subscales that relate to (1) positive beliefs about voices, (2) metaphysical beliefs and (3) beliefs about loss of control. Participants respond on a four-point scale from 'not at all' to 'very much' to indicate how much they endorse each belief. Items include 'they will take over my mind' and 'they are a sign that I am evil'.

Appraisals of paranoia

The Beliefs about Paranoia Scale¹⁴³ contains 18 items relating to paranoia, such as 'my paranoid thoughts worry me' and 'paranoia is normal'. The scale has been found to have three subscales, namely (1) negative beliefs about paranoia, (2) beliefs about paranoia as a survival strategy and (3) normalising beliefs. The three-factor structure has been validated in a large clinical sample.¹⁴⁴

Beliefs about self and others

The Brief Core Schema Scale (BCSS)¹⁴⁵ is a 24-item measure assessing beliefs about self and others. It consists of four subscales: (1) positive beliefs about self, (2) negative beliefs about self, (3) positive beliefs about others and (4) negative beliefs about others. Participants respond 'yes' or 'no' to a question about whether or not they endorse each belief and then, if they reply 'yes', state how much they believe this on a scale from 1 (believe it slightly) to 4 (believe it totally).

Working memory

The letter–number span (LNS)¹⁴⁶ was completed at baseline and 9 months only and was read aloud to the participant by the RA. In this test, a participant is presented with a string of letters and numbers and asked to respond by reciting first the numbers in ascending numerical order and then the letters in alphabetical order. The sequences provided begin with two items (e.g. D-6) and increase until they are seven items long (e.g. C-7-G-4-Q-1-S). There are four sequences of each length and the test is stopped when the participant answers all four of any one length incorrectly. The highest possible score is 24.

Attachment

The Psychosis Attachment Measure (PAM-SR)¹⁴⁷ is a 16-item measure of adult attachment styles that was developed specifically for use with individuals with psychosis. The PAM-SR has two subscales relating to anxious attachment and avoidant attachment styles. It has been found to be a reliable and valid measure.¹⁴⁷

Stigma

The Internalised Stigma of Mental Illness (ISMI) scale¹⁴⁸ assesses the individual's experience of stigma. It consists of 29 items, each rated on a four-point scale between strongly disagree and strongly agree. The measure includes items such as 'others think that I can't achieve much in life because I have a mental illness'. It has five subscales – (1) alienation, (2) stereotype endorsement, (3) perceived discrimination, (4) social withdrawal and (5) stigma resistance – and has been found to be reliable and valid.¹⁴⁸

Childhood trauma

The Childhood Trauma Questionnaire (CTQ)¹⁴⁹ was designed to retrospectively assess childhood trauma. It has 28 items on a five-point scale, ranging from 'never true' to 'very often true'. It consists of five subscales – (1) physical abuse, (2) emotional abuse, (3) sexual abuse, (4) emotional neglect and (5) physical neglect – and is thought to be a reliable and valid measure.¹⁴⁹ This measure was administered at 9 months only and delivered in line with a protocol developed in collaboration with members of a service user reference group for managing any distress that could arise from completing this measure. Participants were all offered a list of support services in relation to experience of abuse and offered a follow-up telephone call for the next day.

Semistructured clinical interview for psychosis subgroups

The semistructured clinical interview for psychosis subgroups (SCIPS)¹⁵⁰ assesses areas of life and events before the onset of psychotic symptoms. The items cover psychosocial factors and comorbid conditions that have been proven to be associated with psychosis to allow for the classification of a specified subgroup: traumatic, drug related, anxiety or stress sensitivity. SCIPS was administered at 12-month follow-up (21 months) for participants who reached this time point by October 2015; all other participants completed SCIPS at the end-of-treatment assessment (9 months).

Demographic characteristics were captured for each participant at baseline. These included years in full-time education, ethnicity, the participant's estimate of their DI and duration of untreated psychosis (DUP). Participants were also asked if they considered themselves to be experiencing mental health problems. If they agreed with this, they were asked to rate the degree to which they felt their difficulties to be caused by biological/genetic origins or by life stress/problems or experiences. At each assessment time point, a record was taken of a participant's current medication. This included dose and duration of time taking clozapine or duration of time since discontinuation of clozapine and the reason for discontinuation. Augmentation with a second antipsychotic was also recorded, as well as other medications for both mental and physical health.

Unless specified above, each outcome measure was administered at baseline and subsequently at 9 and 21 months by RAs who were trained in the use of all the instruments and scales.

Participants were offered choices regarding the length of the assessments, including the option of breaks and multiple visits.

Economic assessment

Health economics

At each face-to-face assessment, and additionally at assessment by telephone at 3, 6, 13 and 17 months, an economic patient questionnaire (an assessment of health service receipt) was completed with each participant. See *Chapter 5* for more detail regarding this measure. For those participants who received psychiatric inpatient care during the trial, a psychiatric hospital record was also completed by screening their medical records for services received while hospitalised.

The EuroQoL-5 Dimensions (EQ-5D)¹⁵¹ health questionnaire assesses health outcomes and can be used across a range of health conditions. Participants are asked to rate each item in relation to their health on that day. The items rated are mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Participants then rate their health that day between 0 (the worst health imaginable) and 100 (the best health imaginable). The EQ-5D has been found to have acceptable validity among participants with a schizophrenia diagnosis.¹⁵²

Trial interventions

The intervention to be assessed was CBT. This was delivered by appropriately qualified psychological therapists over a 9-month period. Therapists were employed at NHS band 7, which is the starting point for most psychological and nurse therapists and is representative of CBT delivered within NHS services. Participants were offered up to 30 hours of CBT on an approximately weekly basis during the treatment window. The sessions were provided on an individual basis. Most therapy appointments were delivered in the participants' own homes to help increase the acceptability and accessibility of the intervention.

The CBT was based on a specific cognitive model⁶³ and was manualised.¹⁰⁴ For a more detailed outline of the intervention, see Pyle *et al.*¹²⁷ The specific CBT interventions used were dependent on the individual formulation, but had to be consistent with the intervention model. The range of permissible interventions was provided in published treatment manuals.^{64,153} The therapy was flexible, but aimed to involve four phases: (1) assessment, engagement and formulation, (2) change strategies, (3) longitudinal aspects and (4) consolidation. Key milestones were included in each phase. The aims of CBT were to reduce distress (particularly that associated with psychotic symptoms) and to improve quality of life, often by changing the impact of psychotic experiences and beliefs. The CBT was delivered in a collaborative relationship between the participant and therapist and addressed the problems and goals that were agreed between the participant and therapist. Therefore, target of treatment could include positive symptoms of psychosis, social relational issues and issues of comorbidity including anxiety and depression. Key therapeutic principles included formulation, normalisation, collaboration and evaluation of the client's appraisals of and responses to psychological phenomena.

There was an emphasis on encouraging participants to undertake between-session practice, as research evaluating components of CBT as mechanisms for change suggests that CBT is more effective if between-session tasks are used.¹⁵⁴

By the third session it was expected that there would be a shared list of problems and goals, and shared formulation. It was expected that, by session 12, there would be a shared longitudinal formulation. Milestones regarding formulation were important given the evidence to suggest that formulation is a core component of CBT.¹⁵⁴

Fidelity to the treatment manual

The therapists received weekly CBT-style clinical supervision from the central site to ensure fidelity to the treatment protocol. Additional fortnightly clinical supervision was provided by clinical supervisors, or research site leads, to deal with site-specific clinical issues and ensure that local governance arrangements were followed. All central and local clinical supervisors had expertise and appropriate training in CBT.

To ensure fidelity to the treatment protocol and assess the quality of the therapy delivered, trial therapists regularly submitted audio-recordings of FOCUS trial therapy sessions. These sessions were rated on the Cognitive Therapy Scale – Revised (CTS-R) by the therapist's central supervisor and detailed feedback was provided. Emphasis was placed on therapists submitting sessions across a range of participants, including sessions that they may be finding difficult as a result of obstacles (e.g. thought disorder). At quarterly therapist training days, group-based CTS-R therapy session ratings were carried out. Therapy sessions were attended by trial therapists, clinical supervisors, the principal investigator and site leads. All trial therapists received a group CTS-R rating at least once.

Fidelity to the treatment protocol was also monitored by analysing data on the content of the CBT sessions. Following every CBT session, based on the treatment protocol, therapists completed a record sheet designed to capture the key elements of CBT (e.g. agenda setting, homework setting/review) and what specific CBT strategies were used with the client (e.g. developing a maintenance formulation, specific cognitive, behavioural and meta-cognitive change strategies). Data were analysed to see if the milestones in the treatment protocol were being met (e.g. a maintenance formulation by session 4) and to check for any site differences in fidelity to the treatment protocol. At each therapist training day, the analysis of the fidelity data were presented and discussed.

The control condition was TAU. Referrers were not asked to withhold any treatment. All participants were required to have an allocated keyworker or care co-ordinator and, therefore, should have been receiving regular outpatient follow-up from a multidisciplinary team within secondary mental health services or from an inpatient setting.

Research assistant training and supervision

All RAs received initial training in the outcome measures from the FOCUS trial co-applicants and the trial manager. Initial training on PANSS was delivered by a PANSS Institute certified trainer who was a co-applicant on the FOCUS trial (Professor Thomas Barnes). RAs were required to complete role plays of the PANSS interview and be observed by a senior clinician before conducting the PANSS interview with participants. In addition, RAs were required to demonstrate a minimum interclass correlation coefficient (ICC) of 0.80 on the PANSS gold standard rating provided by Professor Barnes. In addition to training on the outcome measures, RAs were also given training from senior clinicians in clinical risk assessment, and conducting clinical assessment and supporting service users who disclose trauma and abuse (given the use of the CTQ at the end-of-treatment assessment). All RAs were required to complete Good Clinical Practice training from NIHR.

All RAs were supervised by the trial manager on a weekly basis. As the FOCUS trial was a multisite RCT, this supervision was done over the telephone, except in Manchester where it was completed face to face. The agenda for trial management supervision had a specific focus on the recruitment and retention of participants, data quality and assurance (in particular a check on the accuracy of PANSS scores) and a review of blind breaks, withdrawals and SAEs. Trial management supervision provided an opportunity to problem-solve recruitment and retention difficulties, assurance with data quality and systematic reporting of blind breaks and evaluation of how to minimise future breaks and systematic reporting of withdrawals and SAEs. All RAs attended a fortnightly group conference with the trial manager to share learning and best practice regarding recruitment and to ensure consistency across the sites in scoring the primary outcome measure. In addition, RAs received local clinical supervision from the principal investigator at their site. This covered clinical assessment and risk management, compliance with local NHS policy and procedure, and time management.

Research assistant PANSS consensus days were held on 14 occasions over the lifetime of the trial. At PANSS consensus days, the RAs were required to independently rate a PANSS interview. The ICC across all RAs' ratings was calculated for each PANSS consensus day. The mean ICC was 0.83 [standard deviation (SD) 0.06] using single measures and 0.96 (SD 0.04) using average measures, demonstrating a good level of inter-rater reliability across the FOCUS trial assessors.

Randomisation and blinding

Randomisation (at the individual level) was independent and concealed, using randomised permuted blocks of random size (blocks of four or six) and stratified by site. The Centre for Healthcare Randomised Trials (CHaRT), Health Services Research Unit, University of Aberdeen, a fully registered (registration number 007) UK Clinical Research Collaboration Clinical Trials Unit (CTU), provided advice regarding the development of the randomisation algorithms and was also consulted regarding the web-based technology. Randomisation was undertaken using OpenCDMS (Open Clinical Data Management System), a web-based system developed with the Mental Health Research Network that has been successfully used in several multisite trials. Utilising this web-based technology ensured that randomisation was centralised, preventing the investigators who were enrolling participants from predicting the randomisation sequence and, therefore, avoiding selection bias. Assessors were blind to treatment allocation. Masking was maintained using a wide range of measures, such as separate offices for therapists and researchers; protocols for answering phones, message taking and secretarial support; separate diaries; and security for electronic randomisation information. When accidental blind breaks did occur, these were reported to the trial manager, and, when possible, a second RA who remained blind to allocation independently rated the assessment. The DMEC and TSC regularly monitored blind breaks by each centre, and implemented corrective action if necessary. Outcome analyses were repeated, excluding those participants for whom a blind break had occurred, to determine the robustness of the findings. Following baseline assessment, eligible participants were randomised within 2 working days. Each randomised allocation was made known to the trial manager (in order to monitor adherence to the randomisation algorithm), the trial administrator and trial therapists by e-mail. The allocation was also made known to the participant by letter, sent by the trial administrator. Blinding of the allocation code was maintained for RAs until all outcome measures for all participants had been collected.

Patient and public involvement

Two co-applicant members of the trial management group are employed as user-researchers (SS and RB). Both contributed to the development of the study protocol, and to oversight of the study during the lifetime of the trial through regular attendance at trial management meetings and involvement with training staff. These two co-applicants also wrote the end-of-study information sheet for participants. In addition, both the trial DMEC and TSC include a service user representative. All trial-specific materials, such as PISs, were developed with patient and public input from the Psychosis Research Unit Service User Reference Group (SURG), the members of which all have experience of psychosis. A key example of the SURG members' valuable contribution was the recommendation for a standardised protocol for managing distress arising from sensitive disclosures during trial assessments. This included offering a telephone contact within 48 hours of assessments to check on well-being. Along with the key patient and public involvement (PPI) contributions described above, Rory Byrne and Suzy Syrett along with a third user-researcher (Caroline Asher) also undertook an add-on qualitative study to evaluate trial participants' experiences of CBT. All qualitative interviews, transcriptions and analyses for this study were user led.

Change to the protocol

During the lifetime of the trial, some aspects of the original protocol were changed. All changes were approved by the DMEC, TSC, funder and REC. A summary of these changes can be found in *Table 1*.

Statistical methods and trial analysis

Ground rules for the statistical analysis

The trial analysis followed a statistical analysis plan (SAP), which was agreed by the DMEC. The SAP was published on the CTU's website in advance of pre access to data and, therefore, pre analysis and can be found at <http://w3.abdn.ac.uk/hsru/chart/publicfiles/sapfocus.pdf> (accessed 23 November 2018).

The main analyses were based on the intention-to-treat (ITT) (i.e. analyse as randomised) principle and took place after full recruitment and follow-up. Baseline and follow-up data were summarised using appropriate descriptive statistics and graphical summaries. Statistical significance was at the two-sided 5% level with corresponding confidence intervals (CIs) derived. There was no adjustment for secondary outcome CIs for multiple testing. All analysis was done using Stata® version 14 software (StataCorp LP, College Station, TX, USA).

TABLE 1 Details of the protocol amendments approved by NRES Committee North West – Lancaster

Details of the protocol amendment	Protocol version	Date of approval by the REC
Change of inclusion criteria specifically relating to clozapine augmentation with another antipsychotic medication from 'Treatment for ≤ 24 weeks at a stable dose of ≥ 400 mg of clozapine a day, unless the size of the dose was limited by side effects, without remission of psychotic symptoms, or have discontinued clozapine because of adverse reactions (including agranulocytosis) or lack of efficacy in the past 24 months' to 'Treatment of clozapine at a stable dose of ≥ 400 mg or more (unless limited by tolerability) for ≤ 12 weeks, or if currently augmented with a second antipsychotic that this has been given for at least 12 weeks, without remission of psychotic symptoms, or have discontinued clozapine because of adverse reactions (including agranulocytosis) or lack of efficacy in the past 24 months'. The number of items in the economic patient questionnaire was reduced (time use items removed as these were not necessary for the economic evaluation). The version of the EQ-5D was updated to the most current five-point version and the QPR was reduced to the 15-item version (following publication of a confirmatory factor analysis indicating that the 15-item version was a better model for this measure)	V2, 1 November 2012	4 December 2012
Changes to the protocol that related to (1) notifying teams of the outcome of randomisation and (2) reflecting the change in the CTU from Glasgow to Aberdeen	V3, 4 February 2013	21 March 2013
Inclusion of three measures: (1) CGI scale (patient and rater version), (2) measure of memory (Maryland LNS) and (3) the adverse effects measure (A and B for completers and early discontinuation). Addition of a nested qualitative study in the trial to assess the acceptability of CBT	V4, 18 August 2013	2 September 2013
Addition of the SCIPS and £10 token of appreciation for the participants who take part in the nested qualitative study	V5, 19 March 2014	9 May 2014
Removal of Heinrichs Quality-of-Life Scale. Owing to an administrative error, when the battery of assessments was initially collated, the Heinrichs Scale was taken from the appendix of the original publication, which only contained four items, instead of 21 items. This mistake was not identified and, therefore, at the time the amendment was submitted only four items had been administered to FOCUS trial participants. There were a number of other secondary outcome measures that related conceptually to quality of life, including the Personal, Social and Performance Subscale, the QPR and the EQ-5D. It was agreed with the independent DMEC, TSC and funder that we should remove this measure. Change to the protocol also included inviting participants at the end of the final assessment (21 months) who were at the Manchester site to take part in an experimental study looking at the impact of manipulating response styles on distress and frequency of words detected in an ambiguous auditory task. In addition, three self-report measures of perseverative thinking, rumination and anxiety were added at the final assessment (21 months) for the Newcastle upon Tyne site only	V6, 30 April 2015	20 May 2015
Addition of a nested qualitative study with the trial therapists to explore the therapists' experiences and views of delivering Cognitive Behavioural Therapy for Psychosis (CBTp) on the FOCUS trial	V7, 27 June 2016	26 July 2016
V, version.		

Sample size

The FOCUS trial was designed to estimate treatment effects across a range of outcomes, in addition to psychiatric symptoms. Therefore, we powered the study to detect a generic ES of 0.33. A sample size of 194 participants per group was required to provide 90% power to detect a difference in means using a *t*-test with a significance level of 5%. To allow a drop-out rate of 20%, 485 participants (97 per site) were required.

Primary and secondary outcome analyses

The primary outcome, PANSS total score assessed at 21 months, was analysed using a linear model with adjustment for prespecified baseline covariates (baseline score, sex and age) and including a random effect for site. Treatment effects over time were explored using repeated-measures mixed-effects models. A sensitivity analysis of missing PANSS data was conducted; these models explored the robustness of the treatment estimates, imputing missing outcome data using multiple imputation.¹⁵⁵ If baseline PANSS data were missing, data were imputed with the centre specific mean.

Secondary outcomes were analysed in a similar way using a linear model and adjusted for prespecified baseline covariates; for the CGI improvement score, no adjustment for baseline score was made as this was not collected.

Planned subgroup analysis

Subgroup analyses explored the potential moderating effect of covariates through the use of treatment-by-subgroup interactions. The subgroups explored were as follows:

- age
- sex
- positive and negative core beliefs from the BCSS
- working memory using the LNS
- trauma in childhood using CTQ collected at 9 months
- substance use from DAST
- alcohol use from AUDIT
- difficulty with abstract thinking using item N5 on the PANSS questionnaire
- conceptual disorganisation using item P2 on the PANSS questionnaire
- duration of illness
- duration of untreated psychosis
- age at onset of psychotic symptoms
- dose of clozapine
- number of antipsychotic drugs prescribed
- attachment using the attachment avoidance subscale taken from PAM-SR
- psychosis subgroups.

All subgroups were captured at baseline unless otherwise stated.

Risk modelling

We modelled response to treatment, defined as change in PANSS total score from baseline to 21 months, using a general linear model. The baseline covariates included age, age at onset, DI, duration of untreated psychosis, number of antipsychotics, dose of clozapine, PANSS items on conceptual disorganisation and difficulty in abstract thinking, sex, memory and treatment allocation. We explored the impact of missing data at 21 months using a range of strategies, for example using 9-month data if available and multiple imputation based on observed covariates.

Complier-average causal effect analysis

We used instrumental variable methods to estimate the complier-average causal effect (CACE) to explore the impact of compliance with allocated treatment on effect estimates. We considered six or more sessions as a measure of compliance. Randomisation was used as the instrumental variable.

Timing and frequency of analysis

A single principal analysis was carried out when the final participant reached the 21-month time point.

Economic evaluation methods

Aims and objectives

The economic evaluation was a within-trial analysis using patient-level data collected during baseline and follow-up FOCUS trial time points. The aim was to estimate the cost-effectiveness of usual care plus CBT, relative to usual care alone, for people unable to tolerate, or with an inadequate response to, clozapine, in a UK secondary care setting.

Using the patient-level data available from the trial, the objectives for the economic evaluation were to:

- estimate the costs of health and social care in the intervention and TAU groups and assess whether or not there were differences between groups
- estimate the QALYs of participants in the intervention and TAU groups and assess whether or not there were differences between groups
- assess whether or not any additional benefit is worth any additional cost.

Descriptive analysis and data manipulation was conducted using IBM SPSS (Statistical Product and Service Solutions) Statistics version 23 (IBM Corporation, Armonk, NY, USA). The main statistical analyses and estimation of net benefit statistics and cost-effectiveness analysis were conducted using Stata® version 13.

Intervention and comparator, study sample, time horizon and perspective

The study sample comprised all of the participants randomised in the trial. The time horizon of the economic evaluation was 21 months (in line with the final trial follow-up). Costs, QALYs and the secondary outcome measures were estimated from baseline to the end of the scheduled follow-up, to estimate the incremental cost-effectiveness of the CBT intervention. The perspectives for the primary analysis were health and social care service providers (costs) and service users (health benefits). Costs and outcomes were discounted at a rate of 3.5%, in line with UK guidelines.¹⁵⁶

Measure of health benefit

Quality-adjusted life-years were the measure of health benefit used in the primary analysis, on the premise that the intervention and comparator would have a differential impact on participants' overall health status. QALYs were estimated from the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), and associated utility tariffs¹⁵⁷ completed at baseline, 9 months and end of scheduled follow-up (21 months). Resulting health status profiles were converted to utility values using the most recently published utility tariffs for the EQ-5D-5L for a UK population.¹⁵⁷ These utility values represent the weight of preference for each health state of a sample of 912 adults in England.

The EQ-5D has been shown to be a valid and responsive measure of health in people with psychosis.^{152,158} The QALY and the EQ-5D are the measures recommended for economic evaluations by NICE.¹⁵⁶ However, the EQ-5D is not a condition-specific measure, and so may miss differences in symptoms that are important to service users. Accordingly, the measure of health benefit was varied in the sensitivity analysis.

Total QALYs were estimated as follows:

$$QALY = \sum [(U_i + U_{i+1})/2] \times (t_{i+1} - t_i). \quad (1)$$

Here, U = utility value and t = time between assessments. The time between assessments is the time from baseline data collection to 21-month follow-up; this varied by participant. QALY calculations also accounted for mortality during the trial period.

Resource use and costs

Direct costs of health-care services used by trial participants were estimated for the primary analysis. The total direct costs of service use for each trial arm were estimated by summing the costs of each

resource used to provide health and social care. Data on the resources used for each participant were collected using a tailored service use questionnaire at baseline and follow-up (3, 6, 9, 13, 17 and 21 months). The questionnaire was adapted from those used successfully in previous large mental health-based integrated clinical and economic trials, including two trials of first- and second-generation antipsychotic drugs in people with severe schizophrenia.^{159,160} In addition, it was anticipated that use of psychiatric inpatient care would be a key component of total cost. Accordingly, data on psychiatric hospital admissions were also collected by case note review. When there were discrepancies between case note and patient reports on admission or length of stay, the case note review data were used. This was based on the assumption that the patient report data may be subject to problems of participant recall.

Services covered by the questionnaire included hospital inpatient stays (psychiatric and non-psychiatric), hospital outpatient visits, primary care services (e.g. GP), community care services (e.g. CMHT) and accident and emergency services.

The cost of providing CBT in the intervention arm was added to the costs of other services used by participants to estimate the total costs of TAU plus CBT. The number of CBT sessions attended by each participant was recorded. The protocol specified that participants would receive up to 30 hours of CBT (rather than a set number of sessions) as shorter sessions may be more appropriate for some people. CBT sessions were usually delivered at home; thus, the cost of a home-based CBT session was applied to the number of sessions to calculate a per-participant cost of CBT.

The unit costs of NHS and social care services were derived from national average unit cost data. These unit costs are published annually in the NHS reference costs database,¹⁶¹ and in the *Unit Costs of Health and Social Care* document published by the Personal Social Services Research Unit (PSSRU), University of Kent.^{162–164} The price year was 2016 and costs are presented in Great British pounds (GBP).

Missing data

Analysis of the economic data was based on ITT principles, namely that outcome data for all trial participants were included in the analysis regardless of whether or not the participant completed the planned treatment. Missing data occurred as a result of both loss to follow-up and incomplete data collection.

Single imputation was used to impute values for missing baseline data.¹⁶⁵ Multiple imputation (MI) was used to impute missing cost and utility data and passively calculate missing total cost and QALYs for each participant. MI was used for the primary and sensitivity economic analyses. MI of both costs and QALYs is increasingly recognised as an appropriate approach to deal with missing observation and missing follow-up data.¹⁶⁶ Missing cost and utility data were treated as missing at random. Missing values were imputed for each time point, rather than as total values covering the whole follow-up period. To ensure that all available data were used, we imputed values by health-care category for costs (inpatient, outpatient and primary/community care) and utility, rather than as total costs or QALYs.

Imputations were conducted in Stata® version 13, using predictive mean matching and sequential chained equations. The choice of independent variables for the imputation regression models was based on initial descriptive analyses and regression analyses. These were used to identify key baseline and follow-up variables (e.g. age, sex, PANSS score) that were significantly associated with either costs or outcomes. These initial analyses were informed by published literature.^{159,160}

Primary analysis

The incremental cost-effectiveness ratio (ICER) was the primary measure of interest for the economic evaluation. Rather than considering costs and health outcomes separately, the ICER is a joint measure of both. It is calculated by dividing the difference in costs (net costs) by the difference in QALYs (net QALYs)

between any two interventions. For this analysis, the ICER represents the additional cost of CBT per additional QALY gained compared with usual care.

$$\text{ICER} = \frac{\text{Cost}_{\text{CBT}} - \text{Cost}_{\text{TAU}}}{\text{Utility}_{\text{CBT}} - \text{Utility}_{\text{TAU}}}. \quad (2)$$

Regression analysis was used to estimate the net costs and QALYs of CBT. Key covariates were included in the regression models to control for factors that may influence costs or QALYs. The covariates for these analyses were identified using the approach outlined for the MI described in *Missing data*.

The estimates of net costs and health outcomes from the regression were bootstrapped¹⁵⁶ to simulate 10,000 pairs of incremental cost and QALY outcomes of the FOCUS trial intervention. This captures the relationship between costs and QALYs and looks at how the pairs of net costs and QALYs are distributed on the cost-effectiveness plane. This allowed parameter uncertainty to be captured in our economic evaluation and enabled the undertaking of cost-effectiveness acceptability analysis, which is recommended by NICE for health technology appraisals.¹⁵⁶

The ICER measures the cost per QALY gained by an intervention, which then raises the question of whether or not the additional cost to service providers of a QALY is economically acceptable. To help address this, the ICER can be compared with benchmark or threshold values of how much decision-makers may be willing to pay to gain 1 additional QALY. This is analogous to placing a monetary value on 1 QALY. However, in the UK there is no universally agreed cost-effectiveness threshold value. One commonly reported threshold in the UK, from NICE, is approximately £20,000 to £30,000 per QALY.¹⁵⁶ However, some argue that this may have decreased in recent years as expenditure has been constrained.¹⁶⁷ In 2013, the threshold was re-estimated to be £18,317 per QALY (taking into account expenditure breakdown and mortality), although this was noted to be variable depending on other factors (e.g. disease category and primary care trust).¹⁶⁸ In February 2015, this estimate was revised to ≈£13,000 per QALY.¹⁶⁹ Recognising this lack of consensus, the monetary value of our simulated QALYs used a mid-estimate threshold value of £15,000 per QALY gained. This was varied from £0 to £30,000 to reflect a range of hypothetical thresholds for decision-makers' willingness-to-pay for an additional QALY [willingness-to-pay thresholds (WTPTs)], from nothing (i.e. they are interested only in the lowest-cost option) to £30,000.

Each of the net QALY estimates from the bootstrap simulation results was revalued by multiplying it by a WTPT. Using these revalued QALY estimates, a net benefit statistic for each pair of simulated net costs and net outcomes was produced as:

$$\text{Net benefit} = (O \times \text{WTPT}) - C, \quad (3)$$

where O is the net outcome score and C is the net cost. This process was repeated for the WTPT values of interest to generate a cost-effectiveness acceptability curve. For the simulated net cost and QALY pairs, the cost-effectiveness acceptability curve shows the probability that the intervention is cost-effective for each WTPT value (i.e. provides a positive net benefit). This probability varies at different ICER threshold values. For example, if decision-makers are willing to pay more for an additional QALY, the additional health benefits from an intervention would become more valuable. A cost-effectiveness acceptability curve was used to plot the proportion of bootstrapped simulations in which the net benefit of an intervention is equal to or greater than zero for each WTPT value.

Sensitivity analysis

Sensitivity analyses were used to test the impact of the study design on the ICER and results of the cost-effectiveness acceptability analysis. *Table 2* details these.

TABLE 2 Variables assessed in the sensitivity analysis

Parameters	Rationale	Measure
Complete-case analysis	If the level of missing observations for the cost and QALY measures is high (> 10%), then MI to estimate these data is more open to bias and imprecision. Complete-case analysis may also be biased and the subsample may not be representative of all trial participants. These factors make it important to analyse both sets of data and assess whether or not the results indicate similar conclusions	Costs and QALYs for participants with complete data at 21-month follow-up
Time horizon	It was anticipated that results may vary at different time horizons, depending on when (if any) effect of CBT occurred and how long this was sustained for	Baseline to 9 months costs and QALYs
Measure of health benefits	The EQ-5D-5L is a general measure of health, recommended for use in economic evaluations to calculate a generate QALY. However, there is debate about whether or not this is sensitive to clinically relevant changes in mental health. Accordingly, the impact on the results of using mental health-specific measures was assessed. The alternative health benefit measures used were clinically relevant improvements on the PANSS and QPR. The PANSS is a commonly used scale for measuring symptoms in schizophrenia, and the primary outcome of the trial. The QPR captures items of recovery that are important to people with a psychosis diagnosis	The PANSS and QPR were used to estimate whether or not participants had a clinically relevant improvement in symptoms or recovery at the 25% and 50% levels ¹²⁹
Utility value set to estimate QALYs	Until recently, utility scores for the EQ-5D-5L were calculated using a crosswalk method that mapped values from the three-level version (van Hout <i>et al.</i> ¹⁷⁰). In 2016, a new value set, specific to the five-level version, was released (Devlin <i>et al.</i> ¹⁵⁷) and was used for the primary analysis. The crosswalk value set provides a link between the three- and five-level versions of the EQ-5D, allowing some comparison between studies	The crosswalk value set was used to estimate QALYs (van Hout <i>et al.</i> ¹⁷⁰)
Inclusion of indirect costs/benefits of employment	Health measures may not fully reflect the impact of treatment on non-health aspects that are of benefit to participants or society. Employment and productive activity is one such area. To minimise participant burden, limited information was collected at follow-up about whether the participant was employed, engaged in other productive activity or unemployed. Detailed information about type of paid or unpaid employment or time spent in different productive activities was not collected. Accordingly, a measure of whether or not the participant was engaged in any productive activity was used to estimate the net cost per person employed	Whether or not the participant was in paid or unpaid employment, education or training at the 21-month follow-up assessment

Chapter 3 Baseline results

Reliability of outcome measures

The reliability of all outcome measures (total scores and subscales) at baseline were assessed using Cronbach's alpha reliability statistic. The reliability statistics can be seen in *Table 3*. The reliability of all measures was acceptable (as indicated by $\alpha \geq 0.7$) except for PANSS positive, PANSS excitement, PANSS emotional distress and ISMI scale stigma resistance.

TABLE 3 Reliability alpha

Measure	α
PANSS total	0.78
PANSS positive	0.58
PANSS negative	0.73
PANSS disorganised	0.75
PANSS excitement	0.51
PANSS emotional distress	0.63
CDSS	0.77
AnTi	0.84
QPR	0.93
AUDIT	0.80
DAST	0.80
PSYRATS – delusion	0.86
PSYRATS – auditory hallucinations	0.95
PSYRATS unusual beliefs – cognitive	0.82
PSYRATS unusual beliefs – emotional	0.85
PSYRATS voices – cognitive	0.75
PSYRATS voices – emotional	0.94
PSYRATS voices – physical	0.94
PSYRATS voices – loudness	0.87
ISMI scale alienation	0.84
ISMI scale stereotype endorsement	0.73
ISMI scale discrimination experience	0.83
ISMI scale social withdrawal	0.87
ISMI scale stigma resistance	0.68
ISMI scale total	0.92

Participant baseline characteristics

Trial recruitment

In total, 487 participants were recruited from five centres (*Table 4*): 242 were randomised to CBT and 245 were randomised to TAU. The referral pathway by the different service type for the participants randomised overall and by centre is shown in *Appendix 1*. The highest recruiter across all centres was the CMHTs, followed by the clozapine clinic. Participants were recruited to the trial between 1 January 2013 and 31 May 2015 and followed up to March 2017. The trajectory of recruitment from all centres is shown in *Figure 1*.

TABLE 4 Recruitment by centre

Centre	Participants, n (%)					
	Eligible (N = 565)	Ineligible (N = 47)	Declined (N = 31)	Randomised (N = 487)	Randomised to CBT (N = 242)	Randomised to TAU (N = 245)
Manchester	129 (22.8)	11 (23.4)	10 (32.3)	108 (22.2)	54 (22.3)	54 (22.0)
Southampton	121 (21.4)	10 (21.3)	6 (19.4)	105 (21.6)	52 (21.5)	53 (21.6)
Newcastle	109 (19.3)	8 (17.0)	9 (29.0)	92 (18.9)	46 (19.0)	46 (18.8)
Edinburgh	100 (17.7)	6 (12.8)	2 (6.5)	92 (18.9)	46 (19.0)	46 (18.8)
Glasgow	106 (18.8)	12 (25.5)	4 (12.9)	90 (18.5)	44 (18.2)	46 (18.8)




FIGURE 1 Recruitment over time.

Participant flow

Figure 2 shows the Consolidated Standards of Reporting Trials (CONSORT) flow diagram for the trial. Of the patients, 898 were identified as potentially eligible for inclusion in the trial and were referred, and of these 565 were found to be eligible at the referral stage. Of the 78 patients excluded from the trial, 47 were found to be ineligible and 31 declined. Details of the reasons for patients being ineligible at the referral stage and before randomisation are shown in *Appendix 1*. All randomised participants completed the baseline questionnaires. In the CBT arm, 230 participants received treatment; further detail on the number of sessions attended is in *Chapter 5*. At 21 months, 425 participants (87.2%) were included in the primary analysis: there were 10 deaths, 36 participants withdrew from the trial and declined to provide outcome data and a further six were not contactable at follow-up.




FIGURE 2 The CONSORT flow diagram. Reprinted from *Lancet Psychiatry*, Volume 5, Morrison *et al.*, Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial, Pages 633–43, © 2019, with permission from Elsevier.¹⁷¹

Baseline characteristics

Baseline characteristics are shown in *Table 5*. The treatment groups were well balanced. The mean age of participants was 42 years in the CBT group and 43 years in the TAU group; > 70% of participants were male, the majority were unemployed (203 participants in the CBT group and 204 in the TAU group) and 71% were living independently. The median duration of untreated psychosis was 9 months [interquartile range (IQR) 1–24 months] in the CBT group and 18 months (IQR 2–48 months) in the TAU group, and the median DI was 216 months (IQR 132–300 months) and 240 months (IQR 144–300 months) in the CBT and TAU groups, respectively. The mean PANSS total score, the primary outcome, was 82.8 points (SD 13.7 points) in the CBT group and 83.3 points (SD 14.0 points) in the TAU group. The PANSS positive and negative scores were also similar in both groups.

TABLE 5 Baseline characteristics

Characteristic	Trial arm	
	CBT (N = 242)	TAU (N = 245)
Age (to the closest year), mean (SD)	42.2 (10.7)	42.8 (10.4)
Sex, n (%)		
Male	176 (72.7)	173 (70.6)
Female	66 (27.3)	72 (29.4)
Ethnicity, n (%)		
White	222 (91.7)	222 (90.6)
Asian	9 (3.7)	4 (1.6)
Black	5 (2.1)	3 (1.2)
Mixed	4 (1.7)	12 (4.9)
Other	2 (0.8)	3 (1.2)
Refused to answer	0 (0.0)	1 (0.4)
Employment, n (%)		
Paid (full or part time)	10 (4.1)	10 (4.1)
Voluntary	14 (5.8)	16 (6.5)
Education or training	9 (3.7)	5 (2.0)
Other unpaid activity	6 (2.5)	8 (3.3)
Unemployed	203 (83.9)	204 (83.3)
Missing	0 (0.0)	2 (0.8)
Residential status, n (%)		
Inpatient	17 (7.0)	16 (6.5)
Rehabilitation ward	13 (5.4)	8 (3.3)
Support accommodation	39 (16.1)	45 (18.4)
Independent living	172 (71.1)	174 (71.0)
Missing	1 (0.4)	2 (0.8)
Years in full-time education, median (25th, 75th percentile); n	12 (11, 14); 223	12 (11, 14); 229
Duration of untreated psychosis (months), median (25th, 75th percentile); n	8 (1, 24); 195	18 (2, 48); 203
Duration of illness (months), median (25th, 75th percentile); n	216 (132, 300); 227	240 (144, 300); 231

TABLE 5 Baseline characteristics (*continued*)

Characteristic	Trial arm	
	CBT (N = 242)	TAU (N = 245)
Primary outcome, mean (SD)		
PANSS total	82.8 (13.7)	83.3 (14.0)
Secondary outcomes, mean (SD); n		
PANSS positive	24.7 (5.9); 242	25.2 (5.7); 245
PANSS negative	19.3 (6.1); 242	19.4 (6.4); 245
PANSS disorganised	24.7 (6.5); 242	24.8 (6.6); 245
PANSS excitement	18.0 (4.5); 242	17.9 (4.3); 245
PANSS emotional distress	27.0 (5.6); 242	27.4 (5.6); 245
CDSS	7.1 (4.8); 233	7.4 (4.7); 238
AnTI	18.2 (4.8); 226	18.9 (4.9); 236
PSYRATS – delusion	14.3 (5.7); 218	14.9 (5.3); 236
PSYRATS – auditory hallucinations	21.1 (14.1); 214	24.9 (12.6); 200
PSYRATS unusual beliefs – cognitive	9.6 (3.8); 221	9.9 (3.5); 240
PSYRATS unusual beliefs – emotional	4.7 (2.6); 227	5.0 (2.4); 238
PSYRATS voices – cognitive	3.9 (2.8); 224	4.5 (2.5); 213
PSYRATS voices – emotional	4.7 (3.1); 232	5.4 (2.8); 222
PSYRATS voices – physical	5.5 (3.8); 232	6.2 (3.4); 223
PSYRATS voices – loudness	2.5 (1.5); 229	2.6 (1.4); 239
PSP	49.2 (15.5); 242	48.3 (13.5); 245
QPR	48.5 (11.4); 216	47.4 (11.1); 228
AUDIT	4.3 (6.0); 230	3.5 (5.4); 234
DAST	0.7 (1.4); 224	0.7 (1.5); 231
Severity CGI	4.8 (0.9); 158	4.8 (0.8); 162
Participant severity CGI	3.9 (1.4); 152	4.0 (1.6); 157
EQ-5D-5L utility	0.740 (0.201); 223	0.703 (0.225); 230
Diagnosis at baseline, n (%)		
Schizophrenia	209 (86.4)	218 (89.0)
Schizoaffective	28 (11.6)	20 (8.2)
Delusional disorder	2 (0.8)	5 (2.0)
Unspecified psychosis not attributable to a substance or known physiological condition	2 (0.8)	1 (0.4)
Missing	1 (0.4)	1 (0.4)

Note

Reprinted from *Lancet Psychiatry*, Volume 5, Morrison *et al.*, Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial, Pages 633–43, © 2019, with permission from Elsevier.¹⁷¹

Table 6 describes the baseline medication for the trial population; > 90% of participants in both arms were prescribed clozapine. The length of time on clozapine was the same in both groups (median 60 months, IQR 24–120 months). In the CBT group, 19 participants discontinued clozapine, and, in the TAU group, 24 discontinued it, with side effects given as the main reason in both groups. Other antipsychotic medication was taken by 106 participants (43.8%) in the CBT group and 103 (42.0%) in the TAU group. Participants also took other medication, listed in Table 6.

TABLE 6 Baseline medication

Medication	Trial arm	
	CBT (N = 242)	TAU (N = 245)
Prescribed clozapine, n (%)	223 (92.1)	221 (90.2)
Length of time on clozapine (months), median (25th, 75th percentile); n	60 (24, 120); 218	60 (24, 120); 216
Clozapine dose (mg), median (25th, 75th centile); n	400 (300, 525); 221	400 (300, 500); 221
Discontinued clozapine, n (%)	19 (7.9)	24 (9.8)
Length of time discontinued (months), median (IQR); n	9 (5–13); 19	13 (3–20); 24
Reasons for discontinuing clozapine, n (%)		
Side effects	16 (84.2)	23 (95.8)
Lack of efficacy	3 (15.8)	1 (4.2)
Taking other antipsychotic medication, n (%)		
None	136 (56.2)	142 (58.0)
One	99 (40.9)	95 (38.8)
Two	7 (2.9)	7 (2.9)
Three	0 (0.0)	1 (0.4)
Other medication, ^a n (%)		
None	85 (35.1)	81 (33.1)
Antidepressants	113 (46.7)	129 (52.7)
Other mental health medication	52 (21.5)	35 (14.3)
Benzodiazepines	27 (11.2)	30 (12.2)
Medication for the side effects of antipsychotics	27 (11.2)	24 (9.8)
Unknown medication	2 (0.8)	2 (0.8)

a Not mutually exclusive.

Note

Reprinted from *Lancet Psychiatry*, Volume 5, Morrison *et al.*, Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial, Pages 633–43, © 2019, with permission from Elsevier.¹⁷¹

Chapter 4 Outcome and results

Primary outcome

The PANSS total and subscale scores at each time point are described in *Table 7*. *Figure 3* shows the profile for the two treatment groups over the study period. Treatment effect estimates are also included in *Table 7*, based on 425 participants for whom at least one follow-up measurement was available. At 9 months, the total PANSS score was lower in the CBT arm (mean -2.40 , 95% CI -4.79 to -0.02 ; $p = 0.049$), with a standardised ES of 0.16. The mean difference at 21 months was -0.89 (95% CI -3.32 to 1.55 ; $p = 0.475$), with a standardised ES of 0.06. At 9 months, the subscale PANSS positive score was lower in the CBT arm (mean -1.56 , 95% CI -2.53 to -0.59 ; $p = 0.002$), with a standardised ES of 0.24; PANSS excitement was lower in the CBT arm (mean -1.18 , 95% CI -1.85 to 0.50 ; $p = 0.001$), with a standardised ES of 0.28, and PANSS emotional distress was lower in the CBT arm (mean -1.08 , 95% CI -2.02 to -0.13 ; $p = 0.025$), with a

TABLE 7 The PANSS outcome^a

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Cronbach's alpha
Time point	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)				
PANSS total						
Baseline	82.8 (13.7); 242	83.3 (14.0); 245				
9 months	75.2 (15.5); 218	77.8 (14.6); 224	−2.40	−4.79 to −0.02	0.049	0.16
21 months	73.0 (16.7); 209	74.1 (14.8); 216	−0.89	−3.32 to 1.55	0.475	0.06
PANSS positive						
Baseline	24.7 (5.9); 242	25.2 (5.7); 245				
9 months	21.7 (6.6); 218	23.6 (6.2); 225	−1.56	−2.53 to −0.59	0.002	0.24
21 months	21.3 (7.0); 209	22.5 (6.1); 216	−0.85	−1.84 to 0.15	0.095	0.13
PANSS negative						
Baseline	19.3 (6.1); 242	19.4 (6.4); 245				
9 months	18.1 (7.0); 220	18.6 (6.7); 227	−0.49	−1.48 to 0.49	0.327	0.07
21 months	17.8 (6.8); 211	17.5 (6.1); 216	0.29	−0.72 to 1.29	0.578	0.05
PANSS disorganised						
Baseline	24.7 (6.5); 242	24.8 (6.6); 245				
9 months	23.2 (6.4); 218	23.1 (6.0); 225	−0.01	−0.91 to 0.88	0.975	0.00
21 months	22.7 (6.6); 210	22.4 (6.2); 216	0.14	−0.78 to 1.05	0.770	0.02
PANSS excitement						
Baseline	18.0 (4.5); 242	17.9 (4.3); 245				
9 months	16.2 (4.1); 220	17.4 (4.2); 228	−1.18	−1.85 to −0.50	0.001	0.28
21 months	15.4 (3.9); 210	15.9 (4.0); 216	−0.57	−1.26 to 0.12	0.106	0.15
PANSS emotional distress						
Baseline	27.0 (5.6); 242	27.4 (5.6); 245				
9 months	24.1 (6.2); 220	25.4 (6.3); 228	−1.08	−2.02 to −0.13	0.025	0.17
21 months	23.4 (6.6); 210	24.0 (6.0); 216	−0.27	−1.24 to 0.70	0.583	0.04

a Adjusted for baseline score, sex, age and centre.

Note

Reprinted from *Lancet Psychiatry*, Volume 5, Morrison *et al.*, Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial, Pages 633–43, © 2019, with permission from Elsevier.¹⁷¹




FIGURE 3 Profile of PANSS total scores.

standardised ES of 0.17. For PANSS negative and PANSS disorganised, there was no evidence of a difference at either time point. Sensitivity analysis using MI gave similar results (see *Appendix 2*). *Figure 4* shows the site difference and within-site differences for total PANSS score at 9 and 21 months. At 21 months, the Manchester site recorded a greater effect in total PANSS score in favour of CBT.




FIGURE 4 Site differences for PANSS total scores. (a) 9 months; and (b) 21 months. (*continued*)




FIGURE 4 Site differences for PANSS total scores. (a) 9 months; and (b) 21 months.

At the 9-month assessment, a total of 51 blind breaks had occurred. However, 23 of these cases were transferred to a new, independent assessor, meaning that 28 assessments were unblind at the 9-month assessment. At the 21-month assessment, the number of breaks that had occurred was 55. However, 35 of these cases were transferred to a new, independent assessor, meaning that 20 assessments were unblind at the 21-month assessment. Outcome analyses for PANSS were repeated excluding those participants for whom a blind break had occurred; the results are presented in *Table 8*.

The percentage of improvement in PANSS total is shown in *Table 9*. At 9 months, 16 participants (6.6%) in the CBT arm and 11 (4.5%) in the TAU arm had > 50% improvement; the number needed to treat (NNT) was 42. At 21 months, 28 participants (11.6%) in the CBT arm and 14 (5.7%) in the TAU arm had > 50% improvement, and the NNT was 15.

Table 10 shows the effect of time on PANSS total for the sample as a whole. The analysis was adjusted for randomised treatment, age, sex and centre. *Table 10* shows a reduction in PANSS total score of 5.26 at 9 months compared with baseline and a reduction in PANSS total score of 9.1 at 21 months compared with baseline.

TABLE 8 The PANSS total scores excluding participants for whom a blind break had occurred

Time point	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)			
Baseline	82.8 (13.7); 242	83.3 (14.0); 245			
9 months	75.6 (15.5); 194	77.7 (14.5); 222	−2.21	−4.66 to 0.24	0.078
21 months	73.4 (16.7); 193	73.8 (14.6); 214	−0.48	−2.96 to 2.00	0.704

TABLE 9 Improvement in PANSS total scores^a

Improvement	Trial arm, <i>n</i> (%)		NNT	95% CI
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)		
> 25%				
9 months	68 (28.1)	57 (23.3)	18	NNTH 37 to ∞ to NNTB 8
21 months	80 (33.1)	82 (33.5)	318	NNTH 11 to ∞ to NNTB 11
> 50%				
9 months	16 (6.6)	11 (4.5)	42	NNTH 48 to ∞ to NNTB 15
21 months	28 (11.6)	14 (5.7)	15	NNTB 8 to NNTB 81
> 75%				
9 months	2 (0.8)	2 (0.8)	4070	NNTH 57 to ∞ to NNTB 56
21 months	4 (1.7)	2 (0.8)	102	NNTH 78 to ∞ to NNTB 31

NNTB, number needed to treat (benefit); NNTH, number needed to treat (harm).

^a PANSS rescaled.

TABLE 10 The PANSS total effect of time

Time point	Effect estimate	95% CI	<i>p</i> -value
9 months	−5.26	−7.84 to −2.67	< 0.001
21 months	−9.1	−11.71 to −6.48	< 0.001

Secondary outcomes

The PSYRATS subscales at 9 and 21 months are shown in *Table 11*. At 9 months there was a mean difference in favour of CBT for auditory hallucinations (−2.56, 95% CI −4.87 to −0.26; *p* = 0.029) and physical voices (−0.58, 95% CI −1.11 to −0.04; *p* = 0.034). Both subscales were similar in both groups at 21 months. At 21 months the mean difference between groups on emotional unusual beliefs was −0.53 (95% CI −1.05 to −0.00; *p* = 0.049). For the remainder of the PSYRATS subscales, there was no evidence of a difference between the two treatments at 9 or 21 months. Other secondary outcomes were similar with the exceptions of QPR and CGI (*Table 12*).

As indicated in *Table 13*, chi-squared analysis did not indicate any significant difference between the groups regarding access to education, employment or training at either 9 or 21 months.

TABLE 11 The PSYRATS outcomes

Time point	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)			
PSYRATS auditory hallucinations					
Baseline	21.1 (14.1); 214	24.9 (12.6); 200			
9 months	17.8 (14.2); 185	22.4 (13.4); 192	−2.56	−4.87 to −0.26	0.029
21 months	17.1 (14.2); 179	20.3 (14.4); 182	−1.38	−3.75 to 0.99	0.255
PSYRATS delusion					
Baseline	14.3 (5.7); 218	14.9 (5.3); 236			
9 months	12.2 (6.8); 200	13.2 (6.7); 216	−0.42	−1.61 to 0.77	0.493
21 months	11.4 (7.1); 193	12.7 (6.8); 203	−0.76	−1.98 to 0.46	0.224
PSYRATS unusual beliefs – cognitive					
Baseline	9.6 (3.8); 221	9.9 (3.5); 240			
9 months	8.2 (4.5); 201	8.8 (4.3); 216	−0.24	−1.01 to 0.54	0.551
21 months	7.8 (4.7); 194	8.5 (4.4); 205	−0.35	−1.14 to 0.44	0.385
PSYRATS unusual beliefs – emotional					
Baseline	4.7 (2.6); 227	5.0 (2.4); 238			
9 months	3.9 (2.9); 206	4.4 (2.9); 219	−0.29	−0.79 to 0.22	0.269
21 months	3.6 (3.0); 199	4.3 (2.9); 206	−0.53	−1.05 to −0.00	0.049
PSYRATS voices – cognitive					
Baseline	3.9 (2.8); 224	4.5 (2.5); 213			
9 months	3.4 (2.8); 193	4.0 (2.7); 204	−0.32	−0.82 to 0.17	0.195
21 months	3.3 (2.9); 187	3.8 (2.8); 187	−0.17	−0.68 to 0.34	0.514
PSYRATS voices – emotional					
Baseline	4.7 (3.1); 232	5.4 (2.8); 222			
9 months	4.2 (3.3); 202	5.0 (3.0); 208	−0.43	−0.95 to 0.08	0.101
21 months	4.1 (3.3); 199	4.6 (3.3); 197	−0.03	−0.55 to 0.50	0.914
PSYRATS voices – physical					
Baseline	5.5 (3.8); 232	6.2 (3.4); 223			
9 months	4.7 (3.8); 208	5.7 (3.6); 209	−0.58	−1.11 to −0.04	0.034
21 months	4.4 (3.6); 201	5.1 (3.8); 198	−0.30	−0.85 to 0.24	0.279
PSYRATS voices – loudness					
Baseline	2.5 (1.5); 229	2.6 (1.4); 239			
9 months	2.0 (1.6); 206	2.3 (1.6); 219	−0.22	−0.50 to 0.06	0.120
21 months	1.9 (1.7); 199	2.3 (1.6); 206	−0.28	−0.57 to 0.01	0.056
Note Reprinted from <i>Lancet Psychiatry</i> , Volume 5, Morrison <i>et al.</i> , Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial, Pages 633–43, © 2019, with permission from Elsevier. ¹⁷¹					

TABLE 12 Other secondary outcomes

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value
Time point	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)			
CDSS					
Baseline	7.1 (4.8); 233	7.4 (4.7); 238			
9 months	6.3 (4.5); 210	6.8 (4.8); 215	−0.54	−1.31 to 0.23	0.168
21 months	6.0 (4.4); 202	6.6 (5.1); 205	−0.50	−1.28 to 0.29	0.212
AnTI					
Baseline	18.2 (4.8); 226	18.9 (4.9); 236			
9 months	17.5 (5.2); 189	18.0 (5.0); 206	−0.07	−0.88 to 0.73	0.856
21 months	16.9 (5.1); 180	18.1 (5.0); 193	−0.60	−1.44 to 0.24	0.160
PSP					
Baseline	49.2 (15.5); 242	48.3 (13.5); 245			
9 months	53.2 (14.6); 213	50.9 (13.9); 224	1.90	−0.31 to 4.11	0.093
21 months	51.5 (15.2); 206	51.4 (14.7); 214	0.18	−2.07 to 2.44	0.872
QPR					
Baseline	48.5 (11.4); 216	47.4 (11.1); 228			
9 months	50.9 (11.6); 181	48.7 (11.1); 194	1.88	−0.03 to 3.79	0.053
21 months	52.0 (9.6); 165	49.1 (11.7); 185	2.03	0.04 to 4.01	0.045
AUDIT					
Baseline	4.3 (6.0); 230	3.5 (5.4); 234			
9 months	4.4 (6.0); 194	3.5 (5.7); 209	0.69	−0.17 to 1.56	0.116
21 months	4.6 (6.5); 190	3.2 (5.0); 193	0.80	−0.09 to 1.69	0.079
DAST					
Baseline	0.7 (1.4); 224	0.7 (1.5); 231			
9 months	0.7 (1.7); 153	0.9 (1.7); 173	−0.13	−0.43 to 0.18	0.409
21 months	0.6 (1.3); 170	0.6 (1.3); 181	0.12	−0.17 to 0.41	0.417
Condition improvement CGI ^a					
9 months	3.3 (1.1); 141	3.3 (1.1); 157	−0.04	−0.50 to 0.42	0.822
21 months	3.2 (0.9); 131	3.5 (1.0); 147	−0.33	−0.54 to −0.11	0.013
Severity CGI					
Baseline	4.8 (0.9); 158	4.8 (0.8); 162			
9 months	4.2 (1.0); 207	4.3 (1.1); 213	−0.09	−0.30 to 0.12	0.395
21 months	4.1 (1.0); 208	4.2 (1.0); 212	−0.03	−0.24 to 0.18	0.772
Participant severity CGI					
Baseline	3.9 (1.4); 152	4.0 (1.6); 157			
9 months	3.6 (1.7); 197	3.7 (1.5); 186	0.06	−0.27 to 0.39	0.729
21 months	3.7 (1.5); 193	3.7 (1.6); 210	0.12	−0.22 to 0.46	0.483
EQ-5D-5L utility					
Baseline	0.740 (0.201); 223	0.703 (0.225); 230			
9 months	0.760 (0.223); 187	0.721 (0.254); 205	0.035	−0.004 to 0.073	0.079
21 months	0.773 (0.204); 180	0.730 (0.223); 189	0.028	−0.012 to 0.068	0.170

^a Analysed separately at 9 and 21 months as baseline score was not collected.

TABLE 13 Employment status

Employment status	Trial arm, <i>n</i> (%)		<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	
9 months			
NEET	180 (74.4)	186 (75.9)	0.774
EET	41 (16.9)	42 (17.1)	
21 months			
NEET	162 (66.9)	175 (71.4)	0.499
EET	50 (12.4)	41 (16.7)	

EET, in education, employment, volunteering and training; NEET, not in education, employment, volunteering and training.

Compliance with treatment

The median number of CBT sessions attended was 23, and 213 out of 242 participants (88%) attended at least six sessions, which was the minimum number of sessions needed to be classified as having received CBT (*Table 14*). Treatment effects from a CACE analysis, adjusting for compliance at 9 months and the primary and secondary outcomes, are shown in *Appendix 2*. We repeated this analysis using the actual number of sessions attended; results are presented in *Table 15* for 9 months and *Table 16* for 21 months. For every extra session attended, the PANSS total score resulted in a difference of -0.12 (95% CI -0.24 to 0.00 ; $p = 0.059$) at 9 months, which suggests that attending more CBT sessions was beneficial in the short term.

Session record data were analysed to determine if therapy milestones were achieved. The percentage of participants allocated to CBT with whom therapy milestones were achieved is shown in *Table 17*.

Fidelity to the CBT model was evaluated using 57 audio-recordings of therapy sessions. *Table 18* provides descriptive statistics for the total fidelity ratings.

TABLE 14 Number of sessions attended for those randomised to CBT

Number of sessions	CBT arm (<i>N</i> = 242), <i>n</i> (%)
0	12 (5.0)
1–5	17 (7.0)
6–10	20 (8.3)
11–20	48 (19.8)
21–30	124 (51.2)
> 31	21 (8.7)
Median	23
25th centile	13
75th centile	28

TABLE 15 Complier-average causal effect analysis of the actual number of sessions at 9 months

Outcome	Mean difference	95% CI	p-value
PANSS total	-0.12	-0.24 to 0.00	0.059
PANSS positive	-0.02	-0.08 to 0.03	0.347
PANSS negative	-0.08	-0.13 to -0.03	0.001
PANSS disorganised	-0.00	-0.05 to 0.05	0.997
PANSS excitement	-0.06	-0.10 to -0.02	0.001
PANSS emotional distress	-0.06	-0.10 to -0.01	0.028
CDSS	-0.13	-0.25 to -0.01	0.040
AnTI	-0.02	-0.08 to 0.04	0.506
PSYRATS – auditory hallucinations	-0.01	-0.05 to 0.03	0.566
PSYRATS – delusion	-0.01	-0.04 to 0.01	0.283
PSYRATS unusual beliefs – cognitive	-0.02	-0.04 to 0.01	0.206
PSYRATS unusual beliefs – emotional	-0.02	-0.05 to 0.01	0.114
PSYRATS voices – cognitive	-0.03	-0.06 to -0.00	0.038
PSYRATS voices – emotional	-0.01	-0.03 to 0.00	0.112
PSYRATS voices – physical	-0.03	-0.07 to 0.01	0.151
PSYRATS voices – loudness	-0.00	-0.04 to 0.04	0.942
PSP	0.10	-0.02 to 0.21	0.091
QPR	0.10	-0.00 to 0.19	0.061
AUDIT	0.03	-0.01 to 0.08	0.127
DAST	-0.01	-0.02 to 0.01	0.415
Severity CGI	-0.00	-0.02 to 0.01	0.417
Participant severity CGI	0.00	-0.01 to 0.02	0.669
Condition improvement CGI	-0.02	-0.03 to -0.01	0.003
EQ-5D-5L	0.002	-0.000 to 0.004	0.094

TABLE 16 Complier-average causal effect analysis of the actual number of sessions at 21 months

Instrument	Mean difference	95% CI	p-value
PANSS total	-0.04	-0.16 to 0.08	0.547
PANSS positive	0.02	-0.03 to 0.06	0.527
PANSS negative	-0.04	-0.09 to 0.01	0.101
PANSS disorganised	0.01	-0.04 to 0.05	0.745
PANSS excitement	-0.02	-0.06 to 0.01	0.145
PANSS emotional distress	-0.01	-0.06 to 0.03	0.565
CDSS	-0.02	-0.06 to 0.02	0.263
AnTI	-0.03	-0.07 to 0.01	0.156
PSYRATS – auditory hallucinations	-0.06	-0.17 to 0.05	0.310

TABLE 16 Complier-average causal effect analysis of the actual number of sessions at 21 months (*continued*)

Instrument	Mean difference	95% CI	p-value
PSYRATS – delusion	–0.03	–0.09 to 0.02	0.231
PSYRATS unusual beliefs – cognitive	–0.02	–0.05 to 0.02	0.396
PSYRATS unusual beliefs – emotional	–0.02	–0.05 to 0.00	0.050
PSYRATS voices – cognitive	–0.01	–0.03 to 0.02	0.551
PSYRATS voices – emotional	–0.00	–0.03 to 0.02	0.969
PSYRATS voices – physical	–0.01	–0.04 to 0.01	0.267
PSYRATS voices – loudness	–0.01	–0.03 to 0.00	0.057
PSP	–0.00	–0.12 to 0.11	0.941
QPR	0.09	0.01 to 0.18	0.036
AUDIT	0.03	–0.01 to 0.08	0.107
DAST	0.00	–0.01 to 0.02	0.488
Severity CGI	–0.00	–0.01 to 0.01	0.752
Participant severity CGI	0.01	–0.01 to 0.02	0.502
Condition improvement CGI	–0.00	–0.01 to 0.01	0.757
EQ-5D-5L	0.00	–0.00 to 0.00	0.152

TABLE 17 Therapy data

Milestones	CBT, n/N (%)
Problem and goals identified during sessions 1–4	221/242 (91.3)
Maintenance formulation developed during sessions 1–4	185/242 (76.4)
If maintenance formulation was not developed during sessions 1–4, it was developed after	26/57 (45.6)
Longitudinal formulation developed during sessions 1–16	111/242 (45.9)
If longitudinal formulation was not developed during sessions 1–16, it was developed after	21/131 (16.0)
Change strategies were used during sessions 1–5	200/242 (82.6)
If change strategies were not used during sessions 1–5, they were used in sessions 6–10	15/42 (35.7)
Homework set during sessions 1–5	219/242 (90.5)
If homework was set during sessions 1–5, it was completed	181/219 (82.6)

TABLE 18 Fidelity ratings

Fidelity indicator	CTS-R fidelity (N = 57)
Mean (SD)	43.11 (7.56)
Range	29.75–60.50
Number (%) achieving a pass on the CTS-R	45 (78.9)

Subgroup analyses

Results from the subgroup analysis are reported in *Figures 5* and *6* for PANSS total. Results from the subgroup analysis for the secondary outcomes QPR, PSP and PSYRATS – auditory hallucinations are in *Appendix 2*. There was no evidence that the treatment effect was moderated by any of the specified subgroups. Sensitivity analysis for the subgroup LNS including participants who refused at least one question is shown in *Appendix 2*. Overall, there was no evidence of a statistical difference for any of the subgroups on PANSS total at either time point.

For subgroup analyses of QPR (see *Appendix 2*), there was evidence of a significant interaction effect at 9 months for the BCSS subscale 'negative others', which scored < 7.2 , with those subscales that scored ≥ 7.2 (interaction effect -4.96 , 95% CI -8.94 to -0.98 ; $p = 0.015$). All other subgroups showed no evidence of a difference. *Appendix 2* shows the subgroup analysis for PSP. There was evidence of a significant interaction effect for participants with a DI of ≥ 31 years with participants with a DI of $0-15$ years at 9 months (interaction effect -9.03 , 95% CI -16.62 to -1.98 ; $p = 0.013$). For the CTQ physical abuse subscale, there was evidence of a difference at 9 months for participants scoring ≥ 8 with those scoring ≤ 7 (interaction effect 6.29 , 95% CI 0.80 to 11.78 ; $p = 0.025$).




FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years), DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months; (g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months; and (l) BCSS at 21 months. (*continued*)






FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years), DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months; (g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months; and (l) BCSS at 21 months. (*continued*)




FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years), DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months; (g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months; and (l) BCSS at 21 months. (continued)




FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years), DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months; (g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months; and (l) BCSS at 21 months. (*continued*)




FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years), DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months; (g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months; and (l) BCSS at 21 months.




FIGURE 6 Comparison of CBT and TAU by psychosis subgroup. (a) 9 months; and (b) 21 months. (continued)




FIGURE 6 Comparison of CBT and TAU by psychosis subgroup. (a) 9 months; and (b) 21 months.

In the subgroup analyses for PSYRATS – auditory hallucinations (see *Appendix 2*), there was evidence of a difference for participants with a DI of between 16 and 30 years and those with a DI of between 0 and 15 years at 9 months (interaction effect -7.33 , 95% CI -12.41 to -2.25 ; $p = 0.005$). For AUDIT, there was evidence of a difference for participants with a score of ≤ 12 and for those with a score of ≤ 12 (interaction) (interaction effect -9.76 , 95% CI -18.40 to -1.12 ; $p = 0.027$). Furthermore, there was evidence of a difference for PAM-SR attachment avoidance at 9 months for those who scored 17–24 compared with those who scored 1–9 in favour of TAU (interaction effect 8.56 , 95% CI 0.73 to 16.30 ; $p = 0.032$).

Adverse events and potential unwanted side effects of trial participation

In total, three participants experienced an AE that was deemed to be related to the trial or unclear if related; these AEs were reported to the National Research Ethics Committee (*Table 19*). Two of the affected participants were in the CBT arm (unclear if related or not) and one was in the TAU arm (related); one AE was categorised as life-threatening and resulted in self-harm, one was an involuntary hospitalisation to a psychiatric hospital and one was self-harm that required treatment at an accident and emergency department.

TABLE 19 Adverse events and effects

Adverse events and effects	Trial arm, <i>n</i> (%)		Odds ratio	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)			
SAEs					
Participants who had a trial-related SAE	2 (0.8)	1 (0.4)			
Life-threatening/resulted in self-harm		1			
Involuntary hospitalisation	1				
Self-harm that required treatment at A&E	1				
Any AEs					
Participants who had an AE	107 (44.2)	104 (42.4)	1.09	0.81 to 1.46	0.58
Total number of AEs	143	120			
Details ^a					
Death	6	4			
Voluntary hospitalisation	33	24			
Involuntary hospitalisation	10	14			
Prolongation of hospitalisation	4	2			
Risk to others	2	0			
Self-harm	27	6			
Suicide attempt	2	3			
Suicidal crisis (CDSS item 8, rating 2) (<i>n/N</i>)					
9 months	12/215 (5.6)	14/224 (6.3)	0.90	0.40 to 1.10	0.79
21 months	9/209 (4.3)	7/214 (3.3)	1.35	0.49 to 3.73	0.56
Severe symptomatic exacerbation (<i>n/N</i>)					
CGI severity ≥ 6					
9 months	18/207 (8.7)	25/213 (11.7)	0.69	0.36 to 1.33	0.27
21 months	19/208 (9.1)	17/212 (8.0)	1.16	0.57 to 2.33	0.69
CGI improvement ≥ 6 ^b					
9 months	0/131	5/147 (3.4)			0.06
21 months	3/141 (2.1)	6/157 (3.8)	0.45	0.10 to 2.02	0.30
Deterioration in PANSS total (<i>n/N</i>)					
> 25%					
9 months	22/218 (10.1)	28/224 (12.5)	0.75	0.41 to 1.38	0.35
21 months	15/209 (7.2)	21/216 (9.7)	0.68	0.33 to 1.37	0.28
> 50%					
9 months	6/218 (2.8)	7/224 (3.1)	0.77	0.25 to 2.43	0.66
21 months	8/209 (3.8)	8/216 (3.7)	0.90	0.32 to 2.55	0.84
> 75%					
9 months	2/218 (0.9)	1/224 (0.4)	1.78	0.15 to 20.95	0.65
21 months	1/209 (0.5)	3/216 (1.4)	0.26	0.03 to 2.73	0.26

A&E, accident and emergency.

a Two participants had two involuntary hospitalisations, one participant had 22 self-harm events, one participant had two self-harm events and nine participants had two voluntary hospitalisations.

b High scores indicate deterioration.

NoteReprinted from *Lancet Psychiatry*, Volume 5, Morrison *et al.*, Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial, Pages 633–43, © 2019, with permission from Elsevier.¹⁷¹

There were 107 participants (44.2%) in the CBT arm and 104 (42.4%) in the TAU arm who reported at least one AE or adverse effect; there was no significant difference between the groups in the number of people with at least one AE or adverse effect ($p = 0.58$) (see *Table 19*). The main reasons were voluntary hospitalisation to a psychiatric hospital, self-harm, CGI severity of > 6 and $> 25\%$ deterioration on the PANSS. In the CBT group, 22 of the 27 reported self-harm events were from the same participant. There were six deaths in the CBT arm and four in the TAU arm; all were deemed to be unrelated to the study.

At 9 months, 22 participants (9%) in the CBT arm and 28 (11%) in the TAU arm had a deterioration in PANSS total score of $> 25\%$. The number of deteriorations at $> 50\%$ and $> 75\%$ was similar in both groups at 9 and 21 months.

The frequency of participants responding 'quite a lot' or 'very much' to each of the items on the bespoke adverse effects measure developed for the FOCUS trial can be found in *Appendix 2*. There were no significant differences between the groups for any of the 27 items in the adverse effects measure.

Internalised stigma of mental illness

Levels of ISMI subscales for the whole sample at baseline are reported in *Table 20*. For the ISMI alienation scale, 201 participants (41%) had a severe level, and 225 participants (46%) had moderate levels of stigma resistance.

Figure 7 shows the profile for the ISMI subscales for the two treatment groups over the study period and *Table 21* shows the treatment effects. At 9 months, ISMI discrimination experience was lower in the CBT arm than the TAU arm (-0.13 , 95% CI -0.25 to -0.01 ; $p = 0.029$). For the subgroup analysis on the PANSS total, only stigma resistance at 9 months showed evidence of a significant interaction effect (*Figure 8*).

TABLE 20 Levels of ISMI reported in the group at baseline

ISMI subscales	Participants, n (%) ($N = 487$)	ISMI scale levels, n (%)			
		Minimal	Low	Moderate	Severe
ISMI alienation	435 (89.3)	65 (13.3)	95 (19.5)	126 (25.9)	201 (41.3)
ISMI stereotype endorsement	435 (89.3)	186 (38.2)	149 (30.6)	76 (15.6)	76 (15.6)
ISMI discrimination experience	434 (89.1)	104 (21.4)	99 (20.3)	155 (31.8)	129 (26.5)
ISMI social withdrawal	435 (89.3)	76 (15.6)	122 (25.1)	142 (29.2)	147 (30.2)
ISMI stigma resistance	433 (88.9)	46 (9.4)	85 (17.5)	225 (46.2)	131 (26.9)




FIGURE 7 Profile of ISMI subscales. (a) ISMI alienation; (b) ISMI stereotype endorsement; (c) ISMI discrimination experience; (d) ISMI social withdrawal; (e) ISMI stigma resistance; and (f) ISMI total. (*continued*)




FIGURE 7 Profile of ISMI subscales. (a) ISMI alienation; (b) ISMI stereotype endorsement; (c) ISMI discrimination experience; (d) ISMI social withdrawal; (e) ISMI stigma resistance; and (f) ISMI total. (*continued*)




FIGURE 7 Profile of ISMI subscales. (a) ISMI alienation; (b) ISMI stereotype endorsement; (c) ISMI discrimination experience; (d) ISMI social withdrawal; (e) ISMI stigma resistance; and (f) ISMI total.

TABLE 21 The ISMI outcomes

	Trial arm, mean (SD); <i>n</i>				
ISMI subscale	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value
Alienation					
Baseline	2.76 (0.69); 218	2.84 (0.68); 217			
9 months	2.68 (0.74); 179	2.79 (0.67); 198	−0.08	−0.19 to 0.03	0.169
21 months	2.68 (0.64); 164	2.80 (0.68); 180	−0.04	−0.16 to 0.08	0.513
Stereotype endorsement					
Baseline	2.16 (0.51); 218	2.16 (0.54); 217			
9 months	2.08 (0.59); 178	2.14 (0.55); 198	−0.06	−0.16 to 0.03	0.177
21 months	2.03 (0.53); 164	2.17 (0.54); 180	−0.08	−0.17 to 0.02	0.128
Discrimination experience					
Baseline	2.52 (0.63); 218	2.60 (0.66); 216			
9 months	2.34 (0.69); 177	2.50 (0.64); 197	−0.13	−0.25 to −0.01	0.029
21 months	2.36 (0.63); 163	2.52 (0.72); 180	−0.05	−0.18 to 0.07	0.397
Social withdrawal					
Baseline	2.62 (0.65); 218	2.64 (0.69); 217			
9 months	2.50 (0.74); 177	2.56 (0.65); 198	−0.07	−0.19 to 0.05	0.241
21 months	2.52 (0.63); 164	2.63 (0.70); 180	−0.10	−0.23 to 0.02	0.095
Stigma resistance					
Baseline	2.77 (0.51); 217	2.68 (0.53); 216			
9 months	2.78 (0.61); 177	2.74 (0.52); 198	0.02	−0.09 to 0.12	0.747
21 months	2.76 (0.53); 163	2.71 (0.56); 180	0.02	−0.09 to 0.13	0.681
Total					
Baseline	2.46 (0.46); 218	2.50 (0.48); 217			
9 months	2.36 (0.51); 179	2.44 (0.46); 198	−0.07	−0.14 to 0.01	0.090
21 months	2.37 (0.44); 165	2.48 (0.51); 180	−0.04	−0.12 to 0.04	0.303




FIGURE 8 The PANSS total subgroups. (a) Alienation, stereotype endorsement and discrimination experience at 9 months; (b) alienation, stereotype endorsement and discrimination experience at 21 months; (c) social withdrawal and stigma resistance at 9 months; and (d) social withdrawal and stigma resistance at 21 months. (*continued*)




FIGURE 8 The PANSS total subgroups. (a) Alienation, stereotype endorsement and discrimination experience at 9 months; (b) alienation, stereotype endorsement and discrimination experience at 21 months; (c) social withdrawal and stigma resistance at 9 months; and (d) social withdrawal and stigma resistance at 21 months.

Chapter 5 Economic evaluation results

Chapter overview

This chapter describes the results of the economic evaluation conducted as part of the FOCUS trial of CBT compared with TAU for people who cannot tolerate or have had an inadequate response to clozapine. The economic evaluation uses service use and health status data collected in the RCT to compare the costs and QALYs of CBT with those of TAU, and estimate the cost per QALY gained. The analysis used the viewpoint of NHS health and social care service providers (costs) and patients (health benefits) for the 21-month follow-up period of the trial. Full methods are provided in *Chapter 2*.

Missing cost and utility data

Table 22 summarises the number of participants with complete cost or utility data at baseline and at 9- and 21-month follow-up. Overall, complete cost and QALY data at 9-month follow-up were available for 126 out of 245 participants (51%) in the TAU arm, compared with 114 out of 242 participants (47%) in the CBT group. At 21-month follow-up, complete cost and QALY data were available for 93 out of 245 participants (38%) in the TAU arm, compared with 76 out of 242 participants (31%) in the CBT group.

TABLE 22 Available cost and utility data at different assessments

Study follow-up	Available data, <i>n</i> (%)			
	CBT arm (<i>N</i> = 242)		TAU arm (<i>N</i> = 245)	
	Cost	Utility	Cost	Utility
Baseline overall	195 (81)	223 (92)	195 (80)	230 (94)
Hospital inpatient stay (psychiatric)	235 (97)	Not relevant	236 (96)	Not relevant
Hospital inpatient stay (other)	202 (83)	Not relevant	205 (84)	Not relevant
Hospital outpatient, day and A&E care	237 (98)	Not relevant	239 (98)	Not relevant
Primary, community and social care	232 (96)	Not relevant	238 (97)	Not relevant
Baseline to 9 months	135 (56)	187 (77)	144 (59)	205 (84)
Hospital inpatient stay (psychiatric)	214 (88)	Not relevant	215 (88)	Not relevant
Hospital inpatient stay (other)	150 (62)	Not relevant	155 (63)	Not relevant
Hospital outpatient, day and A&E care	178 (74)	Not relevant	182 (74)	Not relevant
Primary, community and social care	168 (69)	Not relevant	175 (71)	Not relevant
Baseline to 21 months	103 (43)	180 (74)	110 (45)	189 (77)
Hospital inpatient stay (psychiatric)	203 (84)	Not relevant	195 (80)	Not relevant
Hospital inpatient stay (other)	122 (50)	Not relevant	120 (49)	Not relevant
Hospital outpatient, day and A&E care	153 (63)	Not relevant	145 (59)	Not relevant
Primary, community and social care	139 (57)	Not relevant	137 (56)	Not relevant
A&E, accident and emergency.				

Baseline clinical and demographic characteristics

Sociodemographic characteristics for the participants were reported in *Table 5*. The data suggested that the two groups were similar at baseline.

Table 23 reports key baseline demographic and clinical characteristics that are statistically significantly associated with either baseline utility or baseline cost data (Kendall's τ -coefficient).

Stepwise linear regression (SPSS version 22), using all the characteristics in *Table 23*, was used to identify the key characteristics to include in the MI of missing data and as covariates for the primary and sensitivity analyses.

Table 24 shows the results of the regression analyses for the characteristics that were statistically associated with utility ($p \leq 0.10$) and included as covariates in the analyses. QALYs are estimated from baseline and follow-up utilities. The EuroQol Visual Analogue Scale (EQ VAS) score was used to adjust for any differences in participants' reported health status at baseline. The EQ VAS is included in the EQ-5D instrument as an alternative measure of self-reported health. None of the baseline characteristics identified in *Table 24* was associated with baseline cost. The characteristics listed in *Table 24* that were statistically significantly associated with cost were included in the MI of missing data and as covariates for the analyses. The baseline cost categories were also included in the MI models, whereas total baseline cost was included as a covariate in the regression models to estimate net costs.^{159,160}

TABLE 23 Baseline demographic and clinical characteristics associated with costs or utility

Demographic or clinical characteristic	Kendall's τ -coefficient; p -value (n)	
	Cost	Utility
EQ VAS	NSS	0.346; < 0.001 (450)
Age	NSS	-0.177; < 0.001 (453)
Years of full-time education	NSS	0.072; 0.043 (419)
Gender	NSS	-0.089; 0.022 (453)
Ethnicity (white British vs. non-white British)	NSS	0.105; 0.007 (453)
Consider themselves to be experiencing mental health problems	NSS	-0.156; < 0.001 (444)
Duration of illness in months	0.083; 0.020 (366)	-0.129; < 0.001 (426)
Impact of health on socially useful activities, including work and study	NSS	-0.143; < 0.001 (453)
Impact of health on personal and social relationships	NSS	-0.107; 0.006 (453)
Taking clozapine	0.131; 0.002 (390)	-0.087; 0.024 (453)
Taking antidepressant medication	NSS	-0.150; < 0.001 (453)
Taking benzodiazepine medication	NSS	-0.077; 0.047 (453)
Total PSP score	-0.070; 0.042 (390)	0.124; < 0.001 (453)
Total PANSS score	NSS	-0.189; < 0.001 (453)
Total QPR score	NSS	0.328; < 0.001 (426)
Total CDSS score	0.113; 0.002 (376)	-0.308; < 0.001 (439)
Study centre	NSS	0.115; 0.001 (453)
EQ VAS, EuroQol Visual Analogue Scale; NSS, not statistically significant.		

TABLE 24 Regression analyses of baseline utility and demographic and clinical characteristics

Baseline characteristic	Utility ($n = 412$, adjusted $R^2 = 0.39$, $p < 0.001$)	
	Coefficient, SE (95% CI)	p -value
Age	0.004, 0.001 (–0.005 to –0.002)	< 0.001
Number of benzodiazepine medications	–0.053, 0.023 (–0.099 to –0.007)	0.023
PANSS	–0.002, 0.001 (–0.003 to –0.001)	0.006
QPR	0.005, 0.001 (0.003 to 0.007)	< 0.001
CDSS	–0.008, 0.002 (–0.013 to –0.004)	< 0.001
Taking clozapine	–0.052, 0.030 (–0.110 to 0.006)	0.080
EQ VAS	0.002, < 0.001 (0.001 to 0.003)	< 0.001
Constant	0.733, 0.079 (0.577 to 0.888)	< 0.001

SE, standard error.

Descriptive analysis of health status, utility, quality-adjusted life-years and cost for participants with complete cost and quality-adjusted life-year data

Health status, utility and quality-adjusted life-years

Table 25 reports the percentage of people with no problems on each of the EQ-5D health domains at each follow-up assessment. A breakdown, reporting across all levels and domains of the EQ-5D-5L, is provided in *Appendix 3*.

TABLE 25 People with no problem on EQ-5D domains for participants with complete cost and QALY data

EQ-5D health states	Trial arm, n (%)	
	CBT ($N = 76$)	TAU ($N = 93$)
Baseline		
No problem with mobility	55 (72)	50 (54)
No problem with self-care	48 (63)	64 (69)
No problem with usual activities	27 (26)	32 (34)
No problem with pain/discomfort	43 (57)	38 (41)
No problem with anxiety/depression	9 (12)	12 (13)
9-month assessment		
No problem with mobility	54 (71)	47 (51)
No problem with self-care	55 (72)	60 (65)
No problem with usual activities	41 (54)	40 (43)
No problem with pain/discomfort	47 (62)	42 (45)
No problem with anxiety/depression	17 (22)	11 (12)
21-month assessment		
No problem with mobility	50 (66)	49 (53)
No problem with self-care	55 (72)	51 (55)
No problem with usual activities	38 (50)	36 (39)
No problem with pain/discomfort	47 (62)	38 (41)
No problem with anxiety/depression	17 (22)	15 (16)

Table 26 reports the EQ VAS scores and the EQ-5D-5L utility scores at each follow-up assessment. The utility values are reported for the crosswalk system,¹⁷⁰ developed to map the EQ-5D-5L to the EQ-5D, three-level version and the new utility value set estimated specifically for the EQ-5D-5L.¹⁵⁷ The new utility value set was used for the primary analysis and the crosswalk system was included in one of the sensitivity analyses.

The length of follow-up (days) and QALYs (derived from the EQ-5D) are presented in Table 27 for participants with complete cost and QALY data. The number of days of follow-up is similar in both groups at both the 9- and 21-month follow-ups.

TABLE 26 The EQ-5D-5L utility scores and EQ VAS scores at each assessment for participants with complete cost and QALY data

Measure	Trial arm, mean, SE (95% CI)	
	CBT (<i>n</i> = 76)	TAU (<i>n</i> = 93)
EQ VAS values		
Baseline	58, 2 (54 to 63)	59, 2 (55 to 64)
9-month assessment	65, 2 (60 to 69)	57, 2 (53 to 62)
21-month assessment	65, 2 (61 to 69)	58, 2 (53 to 62)
EQ-5D utility values, crosswalk system, sensitivity analysis		
Baseline	0.647, 0.028 (0.592 to 0.703)	0.566, 0.030 (0.508 to 0.625)
9-month assessment	0.706, 0.028 (0.655 to 0.765)	0.597, 0.030 (0.538 to 0.657)
21-month assessment	0.717, 0.027 (0.665 to 0.772)	0.592, 0.028 (0.537 to 0.648)
EQ-5D utility values, new value set, primary analysis		
Baseline	0.728, 0.024 (0.680 to 0.776)	0.668, 0.025 (0.619 to 0.7170)
9-month assessment	0.774, 0.024 (0.727 to 0.824)	0.686, 0.028 (0.630 to 0.741)
21-month assessment	0.780, 0.025 (0.731 to 0.831)	0.682, 0.026 (0.631 to 0.733)
SE, standard error.		

TABLE 27 Days of follow-up and QALYs for participants with complete cost and QALY data: new utility value set

Assessment point	Trial arm, mean, SE (95% CI)	
	CBT (<i>n</i> = 76)	TAU (<i>n</i> = 93)
Days of follow-up		
Baseline to 9 months	288, 3 (282 to 294)	288, 3 (282 to 294)
Baseline to 21 months	647, 3 (642 to 653)	644, 2 (640 to 648)
QALYs		
Baseline to 9 months	0.59, 0.02 (0.56 to 0.63)	0.53, 0.02 (0.49 to 0.57)
Baseline to 21 months (discounted)	1.31, 0.04 (1.24 to 1.38)	1.16, 0.04 (1.08 to 1.24)
SE, standard error.		

Costs

Appendix 3 reports unit costs and costs of the different types of service used at each assessment point for participants with complete cost and QALY data. Service use and costs for the 3 months prior to baseline, from baseline to 9 months and from baseline to 21 months are summarised in Tables 28 and 29. Overall, the large standard errors (SEs) and wide 95% CIs indicate that there is a relatively high level of variation in costs between participants. There appear to be differences between the comparator and CBT groups at 9 and 21 months. However, the 95% CIs overlap, suggesting that any differences could be attributable to chance rather than being statistically significantly different.

TABLE 28 Mean number of health and social care visits/admissions for participants with complete cost and QALY data

Service type	Trial arm, mean, SE (95% CI)	
	CBT (n = 76)	TAU (n = 93)
3 months prior to baseline		
Hospital inpatient admission (psychiatric)	0.01, 0.01 (< 0.001 to 0.04)	0.03, 0.02 (0 to 0.07)
Hospital inpatient admission (non-psychiatric)	0.03, 0.02 (< 0.001 to 0.06)	0.02, 0.02 (< 0.001 to 0.05)
Hospital outpatient, day and emergency care	0.97, 0.20 (0.58 to 1.37)	1.17, 0.23 (0.72 to 1.63)
Other community and social care	13.73, 1.52 (10.69 to 16.76)	15.97, 3.2 (9.61 to 22.32)
Baseline to 3 months		
Hospital inpatient admission (psychiatric)	0	0
Hospital inpatient admission (non-psychiatric)	0.01, 0.01 (< 0.001 to 0.04)	0.02, 0.02 (< 0.001 to 0.06)
Hospital outpatient, day and emergency care	0.92, 0.17 (0.58 to 1.26)	1.32, 0.22 (0.88 to 1.77)
Other community and social care	12.88, 1.42 (10.06 to 15.70)	14.87, 3.24 (8.44 to 21.31)
3–6 months		
Hospital inpatient admission (psychiatric)	0	0
Hospital inpatient admission (non-psychiatric)	0.01, 0.01 (< 0.001 to 0.04)	0.06, 0.03 (0.01 to 0.12)
Hospital outpatient, day and emergency care	0.91, 0.18 (0.55 to 1.26)	1.46, 0.25 (0.97 to 1.96)
Other community and social care	10.16, 1.13 (7.91 to 12.41)	14.25, 2.01 (10.25 to 18.25)
6–9 months		
Hospital inpatient admission (psychiatric)	0	0
Hospital inpatient admission (non-psychiatric)	0.03, 0.03 (< 0.001 to 0.08)	0.05, 0.02 (0.01 to 0.10)
Hospital outpatient, day and emergency care	1.34, 0.31 (0.73 to 1.95)	1.28, 0.22 (0.85 to 1.71)
Other community and social care	10.68, 1.02 (8.66 to 12.71)	15.90, 2.60 (10.73 to 21.07)
9–13 months		
Hospital inpatient admission (psychiatric)	0	0
Hospital inpatient admission (non-psychiatric)	0.03, 0.02 (< 0.001 to 0.06)	0.04, 0.03 (< 0.001 to 0.09)
Hospital outpatient, day and emergency care	1.24, 0.22 (0.79 to 1.68)	1.31, 0.20 (0.91 to 1.71)
Other community and social care	14.69, 1.72 (11.27 to 18.11)	16.40, 1.97 (12.48 to 20.32)

continued

TABLE 28 Mean number of health and social care visits/admissions for participants with complete cost and QALY data (*continued*)

Service type	Trial arm, mean, SE (95% CI)	
	CBT (<i>n</i> = 76)	TAU (<i>n</i> = 93)
13–17 months		
Hospital inpatient admission (psychiatric)	0	0
Hospital inpatient admission (non-psychiatric)	0	0.04, 0.02 (0 to 0.09)
Hospital outpatient, day and emergency care	1.37, 0.29 (0.78 to 1.95)	1.40, 0.22 (0.96 to 1.83)
Other community and social care	18.03, 2.62 (12.80 to 23.25)	17.42, 2.67 (12.11 to 22.73)
17–21 months		
Hospital inpatient admission (psychiatric)	0	0
Hospital inpatient admission (non-psychiatric)	0.05, 0.03 (0 to 0.10)	0.05, 0.03 (0 to 0.11)
Hospital outpatient, day and emergency care	1.29, 0.22 (0.85 to 1.73)	2.02, 0.42 (1.19 to 2.85)
Other community and social care	17.22, 2.64 (11.96 to 22.49)	16.71, 2.19 (12.37 to 21.05)
SE, standard error.		

TABLE 29 Costs of health and social care, excluding costs of CBT intervention, for participants with complete cost and QALY data

Costs of services used	Trial arm, mean cost (£), SE (95% CI)	
	CBT (<i>n</i> = 76)	TAU (<i>n</i> = 93)
3 months prior to baseline		
Hospital inpatient admission (psychiatric)	63, 63 (0 to 187)	308, 264 (0 to 829)
Hospital inpatient admission (non-psychiatric)	0	0
Hospital outpatient, day and emergency care	45, 17 (12 to 78)	62, 22 (19 to 104)
General practice, community and social	704, 89 (529 to 879)	616, 63 (491 to 741)
Total cost	718, 100 (521 to 915)	661, 68 (527 to 795)
Baseline to 9 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	234, 170 (0 to 610)	290, 123 (16 to 468)
Hospital outpatient, day and emergency care	125, 27 (67 to 173)	215, 42 (130 to 299)
General practice, community and social	1568, 135 (1260 to 1805)	1899, 195 (1511 to 2294)
Total cost	1927, 251 (1255 to 2184)	2404, 249 (1841 to 2827)
Baseline to 21 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	506, 216 (88 to 1034)	497, 178 (108 to 837)
Hospital outpatient, day and emergency care	295, 63 (152 to 406)	434, 80 (271 to 594)
General practice, community and social	3834, 424 (2886 to 4613)	4345, 484 (3383 to 5329)
Total cost	4635, 529 (3241 to 5204)	5277, 581 (4026 to 6417)
SE, standard error.		

The mean use, length and costs of the CBT intervention are summarised in *Table 30*. In the intervention arm, 230 out of 242 participants (95%) received treatment and provided data on the number of CBT sessions attended. Some information on CBT session length was available for nearly half of participants in the CBT arm (113/242; 47%); complete data on CBT session length for all attended sessions were available for 14 out of 242 participants (6%). The unit cost per session for CBT reported by the PSSRU (£97 per 55-minute session) was used to calculate the cost of CBT for each participant with data on the number of sessions. Those participants allocated to the intervention group but who did not receive CBT were allocated a CBT treatment cost of zero.

Table 31 summarises the total cost per person, including the costs of CBT for participants in the intervention arm of the trial, for the 3 months prior to baseline, from baseline to 9 months and from baseline to 21 months. *Appendix 3* presents the total cost per person for each assessment point. Although the total costs from baseline to 21-month follow-up appear higher for those participants in the CBT group, the variance is high and the 95% CIs overlap, suggesting that any apparent differences may be attributable to chance.

Descriptive analysis of utility, quality-adjusted life-years and cost for all participants, using multiple imputation data

Table 32 reports the utility values and QALYs for all participants, using the MI data. As with the complete-case analysis, utility increases from baseline to end of scheduled follow-up in both groups. The data in *Table 32* indicate that the number of QALYs is similar in each group at 9 months. There appears to be a trend towards a difference in total QALYs between the two groups at 21 months. However, these data are not adjusted for any differences in the characteristics or utility of participants at baseline. Although the QALY estimates include baseline utility, this may not fully capture the impact of differences in baseline utility on utility at follow-up.

TABLE 30 Mean use, length and costs of CBT intervention

Item	Mean (SE)	Range	95% CI
All participants receiving one or more CBT sessions (n/N = 230/242)			
Number of sessions	21 (1)	1–46	20 to 23
Session length (minutes) (n/N = 113/242)	51 (1)	5–76	48 to 54
Average cost per participant receiving one or more CBT sessions (£)	2038 (58)	95–4370	1924 to 2152
Average cost per participant allocated to CBT (n/N = 242/242) (£)	1937 (62)	0–4370	1815 to 2059

TABLE 31 Total costs of health and social care, including costs of CBT intervention for participants with complete cost and QALY data

Assessment	Trial arm, mean cost (£), SE (95% CI)	
	CBT (n = 76)	TAU (n = 93)
3 months prior to baseline	718, 100 (521 to 915)	661, 68 (527 to 795)
Baseline to 9-month follow-up	4197, 254 (3485 to 4451)	2404, 249 (1841 to 2827)
Baseline to 21-month follow-up	7073, 527 (5478 to 7463)	5468, 581 (4026 to 6417)

TABLE 32 Utility and QALYs for all participants, using MI data

Utility and QALYs, all participants, multiple imputation data	Trial arm, mean, SE (95% CI)	
	CBT (<i>n</i> = 242)	TAU (<i>n</i> = 245)
Utility		
Baseline (single imputation)	0.734, 0.013 (0.708 to 0.760)	0.704, 0.014 (0.675 to 0.732)
9 months	0.769, 0.014 (0.741 to 0.796)	0.723, 0.016 (0.691 to 0.755)
21 months	0.781, 0.013 (0.756 to 0.808)	0.740, 0.014 (0.712 to 0.768)
QALYs		
Baseline to 9 months	0.61, 0.01 (0.59 to 0.63)	0.57, 0.01 (0.55 to 0.60)
Baseline to 21 months (discounted)	1.32, 0.02 (1.28 to 1.36)	1.24, 0.02 (1.19 to 1.28)

Costs

Appendix 3 reports the average costs by cost category at each assessment point estimated for all participants, from the MI data. The costs by category are summarised in *Table 33* for the 3 months prior to baseline, from baseline to 9 months and from baseline to 21 months. One point to note is that the costs at follow-up are higher in the MI data than in the complete-case data. This is mainly because complete cost and QALY data at 21-month follow-up were not available for participants who were inpatients during scheduled follow-up. In contrast, the mean costs estimated from the MI data do include the cost of inpatient stays in psychiatric hospitals. The pooled available case data indicate that the mean cost of an inpatient psychiatric hospital stay was £9525 (SE £1447, 95% CI £6681 to £12,368; *n* = 429) from baseline to 9-month follow-up and

TABLE 33 Costs of health and social care from the MI data

Costs of services used	Trial arm, mean cost (£), SE (95% CI)	
	CBT (<i>n</i> = 242)	TAU (<i>n</i> = 245)
3 months prior to baseline		
Hospital inpatient admission (psychiatric)	2170, 515 (1158 to 3183)	2581, 553 (1494 to 3668)
Hospital inpatient admission (non-psychiatric)	48, 25 (0 to 97)	44, 24 (0 to 92)
Hospital outpatient, day and emergency care	95, 19 (57 to 133)	95, 21 (54 to 135)
General practice, community and social	796, 65 (668 to 924)	830, 78 (677 to 982)
Total cost	959, 69 (823 to 1095)	1011, 102 (810 to 1212)
Baseline to 9 months		
Hospital inpatient admission (psychiatric)	9099, 1891 (5383 to 12,814)	8104, 1744 (4678 to 11,530)
Hospital inpatient admission (non-psychiatric)	182, 71 (42 to 322)	269, 84 (102 to 436)
Hospital outpatient, day and emergency care	178, 23 (133 to 224)	304, 44 (218 to 391)
General practice, community and social	1972, 180 (1619 to 2325)	2190, 160 (1874 to 2505)
Total cost (including CBT intervention)	13,368, 1884 (9667 to 17,069)	10,867, 1769 (7390 to 14,344)
Baseline to 21 months		
Hospital inpatient admission (psychiatric)	17,492, 3587 (10,443 to 24,541)	15,482, 3340 (8919 to 22,045)
Hospital inpatient admission (non-psychiatric)	589, 140 (313 to 866)	573, 146 (287 to 860)
Hospital outpatient, day and emergency care	492, 72 (351 to 633)	601, 74 (456 to 746)
General practice, community and social	4882, 416 (4065 to 5698)	4842, 315 (4221 to 5462)
Total cost (including CBT intervention)	25,392, 3638 (18,244 to 32,540)	21,499, 3399 (14,820 to 28,178)

£19,095 (SE £2962, 95% CI £13,271 to £24,919; $n = 389$) from baseline to 21-month follow-up. However, participants for whom complete data were available at 21 months did not have a psychiatric hospital inpatient stay. This suggests that the subsample of participants with complete data was not representative of the full sample.

Overall, the MI results indicate some variation between participants and between the allocation groups in total costs at 9- and 21-month follow-ups. The 95% CIs for the two groups overlap, suggesting that there are no statistically significant differences in costs.

Primary analysis of incremental costs, quality-adjusted life-years and incremental cost-effectiveness ratio

Table 34 shows the net costs and QALYs of CBT compared with TAU at 21 months of follow-up for the primary and sensitivity analyses. Appendix 3 reports the full results of the regression analyses used to adjust for baseline covariates. A linear regression model was used to estimate net QALYs and alternative measures of health benefit and a generalised linear model with gamma log distribution was used for the costs, to account for the skewed distribution of costs towards zero. The data from each of the primary and sensitivity analyses were bootstrapped to generate 10,000 pairs of net cost and net QALY estimates.

The primary analysis indicates that CBT is associated with a net gain in QALYs and a net cost. The net QALY gain is statistically significant. In contrast, the net cost is associated with a high level of variability

TABLE 34 Net costs and QALYs of CBT vs. TAU: primary and sensitivity analyses

Analysis	Net cost (£), SE (95% CI); p -value	Net QALYs, SE (95% CI); p -value
Primary analysis, $n = 487$	5378, 9382 (–13,010 to 23,766); 0.566	0.052, 0.025 (0.003 to 0.103); 0.038
Sensitivity analyses		
Complete-case analysis, $n = 169$	2531, 782 (998 to 4065); 0.001	0.153, 0.046 (0.062 to 0.243); 0.001
9-month time horizon, $n = 487$	3851, 8977 (–13,744 to 21,447); 0.67	0.023, 0.013 (–0.003 to 0.049); 0.077
Crosswalk value set used to estimate utility values	5378, 9382 (–13,010 to 23,766); 0.566	0.074, 0.028 (0.019 to 0.130) p ; 0.009
Clinically relevant improvement, PANSS (25%)	5378, 9382 (–13,010 to 23,766); 0.566	–0.066, 0.206 (–0.470 to 0.339); 0.750
Clinically relevant improvement, PANSS (50%)	5378, 9382 (–13,010 to 23,766); 0.566	0.245, 0.277 (–0.298 to 0.788); 0.376
Clinically relevant improvement, QPR (25%)	5378, 9382 (–13,010 to 23,766); 0.566	0.426, 0.272 (–0.107 to 0.958); 0.117
Clinically relevant improvement, QPR (50%)	5378, 9382 (–13,010 to 23,766); 0.566	–0.104, 0.415 (–0.918 to 0.710); 0.802
Engaged in productive activity	5378, 9382 (–13,010 to 23,766); 0.566	0.318, 0.249 (–0.169 to 0.805); 0.201
Unless stated otherwise, all the results are based on the MI data set, estimated from the 10,000 bootstrap iterations, over a time horizon of baseline to 21 months.		

and is not statistically significant. The additional net cost associated with CBT is attributable to the costs of delivering the intervention and the higher costs of care overall. Excluding the cost of CBT, the net cost of care for the intervention was £2123 (SE £4595, 95% CI –£6883 to £11,129; $p = 0.644$); however, the difference in cost between CBT and TAU was not statistically significantly.

It is important to consider the joint uncertainty associated with the pairs of net cost and QALY estimates, because these are combined to estimate the ICER, which is the overall outcome measure for the economic evaluation. This uncertainty is illustrated in *Figure 9* with a scatterplot of the 10,000 pairs of net cost and QALYs, from the bootstrapped data, in the form of a cost-effectiveness plane. The cost-effectiveness plane demonstrates that the majority of pairs of net cost and QALYs are to the right-hand side of the horizontal axis, indicating that the CBT intervention is associated with a net gain in QALYs and health benefit. However, the majority of pairs also lie in the top half of the vertical axis, indicating a net cost to CBT.

Table 35 reports the ICER, the likelihood that CBT is cost-effective at a WTPT of £15,000 and the estimated net monetary benefit statistic of CBT, when compared with TAU. There is no universally agreed monetary value to attach to QALYs. Therefore, the simulated net QALYs were revalued using a range of values that a decision-maker may be willing to pay to gain 1 QALY, ranging from £0 to £30,000. This was based on the range of willingness-to-pay values historically used in NICE decisions.^{167,172} This approach takes into account uncertainty about the amount that decision-makers would be willing to pay to gain 1 additional QALY from the CBT intervention. The impact of different WTPT values on the likelihood that CBT is cost-effective is shown in the cost-effectiveness acceptability curve in *Figure 10*.

The primary analysis indicates that, although CBT is associated with higher health benefits than TAU in terms of QALYs, the additional costs mean that it is unlikely to be cost-effective if decision-makers are willing to pay £15,000 to gain 1 QALY. The probability that CBT is cost-effective (in this analysis of 10,000 net cost and QALY pair estimates) is 0.13, or 13% (see *Table 35*). If decision-makers are willing to pay £30,000 to gain 1 QALY, the chance that CBT is cost-effective is < 50%, at 17% (see *Figure 10*).





FIGURE 9 Cost-effectiveness plane of 10,000 pairs of net costs and QALYs: bootstrapped MI data.

TABLE 35 Cost-effectiveness of CBT when compared with usual care: primary and sensitivity analyses

Analysis	ICER (£)	Probability that CBT is cost-effective (WTPT = £15,000 to gain 1 QALY)	Net monetary benefit statistic, mean (£), SE (2.5th, 97.5th percentiles)
Primary analysis	103,423	0.13	-5414, 53 (-14,184, 3483)
Sensitivity analyses			
Complete-case analysis	16,542	0.40	-280, 11 (-2700, 1775)
9-month time horizon	167,435	0.08	-3801, 36 (-8788, 1159)
Crosswalk value set used to estimate utility values	72,676	0.14	-5093, 50 (-13,935, 3780)
Clinically relevant improvement, PANSS (25%)	Dominated by TAU	0.09	-7236, 59 (-17,710, 2976)
Clinically relevant improvement, PANSS (50%)	21,951	0.35	-2498, 89 (-20,636, -265)
Clinically relevant improvement, QPR (25%)	12,624	0.54	392, 56 (-17,249, 3391)
Clinically relevant improvement, QPR (50%)	Dominated by TAU	0.15	-7690, 59 (-28,345, -7709)
Engaged in productive activity	16,912	0.43	-1274, 68 (-18,547, 2147)

**FIGURE 10** Cost-effectiveness acceptability curve: primary analysis.

Sensitivity analyses of incremental costs, quality-adjusted life-years and incremental cost-effectiveness ratio

The cost-effectiveness acceptability curves in *Figures 11* and *12* show the sensitivity analyses for the complete-case analysis, 9-month time horizon, QALYs estimated from crosswalk utility values (see *Figure 11*) and the alternative health benefit measures (see *Figure 12*). These indicate that CBT has a likelihood of being cost-effective of < 50%. This is the case for a WTPT of up to £30,000 per QALY gained (or, for the alternative health benefit measures, a WTPT of up to £30,000 per person with a clinically relevant improvement gained). The exception is the analysis using $\geq 25\%$ improvement in QPR. In this case, CBT had a 54% chance of being cost-effective.




FIGURE 11 Cost-effectiveness acceptability curve: sensitivity analysis 1.




FIGURE 12 Cost-effectiveness acceptability curve: sensitivity analysis 2.

The complete-case analysis suggests that there is a 40% chance that CBT is cost-effective if decision-makers are willing to pay up to £15,000 to gain 1 QALY. This rises to an 89% chance of being cost-effective if decision-makers are willing to pay up to £30,000 to gain 1 QALY. However, the complete-case analysis consists of the subset of participants with complete data on costs and QALYs over the 21-month follow-up period. These participants did not use inpatient psychiatric hospital care over the 21-month follow-up period.

Chapter 6 Discussion

Summary

The FOCUS trial is, to our knowledge, the first definitive RCT to evaluate the long-term clinical effectiveness and cost-effectiveness of CBT in comparison with TAU for people who meet the criteria for CRS. In addition, we utilised baseline data to develop a risk model of factors that may predict a good outcome from CBT. The FOCUS trial was methodologically robust with a low risk of bias.

No effect on the primary outcome of PANSS total score was found at the 21-month assessment and the CIs around estimated treatment effect rule out the hypothesised ES. Many of the secondary outcomes were not found to be significant; however, there was a significant effect of CBT over TAU for the main secondary outcome of PANSS total at the end of treatment (9-month assessment) and an encouraging NNT for achieving a good outcome on the PANSS total score at 21 months. The results also indicated small but significant effects of CBT over TAU for self-rated recovery, emotional distress associated with delusions and CGI improvement at long-term follow-up, and at the end of treatment on PANSS total score, positive symptoms, emotional distress and auditory hallucinations. With 88% of those who were allocated to CBT having six sessions or more, it is clear that CBT is acceptable to the majority of those who are offered it. We did not find a difference between CBT and TAU in reportable SAEs or in the number of participants who had one or more AE. The number of reportable SAEs and the absence of any significant difference between the groups on non-reportable AEs suggest that CBT is a safe treatment for this population.

The results of the risk modelling did not reveal any factors that predict a good response to CBT. There was no evidence that the treatment effects of CBT varied over any of the subgroups investigated in the FOCUS trial population for PANSS total score or the PANSS subscales.

Overall, CBT was associated with a net cost and net QALY gain compared with TAU. The additional cost for the CBT group was the result of higher use of health and social care services by participant as well as the additional cost of the CBT intervention. There was a high level of variance in the costs of different services and total costs, and the differences in cost between the two groups were not statistically significant. This indicates uncertainty about whether the CBT group incurred higher costs than the TAU group or whether the difference found was attributable to chance. Nevertheless, the cost-effectiveness acceptability analysis indicated a low likelihood that CBT was cost-effective, in the primary and sensitivity analyses (probability of < 50%). There are a number of limitations that increase the uncertainty of the results, which are discussed in *Strengths and limitations*.

Findings in context

The results of the FOCUS trial showed no lasting effect of CBT for people who meet the criteria for CRS on total symptoms as measured by PANSS. However, there was a statistically significant impact on overall health for those who received CBT in comparison with those who received TAU. Clinically significant improvement on PANSS total score has been defined in meta-analyses of antipsychotic medication as $\geq 50\%$ improvement in the PANSS total score (rescaled) from baseline;³² our NNT for a good improvement in PANSS total score was 15. A recent meta-analysis of all double-blind, placebo-controlled RCTs of antipsychotic medications, except clozapine, found a NNT of eight for $\geq 50\%$ improvement on PANSS.³² More specifically, for clozapine the NNT has been reported as eight.⁴⁷ However, the participants in the FOCUS trial had experienced a poor response to treatment with both standard antipsychotic medication and clozapine and, therefore, our NNT of 15 is encouraging, particularly as this was at long-term follow-up.

In addition, the effect of CBT at end of treatment on PANSS total, PANSS subscales (positive symptoms, emotional distress and excitement) and auditory hallucinations demonstrates that CBT can change symptoms of psychosis in the short term. The reasons for the short-term effect of CBT are unclear; however, given the long DI experienced by our sample, it is possible that a greater number of CBT sessions or longer duration of the treatment window may be required to yield a long-term benefit. It could also be argued that the effects seen at the end of treatment are a result of the non-specific aspects of therapy, such as the therapeutic relationship, rather than the active components of CBT. Therapeutic alliance has been shown to contribute to both improvement and deterioration in PANSS scores for CBT and other psychological therapies, such as supportive counselling.¹⁷³ However, not all FOCUS trial participants completed CBT over the full 9-month treatment window and, therefore, it is not possible to say with any confidence that the effects of CBT seen at the end of treatment were indicative that it works only while treatment is ongoing.

The ES of CBT in this trial is similar to those reported by meta-analyses of CBT for psychosis trials that are deemed to be methodologically robust.^{67,69} The authors of the most current meta-analysis have proposed that the field of CBT for psychosis research is lacking evidence from a large and methodologically robust trial.⁶⁹ Prior to the FOCUS trial, there had been no definitive trials of CBT for CRS. The FOCUS trial has clearly addressed this need for the CRS population and also addressed methodological limitations of previous trials. Jauhar *et al.*⁶⁹ reported an ES of 0.15 from trials at a low risk of masking bias and 0.62 from trials at a high risk of bias. For the FOCUS trial, the risk of this particular bias is low, with only 6.17% of assessments at 9 months (end of treatment) being conducted by an unmasked assessor and our ES at the end of treatment being 0.16, consistent with the pooled estimate from low-risk trials reported by Jauhar *et al.*⁶⁹

With regard to other outcomes, meta-analyses have shown very small ESs for trials with a low risk of bias from masking for positive symptoms.^{67,69} Jauhar *et al.*⁶⁹ found, at the end of treatment, an ES of 0.08 for positive symptoms and concluded, therefore, that it is not justified to propose that CBT is effective for positive symptoms. However, the end-of-treatment results for the FOCUS trial indicate an ES of 0.24 and, although this is a small effect, this finding comes from a methodologically robust trial and is encouraging as it indicates that for positive symptoms, CBT can have small short-term benefits for people who meet criteria for CRS, while in receipt of treatment. This finding is particularly encouraging given that our participants have experienced positive symptoms with a poor response to antipsychotic medication and their DI, on average, was long. This finding also demonstrates, in line with psychological models of psychosis, that hallucinations and delusions can change in response to consideration of the person's interpretation of these experiences and their associated behavioural responses.

Cognitive-behavioural models of psychosis and schizophrenia recognise the link between cognitions, emotions and behaviours; the CBT delivered in this trial permitted work on emotional distress and dysfunction, including prioritising depression and anxiety (if the participant prioritised this as part of their problem list or goals for therapy). Given the role of emotion in psychosis, it has been argued that CBT for psychosis trials should include emotional distress as a secondary outcome¹²¹ and the results of the FOCUS trial indicate that CBT can have small but significant effects at the end of treatment for this important secondary outcome.

There were also some small long-term treatment effects at the 21-month assessment, including for self-rated recovery and an encouraging NNT of 15 to achieve a good response (> 50% improvement on PANSS at 21 months). The primary health economics analysis also suggested that CBT is associated with higher health benefits than TAU in terms of QALYs. Service users advocate that outcomes used in research and clinical services should refocus to ones of personal recovery goals, rather than the reduction or absence of symptoms, which has traditionally been the key outcome advocated by clinicians.¹¹⁸ UK policy places an emphasis on recovery-orientated outcomes and services for people who experience psychosis and schizophrenia³⁰ and, for this reason, our finding that CBT can have a lasting effect on self-rated recovery is arguably more important for service users and services.

The primary health economics analysis uses the EQ-5D-5L and new value set rather than the earlier, interim, crosswalk value set. The crosswalk value set mapped utility values from the older EQ-5D-3L measure to the EQ-5D-5L.¹⁷⁰ The new set of utility values¹⁵⁷ is intended to replace the crosswalk system. The data for the new value set were collected using a different methodology, at a different time and on a different sample to the original utility value set used for the EQ-5D-3L and the crosswalk value set. This means that differences in utility between the crosswalk and new value set may reflect differences in methods, time and sample rather than underlying preferences and/or changes in preferences over time. Thus, the crosswalk-derived values were used to facilitate comparison between utility values estimated using the older three-level version of the EQ-5D and the more recent five-level version.

Table 36 compares the UK population norms for the EQ-5D-3L utility values and those of the FOCUS trial participants using the EQ-5D-5L and crosswalk value set. This indicates that FOCUS trial participants have lower utility values across all age group, and, overall, than the sample of the general population used to generate the population norms.¹⁷⁴

The utility values for FOCUS trial participants were similar to those reported in other studies. Barton *et al.*¹⁵⁸ reported EQ-5D-3L baseline utility values of 0.657 ($n = 32$) to 0.693 ($n = 36$), whereas Crawford *et al.*¹⁷⁵ reported EQ-5D-3L utility values of 0.664 to 0.699 ($n = 409$). The pooled baseline mean utility for participants with severe schizophrenia requiring a change in management in the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) (unpublished analysis of utility data from the CUtLASS trial) was 0.628 (SE 0.017, 95% CI 0.595 to 0.661; $n = 361$).^{159,160} Similarly, another large study,¹⁵⁹ also using the EQ-5D-3L, looked at the use of antipsychotics in a population with schizophrenia and found that the baseline mean utility was 0.61 to 0.67 (SD 0.29 to 0.33; $n = 118$). Finally, a recent large study¹⁷⁶ ($n = 275$) of schizophrenia reported higher values using the EQ-5D-5L, with reported baseline utility values between 0.74 and 0.76.

There is limited evidence about the relative cost-effectiveness of CBT in people with psychosis and schizophrenia. We identified three economic evaluations^{158,177,178} published since 2010 that used broadly similar methods, in a UK setting. Barton *et al.*¹⁵⁸ compared social recovery-orientated CBT with usual care (defined as active case management), over 9 months' follow-up. The authors concluded that social recovery-orientated CBT was cost-effective in 54% of scenarios at a WTPT of £20,000 per QALY.¹⁵⁸ A UK evaluation of CBT combined with motivational care, using a societal perspective and a time frame of 18 months, concluded that the probability of the intervention being cost-effective was 69%, even if decision-makers are not willing to pay to gain a 1-point increase in the Global Assessment of Functioning.¹⁷⁷ McCrone *et al.*¹⁷⁸ evaluated an early intervention service for people with psychosis, which included low-dose medication regimens, CBT, family therapy and vocational rehabilitation. This study found that the intervention did not increase costs and was likely to be cost-effective (probability of 76%) even if decision-makers are not willing to pay to gain an additional person who makes a full or partial vocational recovery.¹⁷⁸

A fourth study¹⁷⁹ compared cognitive remediation therapy plus usual care with usual care alone and found it likely to be cost-effective from a NHS and social care perspective but at a limited time horizon of 40 weeks.

Although using different time horizons and health benefit measures, the findings of these studies differ from the findings of this study, which indicates that CBT is not likely to be cost-effective. All identified studies had limitations, including missing data, small sample sizes and challenges controlling for other medications/treatments received outside the trial intervention. In addition, the participants in this study were people unable to tolerate, or with an inadequate response to, clozapine. This may mean that they are less likely to respond to CBT than people who are not treatment resistant or treatment intolerant. Although CBT was associated with a net gain in QALYs, the costs of CBT were not offset by reduced use of other health and social care services; the participants in the CBT group used more services and had higher costs than the TAU group. However, the greater use of health and social care services found in the CBT group may reflect a desirable outcome for this population who typically have a high level of

TABLE 36 Utility values, population norms (EQ-5D-3L and Time Trade Off values) and FOCUS trial participants (EQ-5D-5L and crosswalk values)

	Age (years)							
EQ-5D utility values	18–24	25–34	35–44	45–54	55–64	65–74	≥ 75	All ages
Population norms, EQ-5D-3L								
Mean	0.940	0.927	0.911	0.847	0.799	0.779	0.726	0.856
SE	0.007	0.006	0.007	0.011	0.012	0.012	0.015	0.004
25th percentile	0.97	0.85	0.85	0.80	0.73	0.69	0.66	0.8
75th percentile	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
95% CI	Not available	Not available	Not available	Not available	Not available	Not available	Not available	Not available
FOCUS trial participants, EQ-5D-5L and crosswalk values, n = 453								
Mean	0.721	0.723	0.643	0.604	0.466	0.662	No cases	0.631
SE	0.057	0.019	0.018	0.025	0.040	0.065	No cases	0.012
25th percentile	0.62	0.63	0.54	0.46	0.20	0.56	No cases	0.50
75th percentile	0.88	0.85	0.82	0.82	0.70	0.76	No cases	0.84
95% CI	0.600 to 0.842	0.685 to 0.761	0.607 to 0.679	0.554 to 0.654	0.385 to 0.547	0.508 to 0.816	No cases	0.607 to 0.655

unidentified and unmet need for health and social care.¹⁸⁰ There is evidence that the physical health needs of this population are severely neglected, often as a result of discrimination by health-care providers.^{180,181} This can arise if health-care providers attribute physical symptoms to a person's mental health condition, often referred to as 'diagnostic overshadowing'.¹⁸¹ Moreover, the fear and shame associated with the public stigmatisation of psychosis and schizophrenia often results in feelings of disempowerment and avoidance of help-seeking for health-care needs.¹⁸² The reduction of stigma and discrimination has been identified as a key target for improving the physical health care of people with a serious mental illness.¹⁸³ The early mortality associated with these unmet needs indicates an area in which improvements in health and social care are needed. It is suggested that one approach to making such improvements could be to utilise interventions that encourage service users with serious mental illness, such as CRS, to become empowered to seek support for their physical health care.¹⁸³ The findings of this trial indicate that participants who received CBT had greater use of the health-care services than people who meet the criteria for CRS have an equal right to access. Increasing the overall level of physical and mental health care for CRS patients may reduce the differences in costs between the TAU and CBT groups in this trial, potentially improving the relative cost-effectiveness of CBT.

Strengths and limitations

The FOCUS trial provides high-quality evidence regarding the clinical effectiveness and cost-effectiveness of CBT for this population, with a low risk of bias across a number of domains. Our trial was pre-registered and our *a priori* SAP was published online and in the public domain. Compared with other trials that have evaluated CBT, the FOCUS trial had many methodological strengths that reduced the potential for bias: randomisation was implemented via a web-based platform centrally and independently, resulting in concealed allocation; outcome assessors were blinded and there were few instances of unblinding; a high proportion of participants received their allocated intervention; and there was low attrition for the primary outcome. Furthermore, the FOCUS trial was adequately powered to detect a clinically meaningful difference at 21-month follow-up. Data from the CONSORT diagram (see *Figure 2*) indicate a representative sample of people who meet CRS criteria. Of people identified for the study, 72% agreed to meet with the research team and, of those, 94.5% agreed to take part in the study. Although there is a subgroup of people who met the CRS criteria who refused to meet with the study team, overall the majority of people referred were engaged. Moreover, the services we recruited from were typical of services for CRS, that is CMHTs, clozapine clinics, psychiatrists and inpatient settings.

The FOCUS trial had strong patient and public involvement (PPI) in the conception of the study design and oversight of the study throughout, with PPI representation on the trial management committee, the Trial Steering Committee and the Data Monitoring and Ethics Committee. The trial documentation was reviewed by two co-applicants, who provided PPI representation, interpreted the results and wrote the participant summary sheet.

The RAs and therapist received training before the trial commenced, or, if they were appointed during the trial, received training before they started to see participants. They received regular supervision throughout the lifetime of the trial to ensure that assessments were conducted reliably and CBT was delivered with fidelity to the model. The small treatment effects should be routinely replicable in the NHS, because almost all of our therapists were band 7, which is the lowest NHS band for psychological therapists. The frequency with which FOCUS trial therapists received supervision is likely to be greater for FOCUS trial therapists than in the NHS; however, it could be argued that for the CRS population, in whom there is a greater degree of complexity, more frequent supervision may be indicated. One limitation to the design of the study was the choice of TAU as the comparator. Although this was specified in the commissioned call by the funder as the comparator, we recognise that a control group that does not include non-specific therapeutic factors, such as contact time, does not allow us to exclude the possibility that any observed change was not attributable to the non-specific therapeutic aspects of CBT.

When placing the above findings in context, it is important to note that, although the effects at the end of treatment and long-term follow-up were statistically significant, the changes observed on the outcome measures are unlikely to reach a threshold of clinically significant change. The NNT of 15 to achieve a good response on our primary outcome, a 50% reduction in PANSS score, at 21 months is encouraging. NNT is reported for 25%, 50% and 75% change in PANSS score from baseline and it is widely accepted that a 50% improvement in PANSS score is a good outcome.³² Clinicians consider NNT to be a useful way to interpret the findings of trials.¹⁸⁴ However, there are limitations to representing the outcome data for this trial as NNT; the amount of change on PANSS from baseline is dependent on the starting point, that is the baseline score, and the use of percentage change to generate the NNT ignores the absolute benefit. The NNT should be presented with CIs; however, when there is no treatment effect, generating an accurate CI is problematic.¹⁸⁵ In the case of the FOCUS trial, the treatment effect on PANSS at 21 months was limited. Therefore, although NNT has been reported here to aid interpretation by clinicians, who regularly use this statistic, its interpretation should be undertaken with caution, with the caveat that the most efficient and least biased way to analyse the trial data is using our primary analysis of a linear mixed model adjusting for baseline. It should also be noted that NNT is one of a number of statistical tests carried out, and multiple hypothesis testing may lead to type I error, inflating the chance of finding a positive result.

The economic analysis was subject to the same strengths and limitations discussed for the clinical evaluation of effectiveness in terms of trial design, trial sample and length of follow-up.

In line with NICE recommendations,¹⁵⁶ the measure of health benefit used for the primary analysis was the QALY, estimated from the published EQ-5D utility values. This enables comparison between different disorders, which is useful for policy-makers and commissioners, who have to consider the distribution of limited budgets between different health-care services. However, the EQ-5D is a generic health status measure that may not be sufficiently sensitive to identify important clinical changes in participants' mental health. The measure covers five domains (mobility, self-care, usual activity, pain and distress and anxiety and depression), but does not include specific symptoms that may be important to service users. This means that the measure could underestimate the benefits of a successful intervention. The descriptive analyses indicated that the EQ-5D health status measure and associated utility index correlated well with the clinical measures used in the trial (see *Appendix 3*). In addition, the sensitivity analyses using clinical measures of improvement in mental health symptoms (PANSS) and indicators of recovery (QPR) also found that CBT was not likely to be cost-effective.

As planned prior to the end of data collection, the new value set was used to estimate utility values from the EQ-5D-5L. More recently, however, NICE advised that the crosswalk mapping system, developed as an interim method of estimating utility values, should be used.¹⁸⁶ This is to allow time for further work to explore and understand differences between two approaches before the NICE methods guidance is updated. Accordingly, we re-estimated the results using the older crosswalk system as one of the sensitivity analyses. The results of this did not differ substantially from the primary analysis.

There were differences between the CBT and TAU groups in utility scores at baseline, although these differences were not statistically significant. The lower score in TAU participants may reflect the lower overall health status of people in the TAU group. This was accounted for, to some extent, by including the baseline utility value in the calculation of total QALYs between baseline and the end of follow-up. In addition, the EQ-5D thermometer or EQ VAS score at baseline was included as a covariate in the analyses to account for possible differences in overall health and utility between the groups.

The proportion of participants with complete-case data (34%) makes imputation of missing data essential but difficult. In addition, none of the participants for whom complete cost and QALY data were available at 21-month follow-up had psychiatric inpatient stays. In contrast, the available case data at each assessment indicated that this service was used by participants. This suggests that the group of participants with complete cost and QALY data may not be representative of the study sample as a whole. To strengthen the robustness of the results, available data were used at each assessment point to impute cost categories

and EQ-5D domains and passively impute total costs and QALYs. The level of missing data for psychiatric inpatient stays was $\leq 20\%$ at baseline and at 9- and 21-month follow-up, which, in part, reflects the use of hospital case note review for participants reporting any psychiatric hospital inpatient stay. Psychiatric inpatient stay was the key cost component of the total cost. In the available and multiple imputation data, it accounted for approximately 70% of the total cost.

With the exception of non-psychiatric hospital stay, the level of missing data for the other cost categories at baseline and 9-month follow-up was $\approx 30\%$. However, it was higher (37–44%) at 21-month follow-up. Constraints on researcher time meant that it was not feasible to review primary and community care or non-psychiatric hospital case notes. The level of missing utility data was lower: $< 10\%$ at baseline and $< 30\%$ at 21-month follow-up.

The greater number of complete data for each cost category means that our approach of imputing cost categories for each assessment point mitigates the overall impact of missing data to some extent (in terms of both bias and imprecision). Nevertheless, the large number of missing cost data at 21-month follow-up means that the results must be interpreted with caution. The extensive uncertainty around estimates from all analysis reflects this.

The primary analysis for the economic evaluation was limited to direct costs, from NHS and social care perspectives. In this population, effective interventions may also affect whether or not a person is employed and the subsequent earnings and benefits they receive. The trial design needed to balance complete and detailed assessment of outcomes and service use with minimisation of participant burden when possible. It was felt to be important to collect detailed service use data at 3-monthly intervals to minimise problems with participant recall. Accordingly, limited information was collected about paid and unpaid work and activities. This covered whether the participant was participating in paid or unpaid/voluntary employment, education or training, other productive activity or was unemployed. The data suggested that there were no statistically significant differences between groups in the proportion of participants engaged in any productive activity or participating in paid employment.

If CBT improves overall health and/or mental health symptoms and recovery, then this may reduce the need for informal carers (e.g. family members), potentially offsetting some of the costs of formal care and CBT. Experience in previous trials indicated a number of barriers to collecting data about the use of informal carers and the time spent by carers. These included incomplete reporting of whether or not participants had family members or friends who they considered to be informal carers. In addition, informed consent was required from participants to contact any informal carers identified, and from informal carers to collect this information. The data collected from informal carers were also incomplete in a number of cases. These factors meant that complete data were available only for a small proportion of participants.^{159,160} Combined with the need to collect detailed formal care-use data, it was felt to be outside the scope of this trial to collect information about the use of informal care. This means that, if CBT reduced or increased the use of informal care, our estimates would underestimate or overestimate the relative cost-effectiveness of CBT.

The economic evaluation was limited to the choice of intervention and comparator included within the trial. Although this leads to a robust comparison, it may not reflect the full range of interventions that are available within a clinical setting. For example, other economic evaluations identified looked at a wider range of psychological therapies in a population with schizophrenia, including cognitive remediation therapy, group art therapy and body psychotherapy.^{179,187,188} A modelling study, informed by a network meta-analysis of trial data, would have the potential to compare costs and outcomes across a wider range of interventions. However, in this treatment-resistant population there are likely to be limited data to inform the model structure and populate the model.

Although PANSS is commonly used as a primary outcome measure in treatment trials for people who meet criteria for a schizophrenia diagnosis (both pharmacological and psychological), it may not have been the most appropriate outcome for this trial for a number of reasons. Although PANSS has been rated

favourably by service users,¹¹⁶ the same study also found that, overall, service users have a preference for self-rated measures. In addition, it has been argued that distinctions between pharmacological and psychological interventions should be made clearer in that psychological interventions, such as CBT, are not a quasi-neuroleptic. Therefore, outcome measures should reflect the target of the specific intervention.¹²¹ For CBT this could be positive symptoms,⁶⁷ but it may be more appropriate to consider the reduction of emotional distress given that this is a primary aim of CBT, or self-rated recovery, given the emphasis in CBT on working with the client's own problem list and goals.

The analysis adjusting for the measure of working memory at baseline needs to be interpreted with caution for two reasons. First, the response rate at baseline was poor because the assessment was introduced 9 months into the recruitment window; a small proportion of data was expected to be missing given that the working-memory assessment was introduced 9 months into the recruitment window. Burden may also explain missing data for this measure. There were a relatively high number of measures in the assessment battery; more specifically, in relation to the working-memory measure, the participant was required to recall and reorder sequences of letters and numbers from a string length of two to seven, and this may have been too burdensome. Second, we proposed a sensitivity analysis using our own algorithm for scoring the measure that was not described by the author.

Although the RAs were blind to allocation, it is not possible to blind participants from the treatment allocation and mask the receipt of CBT when the control is TAU. It could be argued, therefore, that the treatment effect, because it was so small, might be an artefact of the design.

Our inclusion criteria for CRS had been employed in a previous study of clozapine augmentation with a second antipsychotic.⁵² This did not include tests to determine, for each potential participant, whether or not there were any periods of less than full clozapine adherence, that an adequate plasma clozapine level (350 ng/ml) had been achieved consistently for an adequate time or substance use (that may have adversely influenced the effectiveness of the clozapine treatment). It could be argued that such tests were necessary to establish clozapine unresponsiveness; however, given the existing precedent for our inclusion criteria, it was considered unrealistic and impracticable to apply criteria relating to the adequacy of the clozapine trial for each patient being screened for eligibility, which involved checks and investigations that are not routinely done in clinical practice and which, for many patients, could prove to be difficult if not impossible to definitively establish whether or not they were met.

Implications for public health/treatment services

The results of the FOCUS trial suggest that CBT should not be offered routinely with the aim of achieving lasting symptom reduction in people who meet the criteria for CRS. However, the finding that CBT has short-term effects for symptoms and long-term effects for self-recovery, and had a NNT of 15 for good response on our primary outcome, suggests that services could consider offering CBT as a pragmatic individual trial. This may be particularly indicated when the service user's goals relate to acutely distressing positive symptoms and voices or longer-term recovery-orientated goals. The economic evaluation indicates that participants in the CBT group had a net gain in overall health as measured by QALYs. The CBT group also used more services over the course of the trial. Whether this was attributable to chance or to the intervention is unclear. The economic analysis of the participants with complete cost and QALY data also indicates that there may be participants for whom CBT is more likely to be cost-effective. One feature of those with complete cost and QALY data was that they had lower costs in the 3 months prior to the baseline assessment. As outlined, it was not possible to identify any subgroups of participants who had a good outcome from CBT and, therefore, if offering a pragmatic trial of CBT, it should be considered for all service users who meet the criteria for CRS. In addition, the uptake of CBT by FOCUS trial participants provides an optimistic message for the ability to engage people whose experiences are considered 'treatment resistant'.

A commonly used approach to the treatment of CRS is to augment clozapine with a second antipsychotic.⁵³ The treatment ES for augmentation with a second antipsychotic has been shown to be in the small but significant range. The ESs found in the FOCUS trial for CBT are also very similar to those found for pharmacological augmentation with a second antipsychotic.⁵⁵ However, the FOCUS trial provides a more rigorous test of the effects of a treatment for CRS, with a lower risk of bias than the few, small, short-duration, low-quality trials that contribute to the meta-analyses of augmentation with antipsychotics. In addition to the methodological limitations of the clozapine augmentation trials, the current evidence base cannot provide a clear indication from the literature to indicate which clozapine combination strategy is superior.⁵⁸ The adverse effect profile for CBT is also likely to be favourable when compared with the likely cardiovascular risks associated with multiple antipsychotic medications. Therefore, for service users who are reluctant to consider pharmacological augmentation because of the likely side effect burden of polypharmacy, the provision of CBT may be indicated.

A pragmatic trial of CBT may be more effective if offered earlier in the course of clozapine use, when treatment resistance is first established and when DI is shorter, given the personal and social functioning subgroup analysis, which indicated that participants with a shorter DI had greater benefits from CBT in this domain. This may be particularly important as entrenched symptoms may persist for longer and respond more slowly to CBT, which is similar to the use of medication. A person may need to attend more sessions of CBT to derive maximum benefit, given that results of the CACE analysis indicated a potential dose response: for every session of CBT attended, there was a 0.11 reduction in the PANSS total score.

The FOCUS trial recruited people who met the criteria for CRS and, for this reason, the small and short-term effect on symptoms does not mean that CBT will not have stronger effects for less severe or earlier psychosis populations. The NICE guideline for the treatment of psychosis and schizophrenia³⁰ recommends that EIP services routinely offer CBT and family intervention for people with a first episode of psychosis, and meta-analysis of the effects of CBT for this population has demonstrated that it can reduce symptom severity.¹⁸⁹

Finally, it is important to note that the FOCUS trial has an optimistic message for people who meet the criteria for CRS: both the CBT and TAU groups recovered during the trial period to a degree that, on average, approaches clinical significance. Given the DI, poor response to medication and lack of social opportunities (such as employment) among FOCUS trial participants, the finding that, on average, each group had a 10-point improvement in PANSS total scores is a positive one.

Implications for future research

Clearly, this is a population of people who have significant unmet need in relation to their physical and mental health and, therefore, future research to develop and evaluate more effective interventions is required. This could include pharmacological (although issues of physical health and side effects are likely to be important) and other new interventions of either a psychological or social nature. Given the current criticism of CBT for psychosis trials, future RCTs of psychological or social interventions for this population should also demonstrate high methodological rigour and a low risk of bias, as this will help to identify populations most likely to benefit from this intervention.

More specifically, in relation to CBT for this population, approaches to analysis, such as trajectory analysis, may identify responders to CBT; however, it was not possible to use this analytical approach in the FOCUS trial because of the limited number of time points at which our data were collected. There is no research to date to indicate whether or not there are any active ingredients of CBT for the CRS population, and, in the FOCUS trial, a number of techniques were utilised within therapy. Therefore, from the FOCUS trial data, it should be explored if there are any specific therapeutic techniques that result in a good outcome from CBT. Previous research indicates that there is a greater treatment effect from CBT for people considered at risk of developing psychosis if therapy involves between-session tasks and formulation,¹⁵⁴

and mediation analyses of the FOCUS trial data may reveal components of therapy as predictors of response.

The mean health and social care costs for the 3 months prior to the baseline assessment were lower in the analysis of participants with complete cost and QALY data (£686, 95% CI £572 to £801; $n = 169$) than the MI analysis of all participants (£985, 95% CI £863 to £1107; $n = 487$). This indicates that, for whatever reason, these participants were making less use of services. In addition, the analysis indicated that participants in the CBT group used more health and social care services than those in the TAU group, particularly towards the end of the follow-up period. Future research could explore the reasons for high and low service use and whether it indicates higher need for care, or whether CBT helps participants and/or health-care professionals better recognise the need for care.

The economic evaluation was limited to the choice of intervention and comparator included within the trial. Although this leads to a robust comparison, it may not reflect the full range of interventions that are available within a clinical setting. A modelling study, informed by a network meta-analysis of trial data, would have the potential to compare costs and outcomes across a wider range of interventions. This could include comparisons of TAU plus CBT with TAU plus other forms of counselling, supportive care or psychosocial therapy interventions or with TAU plus pharmacological augmentation. However, in this treatment-resistant population, there are likely to be limited data to inform the model structure and populate the model.

Conclusions

Cognitive-behavioural therapy for people who meet the criteria for CRS has small but significant improvements for symptoms of psychosis in the short term, but there is not a lasting effect in the long term (except in relation to self-rated recovery). CBT is a highly acceptable treatment with little evidence of adverse effects for this population. Finally, psychotic symptoms in CRS improved in both groups to a clinically significant extent over 21 months, suggesting that long-term recovery is possible.

Acknowledgements

Thank you to all the participants who agreed to take part in the trial. This study was supported by NHS Research Scotland, through the Chief Scientist Office, the Scottish Mental Health Research Network and the Mental Health Research Network. We are grateful to the Psychosis Research Unit SURG for their consultation regarding the design of the trial and contribution to the developments of trial-related materials. We are grateful to our Independent Trial Steering Committee (Max Birchwood, Daniel Freeman, Rod Taylor, Julia Renton, David Shiers, Yvonne Thomas and Kathryn Harney) and Independent Data Monitoring and Ethics Committee (Richard Bentall, Sabine Landau, Emmanuelle Peters and Tim Rawcliffe) for providing oversight of the trial. We are also grateful to the many researchers, network staff and trial therapists who supported the study, including Elizabeth Murphy, Vicky Brooks, Natasha Holden, Ann Steele, Nicola Chapman, Lisa Wood, Lucy Carter, Rachel Sellers, Eilish Burke, Savas Akgonul, Mary Shinner, Yvonne Slater, Elizabeth Graves, Helen Mander, Trevor Munro-Clarke, Kate Shirvell, Carolyn Asher, Liesbeth Tip, Jane Owens, Shauneen Porter, Clare Jackson, Susan Irving, Caoimhe Clarke, Helen Whitehill, Rachel Allan, Suzan Aydinlar, Mairi Spanswick, Jacqueline McTaggart, James Courtley, Laura McCartney, Toyah Lebert, Maggie Douglas-Bailey, Anna Cummings and Helen Spencer.

The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health Directorate.

Contributions of authors

Anthony P Morrison (Professor of Clinical Psychology) planned the study, contributed to the application for funding, made substantial contributions to the design of the trial protocol, the SAP, managed the trial as chief investigator, contributed to writing and critically read the manuscript.

Melissa Pyle (Research Trial Manager) made substantial contribution to the development of the trial protocol, as well as overall management of the trial and data management and wrote the first draft of the manuscript.

Andrew Gumley (Professor of Psychological Therapy) contributed to the application for funding, made a substantial contribution to the design of the trial and protocol and critically read the manuscript.

Matthias Schwannauer (Professor of Clinical Psychology) contributed to the application for funding, made substantial contribution to the design of the trial and protocol and critically read the manuscript.

Douglas Turkington (Professor of Psychosocial Psychiatry) contributed to the application for funding, made substantial contribution to the design of the trial and protocol and critically read the manuscript.

Graeme MacLennan (Director and Professor, The Centre for Healthcare Randomised Trials) made substantial contribution to the development of the trial design and protocol, as well as the SAP, conducted the analysis and critically read the manuscript.

John Norrie (Professor of Medical Statistics and Trial Methodology) contributed to the application for funding, made substantial contributions to the design of the trial and protocol, the SAP, and critically read the manuscript.

Jemma Hudson (Trial Statistician) made substantial contribution to the development of the trial design and protocol, as well as the SAP, conducted the analysis and critically read the manuscript.

Samantha Bowe (Clinical Psychologist) made substantial contribution to the development of the trial design and protocol, and critically read the manuscript.

Paul French (Mental Health Clinical Lead for Greater Manchester and East Cheshire Strategic Clinical Network, NHS England North Clinical Lead for EIP and Honorary Professor) contributed to the application for funding, made substantial contributions to the design of the trial and protocol, and the SAP, and critically read the manuscript.

Paul Hutton (Associate Professor of Therapeutic Interventions and Honorary Consultant Clinical Psychologist) made substantial contribution to the development of the trial design and protocol, and critically read the manuscript.

Rory Byrne (User-led Researcher) contributed to the application for funding, made substantial contribution to the design of the trial and protocol and critically read the manuscript.

Suzy Syrett (User-led Researcher) contributed to the application for funding, made substantial contribution to the design of the trial and protocol and critically read the manuscript.

Robert Dudley (Consultant Clinical Psychologist and Associate Clinical Lecturer) made substantial contribution to the trial protocol and critically read the manuscript.

Hamish J McLeod (Senior Lecturer in Mental Health and Wellbeing) made substantial contribution to the development of the trial design and protocol, and critically read the manuscript.

Helen Griffiths (Clinical Psychologist and Lecturer in Clinical Psychology) made substantial contribution to the development of the trial design and protocol, and critically read the manuscript.

Thomas RE Barnes (Professor of Clinical Psychiatry) contributed to the application for funding, made substantial contribution to the design of the trial and protocol and critically read the manuscript.

Linda Davies (Professor of Health Economics) contributed to the application for funding, made substantial contributions to the design of the trial and protocol, the health economic analysis plan, and critically read the manuscript.

Gemma Shields (Health Economist) made substantial contribution to the health economics SAP, conducted the health economics analysis, conducted the health economics section of the manuscript and critically read the manuscript as a whole.

Deborah Buck (Health Economist) made substantial contribution to the health economics SAP, conducted the health economics analysis, conducted the health economics section of the manuscript and critically read the manuscript as a whole.

Sarah Tully (Assistant Research Psychologist) contributed to the trial protocol, significantly contributed to writing the manuscript and critically read the manuscript.

David Kingdon (Professor of Mental Health Care Delivery) contributed to the application for funding, made substantial contribution to the design of the trial and protocol, and critically read the manuscript.

All authors read and approved the final manuscript.

Publications

Pyle M, Norrie J, Schwannauer M, Kingdon D, Gumley A, Tukington D, *et al.* Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. *BMC Psychiatry* 2016;**16**:1–12.

Morrison AP, Pyle M, Gumley A, Schwannauer M, Turkington D, MacLennan G, *et al.* Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. *Lancet Psychiatry* 2018;**5**:633–43.

Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to anonymised data may be granted following review.

Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

References

1. Suhail K, Cochrane R. Effect of culture and environment on the phenomenology of delusions and hallucinations. *Int J Soc Psychiatry* 2002;**48**:126–38. <https://doi.org/10.1177/002076402128783181>
2. Freeman D, Garety PA, Kuipers E, Fowler D, Bebbington PE. A cognitive model of persecutory delusions. *Br J Clin Psychol* 2002;**41**:331–47. <https://doi.org/10.1348/014466502760387461>
3. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICES consensus statement on negative symptoms. *Schizophr Bull* 2006;**32**:214–19. <https://doi.org/10.1093/schbul/sbj053>
4. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. *Arch Gen Psychiatry* 1982;**39**:784–8. <https://doi.org/10.1001/archpsyc.1982.04290070020005>
5. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. *Br J Psychiatry* 1980;**137**:383–6.
6. Fletcher PC, Frith CD. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. *Nat Rev Neurosci* 2009;**10**:48–58. <https://doi.org/10.1038/nrn2536>
7. Bobes J, Arango C, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. *J Clin Psychiatry* 2010;**71**:280–6. <https://doi.org/10.4088/JCP.08m04250yel>
8. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. *Schizophr Bull* 2007;**33**:1013–22. <https://doi.org/10.1093/schbul/sbl057>
9. Johns LC, van Os J. The continuity of psychotic experiences in the general population. *Clin Psychol Rev* 2001;**21**:1125–41. [https://doi.org/10.1016/S0272-7358\(01\)00103-9](https://doi.org/10.1016/S0272-7358(01)00103-9)
10. Peters E, Ward T, Jackson M, Morgan C, Charalambides M, McGuire P, et al. Clinical, socio-demographic and psychological characteristics in individuals with persistent psychotic experiences with and without a 'need for care'. *World Psychiatry* 2016;**15**:41–52. <https://doi.org/10.1002/wps.20301>
11. van Os J, Hanssen M, Bijl RV, Ravelli A. Strauss (1969) revisited: a psychosis continuum in the general population? *Schizophr Res* 2000;**45**:11–20. [https://doi.org/10.1016/S0920-9964\(99\)00224-8](https://doi.org/10.1016/S0920-9964(99)00224-8)
12. van Os J. Is there a continuum of psychotic experiences in the general population? *Epidemiol Psychiatr Sci* 2003;**12**:242–52. <https://doi.org/10.1017/S1121189X00003067>
13. World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines*. Geneva: World Health Organization; 1992.
14. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-V)*. 5th edn. Washington, DC: American Psychiatric Association; 2013.
15. van Os J. 'Schizophrenia' does not exist. *BMJ* 2016;**352**:i375. <https://doi.org/10.1136/bmj.i375>
16. Bentall RP. Deconstructing the concept of 'schizophrenia'. *J Ment Health* 1993;**2**:223–38. <https://doi.org/10.3109/09638239309003768>
17. McGorry PD. The concept of recovery and secondary prevention in psychotic disorders. *Aust N Z J Psychiatry* 1992;**26**:3–17. <https://doi.org/10.3109/00048679209068305>
18. Sato M. Renaming schizophrenia: a Japanese perspective. *World Psychiatry* 2006;**5**:53–5.
19. Murray RM. Mistakes I have made in my research career. *Schizophr Bull* 2017;**43**:253–6. <https://doi.org/10.1093/schbul/sbw165>

20. Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustün TB. Age of onset of mental disorders: a review of recent literature. *Curr Opin Psychiatry* 2007;**20**:359–64. <https://doi.org/10.1097/YCO.0b013e32816ebc8c>
21. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. *Can J Psychiatry* 2002;**47**:833–43. <https://doi.org/10.1177/070674370204700904>
22. Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, et al. Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses. *PLOS ONE* 2012;**7**:e31660. <https://doi.org/10.1371/journal.pone.0031660>
23. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med* 2004;**2**:13. <https://doi.org/10.1186/1741-7015-2-13>
24. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 2011;**21**:655–79. <https://doi.org/10.1016/j.euroneuro.2011.07.018>
25. DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry* 2011;**10**:52–77. <https://doi.org/10.1002/j.2051-5545.2011.tb00014.x>
26. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. *J Clin Psychiatry* 2007;**68**(Suppl. 4):4–7. <https://doi.org/10.4088/JCP.0507e12>
27. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry* 2017;**4**:295–301. [https://doi.org/10.1016/S2215-0366\(17\)30078-0](https://doi.org/10.1016/S2215-0366(17)30078-0)
28. Brohan E, Elgie R, Sartorius N, Thornicroft G, GAMIAN-Europe Study Group. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries: the GAMIAN-Europe study. *Schizophr Res* 2010;**122**:232–8. <https://doi.org/10.1016/j.schres.2010.02.1065>
29. Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, INDIGO Study Group. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. *Lancet* 2009;**373**:408–15. [https://doi.org/10.1016/S0140-6736\(08\)61817-6](https://doi.org/10.1016/S0140-6736(08)61817-6)
30. National Institute for Health and Care Excellence. *Psychosis and Schizophrenia in Adults: Prevention and Management*. CG178. London: NICE; 2014. URL: www.nice.org.uk/guidance/cg178 (accessed 28 July 2016).
31. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009;**373**:31–41. [https://doi.org/10.1016/S0140-6736\(08\)61764-X](https://doi.org/10.1016/S0140-6736(08)61764-X)
32. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. *Am J Psychiatry* 2017;**174**:927–42. <https://doi.org/10.1176/appi.ajp.2017.16121358>
33. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Arch Gen Psychiatry* 2006;**63**:1079–87. <https://doi.org/10.1001/archpsyc.63.10.1079>

34. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, *et al.* Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;**353**:1209–23. <https://doi.org/10.1056/NEJMoa051688>
35. Kendall T. The rise and fall of the atypical antipsychotics. *Br J Psychiatry* 2011;**199**:266–8. <https://doi.org/10.1192/bjp.bp.110.083766>
36. Morrison AP, Hutton P, Shiers D, Turkington D. Antipsychotics: is it time to introduce patient choice? *Br J Psychiatry* 2012;**201**:83–4. <https://doi.org/10.1192/bjp.bp.112.112110>
37. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. *CNS Drugs* 2007;**21**:911–36. <https://doi.org/10.2165/00023210-200721110-00004>
38. Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. *Psychol Med* 2010;**40**:1409–22. <https://doi.org/10.1017/S0033291709992297>
39. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. *Br Med Bull* 2015;**114**:169–79. <https://doi.org/10.1093/bmb/ldv017>
40. Barnes T, Buckley P, Schulz S. Treatment-Resistant Schizophrenia. In Hirsch S, Weinberger D, editors. *Schizophrenia*. 2nd edn. Oxford: Blackwell Publishing; 2003. pp. 489–516. <https://doi.org/10.1002/9780470987353.ch26>
41. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. *Int Clin Psychopharmacol* 2014;**29**:63–76. <https://doi.org/10.1097/YIC.0b013e32836508e6>
42. Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P. The burden of mental disorders. *Epidemiol Rev* 2008;**30**:1–14. <https://doi.org/10.1093/epirev/mxn011>
43. Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, *et al.* Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. *Prog Neuropsychopharmacol Biol Psychiatry* 2016;**65**:34–48. <https://doi.org/10.1016/j.pnpbp.2015.08.010>
44. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 1988;**45**:789–96. <https://doi.org/10.1001/archpsyc.1988.01800330013001>
45. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, *et al.* Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. *Am J Psychiatry* 2017;**174**:216–29. <https://doi.org/10.1176/appi.ajp.2016.16050503>
46. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, *et al.* World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry* 2012;**13**:318–78. <https://doi.org/10.3109/15622975.2012.696143>
47. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. *Cochrane Database Syst Rev* 2009;**1**:CD000059. <https://doi.org/10.1002/14651858.CD000059.pub2>
48. Legge SE, Hamshere M, Hayes RD, Downs J, O'Donovan MC, Owen MJ, *et al.* Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. *Schizophr Res* 2016;**174**:113–19. <https://doi.org/10.1016/j.schres.2016.05.002>

49. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 2016;**209**:385–92. <https://doi.org/10.1192/bjp.bp.115.177261>
50. Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. *JAMA Psychiatry* 2016;**73**:199–210. <https://doi.org/10.1001/jamapsychiatry.2015.2955>
51. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. *Am J Psychiatry* 2001;**158**:518–26. <https://doi.org/10.1176/appi.ajp.158.4.518>
52. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *N Engl J Med* 2006;**354**:472–82. <https://doi.org/10.1056/NEJMoa053222>
53. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. *Evid Based Ment Health* 2014;**17**:33–7. <https://doi.org/10.1136/eb-2014-101813>
54. Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. *Eur Neuropsychopharmacol* 2012;**22**:165–82. <https://doi.org/10.1016/j.euroneuro.2011.08.005>
55. Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic – a meta-analysis. *Acta Psychiatr Scand* 2012;**125**:15–24. <https://doi.org/10.1111/j.1600-0447.2011.01792.x>
56. Sommer IE, Begemann MJ, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. *Schizophr Bull* 2012;**38**:1003–11. <https://doi.org/10.1093/schbul/sbr004>
57. Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. *Cochrane Database Syst Rev* 2016;**12**:CD006918. <https://doi.org/10.1002/14651858.CD006918.pub3>
58. Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. *Cochrane Database Syst Rev* 2017;**3**:CD006324. <https://doi.org/10.1002/14651858.CD006324.pub3>
59. Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, Clarke M. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. *BMJ Open* 2017;**7**:e013881. <https://doi.org/10.1136/bmjopen-2016-013881>
60. Beck AT, Rush AJ, Shaw BF, Emery G. *Cognitive Therapy of Depression*. New York, NY: Guilford Press; 1979.
61. Chadwick P, Birchwood M. The omnipotence of voices. A cognitive approach to auditory hallucinations. *Br J Psychiatry* 1994;**164**:190–201. <https://doi.org/10.1192/bjp.164.2.190>
62. Garety PA, Kuipers E, Fowler D, Freeman D, Bebbington PE. A cognitive model of the positive symptoms of psychosis. *Psychol Med* 2001;**31**:189–95. <https://doi.org/10.1017/S0033291701003312>
63. Morrison AP. The interpretation of intrusions in psychosis: an integrative cognitive approach to hallucinations and delusions. *Behav Cogn Psychother* 2001;**29**:257–76. <https://doi.org/10.1017/S1352465801003010>
64. Morrison A, Renton J, Dunn H, Williams S, Bentall R. *Cognitive Therapy for Psychosis: a Formulation-Based Approach*. Hove: Brunner–Routledge; 2004.

65. Brabban A, Byrne R, Longden E, Morrison AP. The importance of human relationships, ethics and recovery-orientated values in the delivery of CBT for people with psychosis. *Psychosis* 2016;**9**:157–66. <https://doi.org/10.1080/17522439.2016.1259648>
66. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, Morgan C. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. *Psychol Med* 2002;**32**:763–82. <https://doi.org/10.1017/S0033291702005895>
67. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. *Schizophr Bull* 2008;**34**:523–37. <https://doi.org/10.1093/schbul/sbm114>
68. Zimmermann G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. *Schizophr Res* 2005;**77**:1–9. <https://doi.org/10.1016/j.schres.2005.02.018>
69. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. *Br J Psychiatry* 2014;**204**:20–9. <https://doi.org/10.1192/bjp.bp.112.116285>
70. Turner DT, van der Gaag M, Karyotaki E, Cuijpers P. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. *Am J Psychiatry* 2014;**171**:523–38. <https://doi.org/10.1176/appi.ajp.2013.13081159>
71. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored formulation-based cognitive behavioural therapy in auditory hallucinations and delusions: a meta-analysis. *Schizophr Res* 2014;**156**:30–7. <https://doi.org/10.1016/j.schres.2014.03.016>
72. McKenna P, Kingdon D. Has cognitive behavioural therapy for psychosis been oversold? *BMJ* 2014;**348**:g2295. <https://doi.org/10.1136/bmj.g2295>
73. Tarrier N, Yusupoff L, Kinney C, McCarthy E, Gledhill A, Haddock G, Morris J. Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. *BMJ* 1998;**317**:303–7. <https://doi.org/10.1136/bmj.317.7154.303>
74. Pinto A, Pia SL, Mennella R, Giorgio D, DeSimone L. Rehab rounds: cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. *Psychiatry Serv* 1999;**50**:901–4. <https://doi.org/10.1176/ps.50.7.901>
75. Kuipers E, Garety P, Fowler D, Dunn G, Bebbington P, Freeman D, et al. London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase. *Br J Psychiatry* 1997;**171**:319–27. <https://doi.org/10.1192/bjp.171.4.319>
76. Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. *Arch Gen Psychiatry* 2000;**57**:165–72. <https://doi.org/10.1001/archpsyc.57.2.165>
77. Turkington D, Sensky T, Scott J, Barnes TR, Nur U, Siddle R, et al. A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. *Schizophr Res* 2008;**98**:1–7. <https://doi.org/10.1016/j.schres.2007.09.026>
78. Durham RC, Guthrie M, Morton RV, Reid DA, Treliving LR, Fowler D, Macdonald RR. Tayside-Fife clinical trial of cognitive-behavioural therapy for medication-resistant psychotic symptoms. Results to 3-month follow-up. *Br J Psychiatry* 2003;**182**:303–11. <https://doi.org/10.1192/bjp.182.4.303>
79. Valmaggia LR, van der Gaag M, Tarrier N, Pijnenborg M, Slooff CJ. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. *Br J Psychiatry* 2005;**186**:324–30. <https://doi.org/10.1192/bjp.186.4.324>

80. Sinclair D, Adams CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. *BMC Psychiatry* 2014;**14**:253. <https://doi.org/10.1186/s12888-014-0253-4>
81. Birchwood M, Peters E, Tarrier N, Dunn G, Lewis S, Wykes T, *et al.* A multi-centre, randomised controlled trial of cognitive therapy to prevent harmful compliance with command hallucinations. *BMC Psychiatry* 2011;**11**:155. <https://doi.org/10.1186/1471-244X-11-155>
82. Haddock G, Slade PD, Bentall RP, Reid D, Faragher EB. A comparison of the long-term effectiveness of distraction and focusing in the treatment of auditory hallucinations. *Br J Med Psychol* 1998;**71**:339–49. <https://doi.org/10.1111/j.2044-8341.1998.tb00996.x>
83. Hayward P, David A, Green N, Rabe-Hesketh S, Haworth E, Thompson N, *et al.* Promoting therapeutic alliance in clozapine users: an exploratory randomized controlled trial. *Clin Schizophr Relat Psychoses* 2009;**3**:127–32. <https://doi.org/10.3371/CSRP.3.3.1>
84. Barretto EM, Kayo M, Avrichir BS, Sa AR, Camargo Md, Napolitano IC, *et al.* A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. *J Nerv Ment Dis* 2009;**197**:865–8. <https://doi.org/10.1097/NMD.0b013e3181be7422>
85. Allott K, Alvarez-Jimenez M, Killackey EJ, Bendall S, McGorry PD, Jackson HJ. Patient predictors of symptom and functional outcome following cognitive behaviour therapy or befriending in first-episode psychosis. *Schizophr Res* 2011;**132**:125–30. <https://doi.org/10.1016/j.schres.2011.08.011>
86. Brabban A, Tai S, Turkington D. Predictors of outcome in brief cognitive behavior therapy for schizophrenia. *Schizophr Bull* 2009;**35**:859–64. <https://doi.org/10.1093/schbul/sbp065>
87. Lincoln TM, Rief W, Westermann S, Ziegler M, Kesting ML, Heibach E, Mehl S. Who stays, who benefits? Predicting dropout and change in cognitive behaviour therapy for psychosis. *Psychiatry Res* 2014;**216**:198–205. <https://doi.org/10.1016/j.psychres.2014.02.012>
88. Rathod S, Kingdon D, Smith P, Turkington D. Insight into schizophrenia: the effects of cognitive behavioural therapy on the components of insight and association with sociodemographics – data on a previously published randomised controlled trial. *Schizophr Res* 2005;**74**:211–19. <https://doi.org/10.1016/j.schres.2004.07.003>
89. Garety P, Fowler D, Kuipers E, Freeman D, Dunn G, Bebbington P, *et al.* London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. II: predictors of outcome. *Br J Psychiatry* 1997;**171**:420–6. <https://doi.org/10.1192/bjp.171.5.420>
90. Drury V, Birchwood M, Cochrane R, MacMillan F. Cognitive therapy and recovery from acute psychosis: a controlled trial. I. Impact on psychotic symptoms. *Br J Psychiatry* 1996;**169**:593–601. <https://doi.org/10.1192/bjp.169.5.593>
91. Morrison AP, Renton JC, Williams S, Dunn H, Knight A, Kreutz M, *et al.* Delivering cognitive therapy to people with psychosis in a community mental health setting: an effectiveness study. *Acta Psychiatr Scand* 2004;**110**:36–44. <https://doi.org/10.1111/j.1600-0447.2004.00299.x>
92. Morrison AP, Turkington D, Wardle M, Spencer H, Barratt S, Dudley R, *et al.* A preliminary exploration of predictors of outcome and cognitive mechanisms of change in cognitive behaviour therapy for psychosis in people not taking antipsychotic medication. *Behav Res Ther* 2012;**50**:163–7. <https://doi.org/10.1016/j.brat.2011.12.001>
93. Naeem F, Kingdon D, Turkington D. Predictors of response to cognitive behaviour therapy in the treatment of schizophrenia: a comparison of brief and standard interventions. *Cognit Ther Res* 2008;**32**:651–6. <https://doi.org/10.1007/s10608-008-9186-x>
94. Johns LC, Cannon M, Singleton N, Murray RM, Farrell M, Brugha T, *et al.* Prevalence and correlates of self-reported psychotic symptoms in the British population. *Br J Psychiatry* 2004;**185**:298–305. <https://doi.org/10.1192/bjp.185.4.298>

95. Manning C, Stickley T. Childhood abuse and psychosis; a critical review of the literature. *J Res Nurs* 2009;**14**:531–47. <https://doi.org/10.1177/1744987109347045>
96. Siegel RK. Hostage hallucinations. Visual imagery induced by isolation and life-threatening stress. *J Nerv Ment Dis* 1984;**172**:264–72. <https://doi.org/10.1097/00005053-198405000-00003>
97. Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM. Meta-analysis of the association of urbanicity with schizophrenia. *Schizophr Bull* 2012;**38**:1118–23. <https://doi.org/10.1093/schbul/sbs096>
98. Hollander AC, Dal H, Lewis G, Magnusson C, Kirkbride JB, Dalman C. Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. *BMJ* 2016;**352**:i1030. <https://doi.org/10.1136/bmj.i1030>
99. Kirkbride JB, Jones PB, Ullrich S, Coid JW. Social deprivation, inequality, and the neighborhood-level incidence of psychotic syndromes in East London. *Schizophr Bull* 2014;**40**:169–80. <https://doi.org/10.1093/schbul/sbs151>
100. Janssen I, Hanssen M, Bak M, Bijl RV, de Graaf R, Vollebergh W, *et al.* Discrimination and delusional ideation. *Br J Psychiatry* 2003;**182**:71–6. <https://doi.org/10.1192/bjpp.182.1.71>
101. Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, *et al.* Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. *Schizophr Bull* 2012;**38**:661–71. <https://doi.org/10.1093/schbul/sbs050>
102. Bentall RP, Wickham S, Shevlin M, Varese F. Do specific early-life adversities lead to specific symptoms of psychosis? A study from the 2007 the Adult Psychiatric Morbidity Survey. *Schizophr Bull* 2012;**38**:734–40. <https://doi.org/10.1093/schbul/sbs049>
103. Arseneault L, Cannon M, Fisher HL, Polanczyk G, Moffitt TE, Caspi A. Childhood trauma and children's emerging psychotic symptoms: a genetically sensitive longitudinal cohort study. *Am J Psychiatry* 2011;**168**:65–72. <https://doi.org/10.1176/appi.ajp.2010.10040567>
104. Morrison AP. A manualised treatment protocol to guide delivery of evidence-based cognitive therapy for people with distressing psychosis: learning from clinical trials. *Psychosis* 2017;**9**:1–11. <https://doi.org/10.1080/17522439.2017.1295098>
105. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. *Neuropsychiatr Dis Treat* 2006;**2**:531–6. <https://doi.org/10.2147/ndt.2006.2.4.531>
106. Goldberg TE, Green MF. Neurocognitive Functioning in Patients with Schizophrenia: an Overview. In Davis KL, Charney D, Coyle JT, Nemeroff C, editors. *Neuropsychopharmacology: the Fifth Generation of Progress*. Brentwood, CA: American College of Neuropsychopharmacology; 2002. pp. 1245–57.
107. Baddeley A. *Working Memory*. Oxford: Clarendon Press; 1986.
108. Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. *Psychol Med* 2009;**39**:889–905. <https://doi.org/10.1017/S0033291708004558>
109. McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, *et al.* The effects of clozapine and risperidone on spatial working memory in schizophrenia. *Am J Psychiatry* 2005;**162**:1013–16. <https://doi.org/10.1176/appi.ajp.162.5.1013>
110. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. *Am J Psychiatry* 2004;**161**:116–24. <https://doi.org/10.1176/appi.ajp.161.1.116>
111. James IA, Reichelt FK, Carlsson P, McAnaney A. Cognitive behavior therapy and executive functioning in depression. *J Cogn Psychother* 2008;**22**:210–8. <https://doi.org/10.1891/0889-8391.22.3.210>

112. Granholm E, McQuaid JR, Link PC, Fish S, Patterson T, Jeste DV. Neuropsychological predictors of functional outcome in Cognitive Behavioral Social Skills Training for older people with schizophrenia. *Schizophr Res* 2008;**100**:133–43. <https://doi.org/10.1016/j.schres.2007.11.032>
113. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? *Schizophr Bull* 2000;**26**:119–36. <https://doi.org/10.1093/oxfordjournals.schbul.a033430>
114. Glaser NM, Kazantzis N, Deane FP, Oades LG. Critical issues in using homework assignments within cognitive–behavioral therapy for schizophrenia. *J Ration Emot Cogn Behav Ther* 2000;**18**:247–61. <https://doi.org/10.1023/A:1007888615752>
115. Kurtz MM. Neurocognition as a predictor of response to evidence-based psychosocial interventions in schizophrenia: what is the state of the evidence? *Clin Psychol Rev* 2011;**31**:663–72. <https://doi.org/10.1016/j.cpr.2011.02.008>
116. Crawford MJ, Robotham D, Thana L, Patterson S, Weaver T, Barber R, et al. Selecting outcome measures in mental health: the views of service users. *J Ment Health* 2011;**20**:336–46. <https://doi.org/10.3109/09638237.2011.577114>
117. Andresen R, Oades L, Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model. *Aust N Z J Psychiatry* 2003;**37**:586–94. <https://doi.org/10.1046/j.1440-1614.2003.01234.x>
118. Bellack AS. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. *Schizophr Bull* 2006;**32**:432–42. <https://doi.org/10.1093/schbul/sbj044>
119. Pitt L, Kilbride M, Nothard S, Welford M, Morrison AP. Researching recovery from psychosis: a user-led project. *Psychiatrist* 2007;**31**:55–60.
120. Leamy M, Bird V, Le Boutillier C, Williams J, Slade M. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. *Br J Psychiatry* 2011;**199**:445–52. <https://doi.org/10.1192/bjp.bp.110.083733>
121. Birchwood M, Trower P. The future of cognitive–behavioural therapy for psychosis: not a quasi-neuroleptic. *Br J Psychiatry* 2006;**188**:107–8. <https://doi.org/10.1192/bjp.bp.105.014985>
122. The Schizophrenia Commission. *The Abandoned Illness: a Report from the Schizophrenia Commission*. London: Rethink Mental Illness; 2012.
123. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. *Neuropsychopharmacology* 2006;**31**:2318–25. <https://doi.org/10.1038/sj.npp.1301147>
124. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behavior therapy versus other psychosocial treatments for schizophrenia. *Schizophr Bull* 2012;**38**:908–10. <https://doi.org/10.1093/schbul/sbs090>
125. Klingberg S, Wittorf A, Meisner C, Wölwer W, Wiedemann G, Herrlich J, et al. Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: the POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. *Trials* 2010;**11**:123. <https://doi.org/10.1186/1745-6215-11-123>
126. Klingberg S, Herrlich J, Wiedemann G, Wölwer W, Meisner C, Engel C, et al. Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. *J Nerv Ment Dis* 2012;**200**:569–76. <https://doi.org/10.1097/NMD.0b013e31825bfa1d>
127. Pyle M, Norrie J, Schwannauer M, Kingdon D, Gumley A, Turkington D, et al. Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. *BMC Psychiatry* 2016;**16**:280. <https://doi.org/10.1186/s12888-016-0983-6>

128. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. *J Clin Psychopharmacol* 2004;**24**:192–208. <https://doi.org/10.1097/01.jcp.0000117422.05703.ae>
129. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? *Schizophr Res* 2005;**79**:231–8. <https://doi.org/10.1016/j.schres.2005.04.008>
130. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* 1987;**13**:261–76. <https://doi.org/10.1093/schbul/13.2.261>
131. van der Gaag M, Cuijpers A, Hoffman T, Remijsen M, Hijman R, de Haan L, *et al.* The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. *Schizophr Res* 2006;**85**:273–9. <https://doi.org/10.1016/j.schres.2006.04.001>
132. van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, *et al.* The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. *Schizophr Res* 2006;**85**:280–7. <https://doi.org/10.1016/j.schres.2006.03.021>
133. Leucht S, Kissling W, Davis JM. The PANSS should be rescaled. *Schizophr Bull* 2010;**36**:461–2. <https://doi.org/10.1093/schbul/sbq016>
134. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). *Psychol Med* 1999;**29**:879–89. <https://doi.org/10.1017/S0033291799008661>
135. Neil ST, Kilbride M, Pitt L, Nothard S, Welford M, Sellwood W, *et al.* The Questionnaire about the Process of Recovery (QPR): a measurement tool developed in collaboration with service users. *Psychosis* 2009;**1**:145–55. <https://doi.org/10.1080/17522430902913450>
136. Law H, Neil ST, Dunn G, Morrison AP. Psychometric properties of the Questionnaire about the Process of Recovery (QPR). *Schizophr Res* 2014;**156**:184–9. <https://doi.org/10.1016/j.schres.2014.04.011>
137. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. *Acta Psychiatr Scand* 2000;**101**:323–9.
138. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. *Schizophr Res* 1992;**6**:201–8. [https://doi.org/10.1016/0920-9964\(92\)90003-N](https://doi.org/10.1016/0920-9964(92)90003-N)
139. Wells A. A multi-dimensional measure of worry: development and preliminary validation of the Anxious Thoughts Inventory. *Anxiety Stress Coping* 1994;**6**:289–99. <https://doi.org/10.1080/10615809408248803>
140. Cassidy CM, Schmitz N, Malla A. Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis. *Can J Psychiatry* 2008;**53**:26–33. <https://doi.org/10.1177/070674370805300105>
141. Skinner HA. The drug abuse screening test. *Addict Behav* 1982;**7**:363–71. [https://doi.org/10.1016/0306-4603\(82\)90005-3](https://doi.org/10.1016/0306-4603(82)90005-3)
142. Morrison AP, Wells A, Nothard S. Cognitive and emotional predictors of predisposition to hallucinations in non-patients. *Br J Clin Psychol* 2002;**41**:259–70. <https://doi.org/10.1348/014466502760379127>
143. Morrison AP, Gumley AI, Schwannauer M, Campbell M, Gleeson A, Griffin E, *et al.* The Beliefs about Paranoia Scale: preliminary validation of a metacognitive approach to conceptualizing paranoia. *Behav Cogn Psychother* 2005;**33**:153–64. <https://doi.org/10.1017/S1352465804001900>

144. Murphy EK, Tully S, Pyle M, Gumley AI, Kingdon D, Schwannauer M, *et al.* The Beliefs about Paranoia Scale: confirmatory factor analysis and tests of a metacognitive model of paranoia in a clinical sample. *Psychiatry Res* 2017;**248**:87–94. <https://doi.org/10.1016/j.psychres.2016.11.012>
145. Fowler D, Freeman D, Smith B, Kuipers E, Bebbington P, Bashforth H, *et al.* The Brief Core Schema Scales (BCSS): psychometric properties and associations with paranoia and grandiosity in non-clinical and psychosis samples. *Psychol Med* 2006;**36**:749–59. <https://doi.org/10.1017/S0033291706007355>
146. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. *Arch Gen Psychiatry* 1997;**54**:159–65. <https://doi.org/10.1001/archpsyc.1997.01830140071013>
147. Berry K, Wearden A, Barrowclough C, Liversidge T. Attachment styles, interpersonal relationships and psychotic phenomena in a non-clinical student sample. *Pers Individ Differ* 2006;**41**:707–18. <https://doi.org/10.1016/j.paid.2006.03.009>
148. Ritsher JB, Otilingam PG, Grajales M. Internalized stigma of mental illness: psychometric properties of a new measure. *Psychiatry Res* 2003;**121**:31–49. <https://doi.org/10.1016/j.psychres.2003.08.008>
149. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, *et al.* Initial reliability and validity of a new retrospective measure of child abuse and neglect. *Am J Psychiatry* 1994;**151**:1132–6. <https://doi.org/10.1176/ajp.151.8.1132>
150. Kinoshita Y, Kingdon D, Kinoshita K, Sarafudheen S, Umadi D, Dayson D, *et al.* A semi-structured clinical interview for psychosis sub-groups (SCIPS): development and psychometric properties. *Soc Psychiatry Psychiatr Epidemiol* 2012;**47**:563–80. <https://doi.org/10.1007/s00127-011-0357-9>
151. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, *et al.* Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res* 2013;**22**:1717–27. <https://doi.org/10.1007/s11136-012-0322-4>
152. Bobes J, García-Portilla P, Sáiz PA, Bascarán T, Bousoño M. Quality of life measures in schizophrenia. *Eur Psychiatry* 2005;**20**(Suppl. 3):313–17. [https://doi.org/10.1016/S0924-9338\(05\)80182-8](https://doi.org/10.1016/S0924-9338(05)80182-8)
153. Kingdon DG, Turkington D. *Cognitive Therapy of Schizophrenia*. New York, NY: Guilford Press; 2005.
154. Flach C, French P, Dunn G, Fowler D, Gumley AI, Birchwood M, *et al.* Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. *Br J Psychiatry* 2015;**207**:123–9. <https://doi.org/10.1192/bjp.bp.114.153320>
155. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. *BMJ* 2011;**342**:d40. <https://doi.org/10.1136/bmj.d40>
156. National Institute for Health and Care Excellence (NICE). *Guide to the Methods of Technology Appraisal*. PMG9. London: NICE; 2013. URL: www.nice.org.uk/process/pmg9/chapter/foreword (accessed 27 February 2017).
157. Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. *Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England*. OHE Research Paper 16/01. London: Office of Health Economics; 2016.
158. Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T, Fowler D. Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. *Br J Psychiatry* 2009;**195**:170–7. <https://doi.org/10.1192/bjp.bp.108.057380>

159. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, *et al.* Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. *Br J Psychiatry* 2007;**191**:14–22. <https://doi.org/10.1192/bjp.bp.106.028654>
160. Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, *et al.* A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. *Value Health* 2008;**11**:549–62. <https://doi.org/10.1111/j.1524-4733.2007.00280.x>
161. Department of Health and Social Care. *NHS Reference Costs: National Schedule of Reference Costs 2015–2016*. 2016. URL: www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016
162. Curtis L. *Unit Costs of Health and Social Care 2014*. Canterbury: PSSRU, University of Kent; 2014. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2014/
163. Curtis L. and Burns A. *Unit Costs of Health and Social Care 2015*. Canterbury: PSSRU, University of Kent; 2015. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2015/
164. Curtis L. and Burns A. *Unit Costs of Health and Social Care 2016*. Canterbury: PSSRU, University of Kent; 2016. URL: www.pssru.ac.uk/project-pages/unit-costs/2016/
165. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. *Stat Med* 2005;**24**:993–1007. <https://doi.org/10.1002/sim.1981>
166. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. *Pharmacoeconomics* 2014;**32**:1157–70. <https://doi.org/10.1007/s40273-014-0193-3>
167. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. *Pharmacoeconomics* 2008;**26**:733–44. <https://doi.org/10.2165/00019053-200826090-00004>
168. Claxton K, Martin S, Soares MO, Rice N, Spackman DE, Hinde S, *et al.* *Methods for the Estimation of the NICE Cost Effectiveness Threshold*. York: Centre for Health Economics, University of York; 2013.
169. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, *et al.* Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. *Health Technol Assess* 2015;**19**(14). <https://doi.org/10.3310/hta19140>
170. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, *et al.* Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health* 2012;**15**:708–15. <https://doi.org/10.1016/j.jval.2012.02.008>
171. Morrison AP, Pyle M, Gumley A, Schwannauer M, Turkington D, MacLennan G, *et al.* Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. *Lancet Psychiatry* 2018;**5**:633–43. [https://doi.org/10.1016/S2215-0366\(18\)30184-6](https://doi.org/10.1016/S2215-0366(18)30184-6)
172. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. *BMJ* 2004;**329**:224–7. <https://doi.org/10.1136/bmj.329.7459.224>
173. Goldsmith LP, Lewis SW, Dunn G, Bentall RP. Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: an instrumental variable analysis. *Psychol Med* 2015;**45**:2365–73. <https://doi.org/10.1017/S003329171500032X>
174. Janssen B, Szende A. Population Norms for the EQ-5D. In Szende A, Janssen B, Cabases J, editors. *Self-Reported Population Health: an International Perspective Based on EQ-5D*. The Netherlands: Springer; 2014. pp. 19–30. https://doi.org/10.1007/978-94-007-7596-1_3

175. Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, *et al.* Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE). *Health Technol Assess* 2012;**16**(8). <https://doi.org/10.3310/hta16080>
176. Priebe S, Pavlickova H, Eldridge S, Golden E, McCrone P, Ockenden N, *et al.* Effectiveness of one-to-one volunteer support for patients with psychosis: protocol of a randomised controlled trial. *BMJ Open* 2016;**6**:e011582. <https://doi.org/10.1136/bmjopen-2016-011582>
177. Haddock G, Barrowclough C, Tarrier N, Moring J, O'Brien R, Schofield N, *et al.* Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. *Br J Psychiatry* 2003;**183**:418–26. <https://doi.org/10.1192/bjp.183.5.418>
178. McCrone P, Craig TK, Power P, Garety PA. Cost-effectiveness of an early intervention service for people with psychosis. *Br J Psychiatry* 2010;**196**:377–82. <https://doi.org/10.1192/bjp.bp.109.065896>
179. Patel A, Knapp M, Romeo R, Reeder C, Matthiasson P, Everitt B, Wykes T. Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis. *Schizophr Res* 2010;**120**:217–24. <https://doi.org/10.1016/j.schres.2009.12.003>
180. Lawrence D, Kisely S. Inequalities in healthcare provision for people with severe mental illness. *J Psychopharmacol* 2010;**24**(Suppl. 4):61–8. <https://doi.org/10.1177/1359786810382058>
181. Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. *Br J Psychiatry* 2011;**199**:441–2. <https://doi.org/10.1192/bjp.bp.111.092718>
182. Corrigan PW, Larson JE, Rüschi N. Self-stigma and the 'why try' effect: impact on life goals and evidence-based practices. *World Psychiatry* 2009;**8**:75–81. <https://doi.org/10.1002/j.2051-5545.2009.tb00218.x>
183. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndeti DM, *et al.* Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. *World Psychiatry* 2011;**10**:138–51. <https://doi.org/10.1002/j.2051-5545.2011.tb00036.x>
184. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. *BMJ* 1995;**310**:452–4. <https://doi.org/10.1136/bmj.310.6977.452>
185. Altman DG. Confidence intervals for the number needed to treat. *BMJ* 1998;**317**:1309–12. <https://doi.org/10.1136/bmj.317.7168.1309>
186. National Institute for Health and Care Excellence (NICE). *Position Statement on the use of the EQ-5D-5L Valuation Set*. London: NICE; 2017. URL: www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisal-guidance/eq5d5l_nice_position_statement.pdf (accessed 27 November 2018).
187. Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, *et al.* Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial. *BMJ* 2012;**344**:e846. <https://doi.org/10.1136/bmj.e846>
188. Priebe S, Savill M, Wykes T, Bentall R, Lauber C, Reininghaus U, *et al.* Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial. *Health Technol Assess* 2016;**20**(11). <https://doi.org/10.3310/hta20110>
189. Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J, Kuipers E. Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review. *Br J Psychiatry* 2010;**197**:350–6. <https://doi.org/10.1192/bjp.bp.109.074526>

Appendix 1 Recruitment information

TABLE 37 Referral pathway of participants randomised

Service setting	Centre, n (%)					
	All (N = 487)	Manchester (N = 108)	Southampton (N = 105)	Newcastle (N = 92)	Edinburgh (N = 92)	Glasgow (N = 90)
CMHT	224 (46.0)	24 (22.2)	69 (65.7)	69 (75.0)	24 (26.1)	38 (42.2)
Clozapine clinic	129 (26.5)	20 (18.5)	19 (18.1)	8 (8.7)	39 (42.4)	43 (47.8)
MHRN	46 (9.4)	44 (40.7)	2 (1.9)	0.00	0.00	0.00
Inpatient unit	42 (8.6)	4 (3.7)	1 (1.0)	7 (7.6)	24 (26.1)	6 (6.7)
Research trial	9 (1.8)	2 (1.9)	4 (3.8)	0.00	3 (3.3)	0.00
EIP	8 (1.6)	3 (2.8)	1 (1.0)	4 (4.3)	0.00	0.00
Supported accommodation	8 (1.6)	2 (1.9)	4 (3.8)	0.00	1 (1.1)	1 (1.1)
Psychiatrist	8 (1.6)	6 (5.6)	1 (1.0)	1 (1.1)	0.00	0.00
Assertive outreach	6 (1.2)	0.00	3 (2.9)	2 (2.2)	0.00	1 (1.1)
Forensic services	2 (0.4)	0.00	0.00	1 (1.1)	0.00	1 (1.1)
Psychologist	2 (0.4)	2 (1.9)	0.00	0.00	0.00	0.00
Voluntary/third sector	2 (0.4)	1 (0.9)	0.00	0.00	1 (1.1)	0.00
Older adults' mental health service	1 (0.2)	0.00	1 (1.0)	0.00	0.00	0.00
MHRN, Mental Health Research Network.						

TABLE 38 Ineligible reasons

Ineligible reasons	n (%)
<i>After patients identified</i>	N = 79
No current positive symptoms of psychosis or problems	21 (26.6)
Dose of clozapine < 400 mg and not limited because of side effects	16 (20.3)
Lacking capacity to consent	9 (11.4)
Current CBT or CBT in previous year	8 (10.1)
Never taken clozapine	7 (8.9)
Diagnosis not schizophrenia spectrum	7 (8.9)
Discontinued clozapine > 2 years ago	6 (7.6)
Moved out of area	2 (2.5)
Diagnosis of a developmental disability	1 (1.3)
Not English speaking	1 (1.3)
Deceased before consented	1 (1.3)
<i>After patients found to be eligible</i>	N = 47
Below threshold on PANSS	40 (85.1)
Diagnosis not schizophrenia spectrum	2 (4.3)
Lacking capacity to consent	2 (4.3)
Dose of clozapine < 400 mg and not limited because of side effects	1 (2.1)
No current positive symptoms of psychosis or problems	1 (2.1)
Unable to complete the baseline assessment	1 (2.1)

Appendix 2 Additional analyses

TABLE 39 The PANSS outcome using MI

PANSS subscale	Mean difference	95% CI	p-value
PANSS total			
9 months	-2.50	-4.98 to -0.02	0.048
21 months	-0.63	-3.22 to 1.96	0.634
PANSS positive			
9 months	-1.64	-2.65 to -0.63	0.002
21 months	-0.74	-1.80 to 0.33	0.174
PANSS negative			
9 months	-0.43	-1.44 to 0.59	0.408
21 months	0.28	-0.77 to 1.32	0.604
PANSS disorganised			
9 months	0.05	-0.88 to 0.98	0.915
21 months	0.22	-0.75 to 1.19	0.657
PANSS excitement			
9 months	-1.14	-1.84 to -0.44	0.001
21 months	-0.51	-1.25 to 0.23	0.176
PANSS emotional distress			
9 months	-1.04	-2.02 to -0.05	0.040
21 months	-0.10	-1.14 to 0.94	0.853

TABLE 40 Complier-average causal effect analysis estimates, using a minimum of six sessions of CBT attendance at 9 months

	Mean difference	95% CI	p-value
PANSS			
Total	-2.50	-5.10 to 0.11	0.060
Positive	-0.52	-1.60 to 0.56	0.348
Negative	-1.67	-2.68 to -0.67	0.001
Disorganised	-0.00	-0.97 to 0.97	0.997
Excitement	-1.28	-2.05 to -0.50	0.001
Emotional distress	-1.17	-2.21 to -0.13	0.028
CDSS	-0.59	-1.41 to 0.22	0.152
AnTI	-0.03	-0.90 to 0.83	0.942
PSYRATS			
Delusion	-0.42	-1.67 to 0.82	0.506
Auditory hallucinations	-2.62	-5.12 to -0.12	0.040
Unusual beliefs – cognitive	-0.24	-1.05 to 0.58	0.566
Unusual beliefs – emotional	-0.29	-0.83 to 0.24	0.283
Voices – cognitive	-0.34	-0.87 to 0.19	0.205
Voices – emotional	-0.45	-1.01 to 0.11	0.114
Voices – physical	-0.63	-1.23 to -0.04	0.038
Voices – loudness	-0.24	-0.54 to 0.06	0.112
PSP	2.05	-0.33 to 4.43	0.091
QPR	2.02	-0.10 to 4.14	0.062
AUDIT	0.72	-0.20 to 1.64	0.127
DAST	-0.15	-0.53 to 0.22	0.414
Severity CGI	-0.09	-0.32 to 0.13	0.418
Participant severity CGI	0.08	-0.27 to 0.42	0.669
Condition improvement CGI	-0.35	-0.58 to -0.11	0.004
EQ-5D-5L	0.036	-0.006 to 0.078	0.094

TABLE 41 Complier-average causal effect analysis estimates, using a minimum of six sessions of CBT attendance at 21 months

	Mean difference	95% CI	p-value
PANSS			
Total	-0.87	-3.69 to 1.96	0.548
Positive	0.36	-0.76 to 1.48	0.527
Negative	-0.95	-2.10 to 0.19	0.102
Disorganised	0.17	-0.87 to 1.22	0.745
Excitement	-0.56	-1.32 to 0.20	0.146
Emotional distress	-0.33	-1.47 to 0.80	0.565
CDSS	-0.51	-1.41 to 0.38	0.263
AnTI	-0.68	-1.61 to 0.26	0.155
PSYRATS			
Delusion	-0.84	-2.22 to 0.54	0.232
Auditory hallucinations	-1.37	-4.01 to 1.27	0.310
Unusual beliefs – cognitive	-0.39	-1.28 to 0.51	0.397
Unusual beliefs – emotional	-0.58	-1.16 to 0.00	0.050
Voices – cognitive	-0.17	-0.75 to 0.40	0.551
Voices – emotional	-0.01	-0.60 to 0.58	0.969
Voices – physical	-0.33	-0.91 to 0.25	0.267
Voices – loudness	-0.32	-0.64 to 0.01	0.057
PSP	-0.10	-2.85 to 2.64	0.941
QPR	2.27	0.15 to 4.39	0.036
AUDIT	0.84	-0.18 to 1.87	0.107
DAST	0.10	-0.18 to 0.38	0.488
Severity CGI	-0.04	-0.26 to 0.19	0.752
Participant severity CGI	0.12	-0.23 to 0.48	0.502
Condition improvement CGI	-0.04	-0.32 to 0.23	0.757
EQ-5D-5L	0.03	-0.01 to 0.07	0.151

TABLE 42 Questionnaire about the Process of Recovery: age, age at onset and sex

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Age (years)								
9 months								
16–32	53.3 (12.1); 40	50.6 (9.6); 40	0.41	–3.67 to 4.50	0.842	–2.33	–7.16 to 2.51	0.345
33–49	51.1 (10.1); 97	48.7 (10.8); 105	2.74	0.16 to 5.33	0.038			
≥ 50	48.3 (13.8); 44	47.0 (12.9); 49	1.23	–2.70 to 5.16	0.540	–1.51	–6.22 to 3.19	0.528
21 months								
16–32	52.5 (8.4); 92	49.4 (11.0); 104	2.52	–0.10 to 5.14	0.059			
33–49	54.6 (9.2); 38	50.9 (11.9); 32	0.80	–3.66 to 5.26	0.724	–1.72	–6.89 to 3.45	0.514
≥ 50	47.9 (11.8); 35	47.2 (12.7); 49	1.78	–2.39 to 5.94	0.403	–0.74	–5.67 to 4.18	0.767
Age at onset (years)								
9 months								
≤ 35	52.2 (10.8); 148	49.0 (10.9); 169	2.45	0.40 to 4.51	0.019			
≥ 36	46.7 (14.3); 22	43.0 (12.8); 16	2.96	–3.24 to 9.16	0.349	0.51	–6.02 to 7.05	0.878
21 months								
≤ 35	52.6 (9.0); 141	49.4 (11.5); 159	1.71	–0.41 to 3.83	0.114			
≥ 36	47.7 (14.5); 15	42.1 (12.5); 15	6.01	–0.60 to 12.61	0.075	4.30	–2.65 to 11.24	0.226
Sex								
9 months								
Female	52.2 (12.1); 51	46.8 (12.9); 59	4.82	1.27 to 8.37	0.008			
Male	50.3 (11.4); 130	49.5 (10.2); 135	0.70	–1.56 to 2.95	0.546	–4.13	–8.33 to 0.08	0.054
21 months								
Female	51.6 (10.2); 48	50.0 (11.7); 53	0.92	–2.80 to 4.64	0.628			
Male	52.1 (9.4); 117	48.7 (11.7); 132	2.45	0.12 to 4.79	0.039	1.53	–2.85 to 5.92	0.493

TABLE 43 Questionnaire about the Process of Recovery: DI, DUP and clozapine

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
<i>DI (years)</i>								
9 months								
0–15	51.8 (12.2); 79	48.8 (11.3); 68	2.20	−0.81 to 5.22	0.153			
16–30	50.7 (10.8); 75	48.8 (10.5); 89	1.60	−1.27 to 4.47	0.275	−0.60	−4.77 to 3.56	0.777
≥ 31	53.7 (10.2); 16	47.3 (13.3); 28	6.51	0.66 to 12.35	0.029	4.30	−2.27 to 10.87	0.199
21 months								
0–15	52.5 (10.3); 75	47.7 (12.6); 59	2.52	−0.66 to 5.70	0.120			
16–30	52.1 (8.8); 68	49.2 (11.0); 85	2.45	−0.53 to 5.42	0.107	−0.08	−4.43 to 4.28	0.972
≥ 31	50.4 (11.5); 13	49.7 (12.4); 30	0.49	−5.60 to 6.59	0.874	−2.03	−8.89 to 4.83	0.562
<i>DUP (years)</i>								
9 months								
0–2	51.6 (11.4); 99	48.2 (10.5); 79	2.00	−0.76 to 4.76	0.156			
2–5	51.7 (8.6); 28	48.8 (11.8); 59	1.33	−3.01 to 5.66	0.548	−0.67	−5.80 to 4.47	0.799
≥ 6	49.5 (11.8); 23	47.3 (11.9); 27	4.97	−0.27 to 10.21	0.063	2.97	−2.96 to 8.90	0.326
21 months								
0–2	52.7 (9.5); 90	48.0 (11.7); 76	2.27	−0.60 to 5.15	0.121			
2–5	52.9 (10.4); 28	49.7 (12.0); 54	1.65	−2.68 to 5.97	0.456	−0.63	−5.82 to 4.56	0.812
≥ 6	51.3 (9.1); 20	47.5 (11.1); 23	6.26	0.65 to 11.87	0.029	3.99	−2.33 to 10.30	0.216
continued								

TABLE 43 Questionnaire about the Process of Recovery: DI, DUP and clozapine (*continued*)

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Number of antipsychotic drugs at baseline								
9 months								
One or less	51.9 (11.0); 109	48.2 (11.5); 123	2.52	0.07 to 4.98	0.044			
Two or more	49.3 (12.3); 72	49.6 (10.6); 71	0.98	−2.07 to 4.04	0.528	−1.54	−5.47 to 2.39	0.442
21 months								
One or less	53.2 (9.1); 97	49.6 (11.8); 114	1.82	−0.76 to 4.40	0.167			
Two or more	50.3 (10.1); 68	48.3 (11.5); 71	2.51	−0.59 to 5.60	0.113	0.69	−3.34 to 4.72	0.738
Clozapine daily dose (mg)								
9 months								
None	50.3 (10.4); 15	47.9 (12.7); 17	5.01	−1.41 to 11.42	0.126			
< 300	54.5 (8.2); 25	47.7 (10.0); 41	5.23	0.52 to 9.93	0.030	0.22	−7.75 to 8.19	0.957
300–600	49.8 (12.5); 106	49.4 (11.1); 103	0.41	−2.15 to 2.98	0.752	−4.59	−11.50 to 2.31	0.192
≥ 600	51.7 (11.3); 35	47.9 (12.1); 33	2.15	−2.22 to 6.51	0.335	−2.86	−10.62 to 4.90	0.470
21 months								
None	50.0 (14.8); 15	51.0 (13.7); 15	0.50	−6.02 to 7.01	0.882			
< 300	55.0 (7.7); 24	49.1 (12.6); 43	4.12	−0.61 to 8.85	0.088	3.62	−4.43 to 11.68	0.378
300–600	51.3 (9.2); 94	49.2 (11.5); 97	1.18	−1.49 to 3.85	0.386	0.69	−6.36 to 7.73	0.849
≥ 600	52.7 (9.0); 32	47.9 (10.0); 30	3.65	−1.00 to 8.31	0.124	3.16	−4.85 to 11.17	0.440

TABLE 44 Positive and Negative Syndrome Scale: difficulty with abstract thinking, conceptual disorganisation and LNS

		Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
		CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Difficulty with abstract thinking (PANSS)									
9 months									
0–4	51.6 (10.9); 114	48.7 (11.6); 124	2.18	–0.20 to 4.57	0.073				
≥ 4	49.7 (12.8); 67	48.7 (10.4); 70	1.32	–1.88 to 4.52	0.418	–0.86		–4.86 to 3.14	0.673
21 months									
0–4	52.7 (9.7); 103	49.0 (11.2); 121	2.61	0.12 to 5.09	0.040				
≥ 4	50.8 (9.4); 62	49.3 (12.5); 64	0.89	–2.41 to 4.19	0.597	–1.72		–5.85 to 2.42	0.416
Conceptual disorganisation (PANSS)									
9 months									
0–4	50.3 (11.6); 153	48.0 (11.0); 159	2.19	0.10 to 4.27	0.040				
≥ 4	53.9 (11.3); 28	51.9 (11.2); 35	0.43	–4.38 to 5.25	0.860	–1.75		–7.00 to 3.50	0.513
21 months									
0–4	51.8 (9.7); 138	48.7 (11.8); 151	2.00	–0.17 to 4.18	0.071				
≥ 4	53.1 (9.6); 27	50.7 (11.2); 34	1.96	–2.88 to 6.81	0.427	–0.04		–5.35 to 5.27	0.988
LN									
9 months									
≤ 8	52.4 (11.9); 23	44.6 (14.6); 17	5.42	–0.59 to 11.44	0.077				
≥ 9	54.6 (9.9); 14	50.9 (14.1); 11	3.02	–4.34 to 10.38	0.421	–2.40		–11.86 to 7.05	0.618
21 months									
≤ 8	51.0 (8.6); 20	51.3 (9.5); 15	–1.11	–7.51 to 5.28	0.733				
≥ 9	51.7 (9.6); 13	52.1 (10.4); 12	–0.58	–7.94 to 6.78	0.877	0.53		–9.19 to 10.26	0.914

TABLE 45 Questionnaire about the Process of Recovery: childhood trauma

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
Emotional abuse								
9 months								
≤ 9	49.2 (11.9); 80	48.6 (10.8); 83	1.54	−1.35 to 4.43	0.296			
≥ 10	52.5 (11.7); 55	46.8 (11.2); 67	3.46	0.03 to 6.88	0.048	1.92	−2.57 to 6.40	0.402
21 months								
≤ 9	50.7 (9.2); 75	49.5 (11.0); 76	1.62	−1.37 to 4.61	0.289			
≥ 10	53.2 (9.9); 48	47.5 (12.0); 65	3.07	−0.45 to 6.60	0.087	1.46	−3.17 to 6.08	0.537
Emotional neglect								
9 months								
≤ 14	51.2 (11.6); 104	49.8 (9.9); 106	2.04	−0.48 to 4.57	0.112			
≥ 15	47.7 (12.7); 34	42.6 (12.3); 40	2.66	−1.71 to 7.04	0.233	0.62	−4.43 to 5.67	0.810
21 months								
≤ 14	52.0 (9.2); 97	50.7 (10.7); 96	1.83	−0.78 to 4.44	0.170			
≥ 15	50.3 (10.6); 27	42.8 (11.6); 41	4.20	−0.40 to 8.79	0.074	2.37	−2.92 to 7.66	0.380
Physical abuse								
9 months								
≤ 7	51.0 (11.5); 93	48.5 (10.8); 92	2.92	0.19 to 5.64	0.036			
≥ 8	49.6 (13.5); 42	46.4 (11.3); 56	2.20	−1.67 to 6.07	0.265	−0.72	−5.46 to 4.02	0.767
21 months								
≤ 7	51.7 (8.6); 85	49.7 (11.0); 92	2.11	−0.65 to 4.88	0.134			
≥ 8	51.7 (11.1); 39	45.8 (12.0); 47	3.64	−0.46 to 7.75	0.082	1.53	−3.43 to 6.48	0.546

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Physical neglect								
9 months								
≤ 7	49.9 (11.7); 72	47.6 (11.0); 72	2.63	−0.50 to 5.75	0.100	−0.26	−4.72 to 4.21	0.911
≥ 8	50.9 (12.4); 64	47.9 (11.0); 79	2.37	−0.81 to 5.55	0.144			
21 months								
≤ 7	50.6 (8.1); 64	49.2 (11.8); 70	1.04	−2.18 to 4.27	0.526	3.11	−1.49 to 7.70	0.186
≥ 8	52.9 (10.6); 58	47.9 (11.2); 72	4.15	0.87 to 7.43	0.013			
Sexual abuse								
9 months								
≤ 7	50.4 (11.8); 102	48.2 (10.1); 110	2.25	−0.31 to 4.81	0.085	1.50	−3.68 to 6.68	0.571
≥ 8	50.6 (13.1); 31	46.9 (13.3); 40	3.75	−0.75 to 8.25	0.103			
21 months								
≤ 7	52.1 (9.0); 94	48.9 (11.0); 104	3.01	0.38 to 5.64	0.025	−1.66	−7.00 to 3.69	0.544
≥ 8	50.3 (11.3); 29	47.1 (12.6); 37	1.36	−3.29 to 6.01	0.568			

TABLE 46 Questionnaire about the Process of Recovery: AUDIT, DAST and PAM-SR attachment avoidance

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
AUDIT								
9 months								
≤ 12	51.3 (11.8); 160	48.5 (11.1); 177	2.03	0.03 to 4.03	0.047			
≥ 13	46.1 (10.6); 17	48.5 (13.7); 11	0.83	−6.07 to 7.73	0.813	−1.20	−8.38 to 5.99	0.744
21 months								
≤ 12	52.1 (9.9); 147	48.8 (11.8); 166	1.76	−0.31 to 3.83	0.095			
≥ 13	51.5 (6.8); 13	51.7 (12.0); 14	1.14	−5.71 to 8.00	0.744	−0.61	−7.77 to 6.54	0.866
DAST								
9 months								
1–2	51.1 (11.6); 160	48.3 (10.9); 175	1.89	−0.08 to 3.87	0.060			
≥ 3	52.0 (5.8); 9	49.8 (16.2); 11	4.92	−3.64 to 13.48	0.260	3.02	−5.77 to 11.81	0.501
21 months								
1–2	52.2 (9.7); 146	48.4 (11.6); 168	2.45	0.40 to 4.49	0.019			
≥ 3	49.7 (11.0); 7	56.9 (10.2); 9	−5.60	−14.93 to 3.74	0.240	−8.06	−17.63 to 1.51	0.099
PAM-SR attachment avoidance								
9 months								
< 9	54.3 (10.2); 116	51.3 (9.9); 113	2.96	0.58 to 5.34	0.015			
9–16	43.5 (12.0); 49	43.7 (11.5); 66	−0.47	−3.92 to 2.98	0.788	−3.43	−7.62 to 0.76	0.109
17–24	48.7 (9.4); 16	50.5 (11.8); 15	−1.03	−8.10 to 6.05	0.776	−3.99	−11.45 to 3.48	0.295
21 months								
< 9	54.3 (9.0); 106	51.2 (10.6); 109	2.89	0.44 to 5.33	0.021			
9–16	46.0 (9.6); 42	44.5 (13.0); 62	0.16	−3.46 to 3.78	0.931	−2.73	−7.10 to 1.65	0.222
17–24	52.5 (7.7); 17	52.8 (6.9); 14	0.52	−7.02 to 8.06	0.892	−2.36	−10.29 to 5.56	0.559

TABLE 47 Questionnaire about the Process of Recovery: BCSS

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
Negative others								
9 months								
< 7.2	54.0 (10.4); 93	48.6 (10.0); 79	4.42	1.65 to 7.18	0.002			
≥ 7.2	47.0 (12.0); 72	48.5 (11.9); 103	−0.54	−3.39 to 2.31	0.709	−4.96	−8.94 to −0.98	0.015
21 months								
< 7.2	53.4 (9.4); 87	49.5 (11.3); 71	2.78	−0.10 to 5.66	0.059			
≥ 7.2	50.2 (10.1); 66	48.4 (12.4); 101	1.79	−1.14 to 4.73	0.231	−0.98	−5.10 to 3.13	0.639
Negative self								
9 months								
< 7.2	54.5 (10.1); 106	50.8 (9.7); 111	2.61	0.17 to 5.04	0.036			
≥ 7.2	45.4 (11.4); 61	44.7 (12.1); 72	1.61	−1.61 to 4.83	0.327	−1.00	−5.04 to 3.05	0.629
21 months								
< 7.2	55.0 (8.4); 99	51.7 (10.4); 107	2.38	−0.11 to 4.88	0.061			
≥ 7.2	46.6 (9.5); 51	44.5 (12.7); 68	1.86	−1.54 to 5.25	0.284	−0.53	−4.75 to 3.69	0.806
Positive others								
9 months								
< 7.2	46.5 (11.2); 36	45.1 (11.7); 59	0.77	−3.08 to 4.62	0.694			
≥ 7.2	52.1 (11.5); 130	50.2 (10.4); 124	2.11	−0.16 to 4.39	0.068	1.34	−3.13 to 5.81	0.557
21 months								
< 7.2	47.3 (11.6); 29	46.3 (12.5); 63	0.97	−3.14 to 5.07	0.644			
≥ 7.2	53.0 (9.2); 121	50.4 (11.2); 111	2.06	−0.32 to 4.43	0.089	1.09	−3.64 to 5.83	0.651
continued								

continued

TABLE 47 Questionnaire about the Process of Recovery: BCSS (*continued*)

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Positive self								
9 months								
< 7.2	45.9 (12.4); 68	44.2 (11.4); 86	2.72	−0.22 to 5.66	0.069			
≥ 7.2	54.6 (9.6); 97	52.2 (9.4); 96	1.64	−0.98 to 4.27	0.219	−1.08	−5.03 to 2.87	0.592
21 months								
< 7.2	47.2 (10.1); 63	45.0 (11.7); 81	2.45	−0.58 to 5.48	0.114			
≥ 7.2	55.2 (8.3); 88	52.0 (11.1); 90	1.92	−0.81 to 4.65	0.168	−0.53	−4.61 to 3.56	0.801

TABLE 48 Questionnaire about the Process of Recovery: psychosis

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
9 months								
Stress sensitivity	51.1 (11.7); 62	47.7 (9.5); 67	3.18	0.00 to 6.36	0.050			
Drug related	51.5 (10.1); 57	49.8 (10.0); 48	1.62	−1.85 to 5.09	0.359	−1.56	−6.27 to 3.15	0.517
Trauma	47.7 (15.2); 7	55.5 (15.9); 4	−12.90	−24.96 to −0.84	0.036	−16.08	−28.56 to −3.61	0.012
Anxiety	47.3 (14.9); 20	47.6 (12.7); 32	1.13	−4.08 to 6.34	0.671	−2.05	−8.16 to 4.05	0.510
Drug and trauma	40.3 (8.0); 3	36.0 (21.5); 4	11.84	−2.00 to 25.68	0.094	11.84	−2.00 to 25.68	0.094
21 months								
Stress sensitivity	52.4 (9.0); 61	48.6 (10.2); 68	2.44	−0.75 to 5.63	0.134			
Drug related	52.6 (9.3); 52	51.2 (9.9); 46	1.77	−1.82 to 5.36	0.335	−0.67	−5.48 to 4.13	0.783
Trauma	46.0 (9.6); 7	47.6 (25.0); 5	−9.26	−20.23 to 1.70	0.098	−11.71	−23.12 to −0.29	0.044
Anxiety	50.5 (12.7); 17	47.1 (13.9); 31	4.99	−0.54 to 10.52	0.077	2.55	−3.84 to 8.94	0.434
Drug and trauma	37.5 (14.8); 2	49.8 (8.4); 4	−2.00	−17.23 to 13.23	0.797	−4.44	−20.02 to 11.14	0.576

TABLE 49 Personal and Social Performance: age, age at onset and sex

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Age (years)								
9 months								
16–32	57.0 (13.0); 48	50.6 (14.3); 41	5.86	0.94 to 10.77	0.019	4.21	–1.55 to 9.96	0.152
33–49	53.8 (14.9); 114	51.7 (13.2); 124	1.65	–1.35 to 4.65	0.281			
≥ 50	48.3 (14.2); 51	49.6 (15.1); 59	–0.66	–5.09 to 3.77	0.770	–2.31	–7.67 to 3.05	0.399
21 months								
16–32	52.2 (15.5); 109	52.1 (15.2); 120	–0.10	–3.15 to 2.96	0.951			
33–49	53.5 (15.3); 47	54.7 (13.3); 38	–0.60	–5.65 to 4.44	0.815	–0.51	–6.41 to 5.39	0.866
≥ 50	47.8 (14.3); 50	47.8 (14.0); 56	1.25	–3.26 to 5.76	0.588	1.34	–4.11 to 6.80	0.629
Age at onset (years)								
9 months								
≤ 35	53.8 (14.6); 178	51.5 (13.7); 191	1.89	–0.53 to 4.31	0.126			
≥ 36	52.0 (13.9); 23	44.8 (14.5); 20	4.13	–3.04 to 11.29	0.259	2.24	–5.33 to 9.81	0.562
21 months								
≤ 35	52.1 (15.4); 169	52.3 (14.5); 181	–0.21	–2.69 to 2.27	0.869			
≥ 36	47.9 (14.5); 24	44.5 (15.3); 20	1.35	–5.73 to 8.43	0.709	1.56	–5.95 to 9.06	0.684
Sex								
9 months								
Female	56.5 (13.3); 59	53.9 (14.9); 64	2.66	–1.52 to 6.84	0.212			
Male	52.0 (14.9); 154	49.7 (13.4); 160	1.59	–1.02 to 4.20	0.231	–1.07	–6.00 to 3.86	0.671
21 months								
Female	54.8 (15.0); 58	56.2 (14.8); 62	–0.90	–5.13 to 3.34	0.678			
Male	50.2 (15.2); 148	49.5 (14.2); 152	0.62	–2.05 to 3.29	0.647	1.52	–3.48 to 6.52	0.552

TABLE 50 Personal and Social Performance: DI, DUP and clozapine

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
DI (years)								
9 months								
0–15	55.4 (13.4); 92	49.7 (13.8); 76	4.80	1.22 to 8.39	0.009			
16–30	54.0 (15.2); 87	51.2 (14.0); 102	1.57	–1.81 to 4.94	0.363	–3.24	–8.17 to 1.69	0.198
≥ 31	44.0 (12.8); 22	52.5 (14.2); 33	–4.50	–10.87 to 1.88	0.167	–9.30	–16.62 to –1.98	0.013
21 months								
0–15	53.0 (16.3); 91	51.3 (14.3); 73	1.28	–2.36 to 4.91	0.491			
16–30	51.6 (14.2); 83	52.3 (15.8); 98	–1.16	–4.61 to 2.29	0.510	–2.44	–7.45 to 2.57	0.341
≥ 31	44.4 (13.7); 19	49.4 (12.7); 30	–1.58	–8.37 to 5.21	0.649	–2.85	–10.56 to 4.85	0.468
DUP (years)								
9 months								
0–2	53.1 (14.9); 112	50.8 (14.3); 94	1.76	–1.52 to 5.04	0.292			
2–5	55.4 (15.2); 35	49.7 (13.9); 62	5.32	0.34 to 10.30	0.036	3.56	–2.41 to 9.52	0.243
≥ 6	51.2 (14.2); 26	51.5 (13.7); 31	0.93	–5.33 to 7.18	0.771	–0.84	–7.90 to 6.22	0.816
21 months								
0–2	51.6 (15.6); 110	51.6 (15.0); 89	–0.33	–3.67 to 3.01	0.846			
2–5	53.6 (16.5); 34	52.5 (14.1); 60	0.99	–4.06 to 6.05	0.700	1.32	–4.75 to 7.40	0.669
≥ 6	47.2 (13.4); 25	47.5 (13.6); 29	0.84	–5.58 to 7.26	0.798	1.17	–6.06 to 8.40	0.751
								continued

TABLE 50 Personal and Social Performance: DI, DUP and clozapine (*continued*)

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
Number of antipsychotic drugs at baseline								
9 months								
One or less	52.1 (14.5); 134	50.6 (14.4); 142	1.57	−1.22 to 4.36	0.270			
Two or more	55.1 (14.5); 79	51.4 (13.0); 82	2.45	−1.20 to 6.10	0.189	0.87	−3.73 to 5.48	0.710
21 months								
One or less	50.4 (15.6); 129	51.5 (14.6); 136	−0.33	−3.18 to 2.53	0.823			
Two or more	53.2 (14.5); 77	51.3 (14.9); 78	1.04	−2.67 to 4.76	0.582	1.37	−3.33 to 6.07	0.567
Clozapine daily dose (mg)								
9 months								
None	52.1 (11.4); 17	46.3 (14.4); 23	5.13	−2.23 to 12.49	0.172			
< 300	56.4 (16.6); 31	53.2 (16.0); 46	0.80	−4.55 to 6.15	0.769	−4.32	−13.44 to 4.79	0.352
300–600	52.3 (14.5); 129	50.4 (13.3); 120	1.98	−0.93 to 4.89	0.182	−3.15	−11.06 to 4.77	0.436
≥ 600	54.4 (14.4); 36	52.7 (12.2); 35	1.93	−3.52 to 7.38	0.488	−3.20	−12.38 to 5.98	0.495
21 months								
None	46.3 (13.7); 17	49.0 (16.5); 21	−2.27	−9.77 to 5.24	0.554			
< 300	54.1 (18.4); 30	53.6 (16.5); 46	−1.98	−7.37 to 3.42	0.473	0.29	−8.97 to 9.54	0.951
300–600	50.0 (14.9); 124	50.6 (14.3); 113	0.11	−2.87 to 3.09	0.943	2.37	−5.70 to 10.45	0.565
≥ 600	56.9 (12.7); 35	52.6 (12.0); 34	4.94	−0.59 to 10.47	0.080	7.21	−2.14 to 16.55	0.131

TABLE 51 Personal and Social Performance: difficulty with abstract thinking, conceptual disorganisation and LN

		Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
		CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Difficulty with abstract thinking (PANSS)									
9 months									
0–4	54.6 (14.4); 126	51.5 (13.5); 142	1.38	–1.46 to 4.21	0.341				
≥ 4	51.3 (14.7); 87	49.9 (14.6); 82	2.72	–0.84 to 6.29	0.135	1.35		–3.22 to 5.91	0.564
21 months									
0–4	53.8 (16.4); 122	51.9 (14.8); 135	0.60	–2.29 to 3.49	0.684				
≥ 4	48.1 (12.7); 84	50.6 (14.5); 79	–0.40	–4.04 to 3.24	0.830	–1.00		–5.66 to 3.66	0.674
Conceptual disorganisation (PANSS)									
9 months									
0–4	53.9 (14.1); 178	52.6 (13.1); 182	1.49	–0.94 to 3.92	0.230				
≥ 4	49.6 (16.4); 35	43.5 (14.9); 42	3.66	–1.63 to 8.94	0.175	2.17		–3.66 to 8.00	0.466
21 months									
0–4	52.9 (15.2); 170	52.7 (14.4); 177	0.73	–1.75 to 3.21	0.563				
≥ 4	44.8 (13.7); 36	45.4 (14.9); 37	–2.27	–7.68 to 3.14	0.410	–3.00		–8.97 to 2.96	0.323
LN									
9 months									
≤ 8	50.9 (12.2); 25	44.6 (14.8); 23	7.05	0.27 to 13.82	0.041				
≥ 9	50.7 (16.4); 17	56.2 (12.8); 11	–7.48	–16.49 to 1.54	0.104	–14.52		–25.75 to –3.29	0.011
21 months									
≤ 8	47.2 (12.2); 24	51.6 (14.3); 23	–3.03	–9.91 to 3.85	0.388				
≥ 9	56.5 (16.3); 15	57.9 (18.5); 11	–2.46	–11.70 to 6.77	0.601	0.57		–10.90 to 12.04	0.922

TABLE 52 Personal and Social Performance: childhood trauma

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Emotional abuse								
9 months								
≤ 9	55.0 (14.3); 89	50.6 (13.5); 88	2.77	−0.70 to 6.25	0.118	0.56	−4.73 to 5.85	0.836
≥ 10	53.0 (15.2); 63	51.7 (15.3); 75	3.33	−0.63 to 7.30	0.100			
21 months								
≤ 9	52.8 (15.5); 84	51.5 (15.1); 88	−0.34	−3.86 to 3.19	0.851	−0.13	−5.51 to 5.25	0.964
≥ 10	50.4 (14.3); 59	52.8 (15.7); 75	−0.46	−4.51 to 3.58	0.823			
Emotional neglect								
9 months								
≤ 14	54.1 (14.8); 113	52.7 (13.2); 114	1.67	−1.39 to 4.73	0.285	3.23	−2.64 to 9.11	0.281
≥ 15	53.5 (14.0); 39	48.2 (16.4); 47	4.90	−0.11 to 9.92	0.055			
21 months								
≤ 14	52.0 (15.3); 109	53.8 (15.6); 114	−1.39	−4.48 to 1.70	0.379	2.74	−3.31 to 8.79	0.375
≥ 15	51.0 (14.2); 35	49.5 (15.4); 46	1.35	−3.85 to 6.55	0.610			
Physical abuse								
9 months								
≤ 7	53.1 (14.4); 102	52.9 (13.2); 103	0.49	−2.72 to 3.71	0.765	6.29	0.80 to 11.78	0.025
≥ 8	55.1 (14.7); 49	48.9 (15.4); 60	6.78	2.34 to 11.23	0.003			
21 months								
≤ 7	51.6 (14.7); 97	53.0 (15.7); 103	−1.03	−4.28 to 2.23	0.536	0.72	−4.87 to 6.32	0.800
≥ 8	50.6 (15.3); 46	51.4 (15.0); 59	−0.30	−4.85 to 4.24	0.896			

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Physical neglect								
9 months								
≤ 7	55.5 (13.8); 77	53.1 (13.6); 75	3.47	−0.29 to 7.23	0.071			
≥ 8	52.2 (15.3); 73	49.6 (14.7); 91	2.12	−1.52 to 5.76	0.254	−1.35	−6.59 to 3.89	0.614
21 months								
≤ 7	53.1 (14.5); 74	53.3 (15.1); 78	0.60	−3.16 to 4.36	0.755			
≥ 8	50.5 (15.5); 68	51.3 (15.8); 87	−0.94	−4.69 to 2.81	0.622	−1.54	−6.85 to 3.77	0.570
Sexual abuse								
9 months								
≤ 7	53.5 (14.8); 114	52.0 (14.8); 115	1.61	−1.40 to 4.62	0.293			
≥ 8	55.7 (14.6); 34	48.7 (12.0); 48	6.53	1.42 to 11.63	0.012	4.91	−1.01 to 10.84	0.104
21 months								
≤ 7	52.1 (14.2); 109	53.5 (15.2); 116	−1.08	−4.12 to 1.96	0.486			
≥ 8	51.1 (15.9); 32	48.5 (15.4); 46	1.70	−3.55 to 6.95	0.525	2.78	−3.28 to 8.85	0.368

TABLE 53 Personal and Social Performance: AUDIT, DAST and PAM-SR attachment avoidance

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
AUDIT								
9 months								
≤ 12	53.6 (14.6); 185	50.9 (13.8); 202	2.64	0.30 to 4.98	0.027			
≥ 13	52.8 (13.1); 20	47.9 (13.7); 14	−0.45	−8.48 to 7.58	0.912	−3.09	−11.46 to 5.28	0.469
21 months								
≤ 12	51.6 (15.7); 176	51.8 (14.7); 192	0.19	−2.21 to 2.59	0.874			
≥ 13	51.4 (11.7); 19	47.3 (13.3); 15	−0.56	−8.52 to 7.39	0.890	−0.76	−9.07 to 7.56	0.858
DAST								
9 months								
1–2	53.8 (14.4); 185	50.9 (13.8); 197	2.22	−0.12 to 4.57	0.063			
≥ 3	48.2 (17.1); 12	46.4 (13.4); 16	0.98	−7.80 to 9.75	0.827	−1.25	−10.34 to 7.85	0.788
21 months								
1–2	52.1 (15.2); 178	51.3 (14.9); 189	0.73	−1.67 to 3.13	0.550			
≥ 3	46.1 (14.9); 11	50.2 (13.0); 14	−4.35	−13.62 to 4.91	0.357	−5.08	−14.66 to 4.49	0.298
PAM-SR attachment avoidance								
9 months								
< 9	55.5 (14.4); 128	53.9 (13.5); 126	0.91	−1.93 to 3.75	0.529			
9–16	50.7 (13.8); 59	46.9 (13.2); 75	3.75	−0.20 to 7.70	0.063	2.84	−2.04 to 7.71	0.254
17–24	47.8 (15.3); 26	47.7 (14.8); 23	0.41	−6.07 to 6.89	0.901	−0.50	−7.58 to 6.58	0.889
21 months								
< 9	54.4 (15.4); 125	54.9 (14.5); 124	−0.88	−3.76 to 1.99	0.547			
9–16	46.3 (14.0); 54	46.8 (14.1); 70	−0.16	−4.27 to 3.96	0.940	0.72	−4.30 to 5.75	0.778
17–24	48.0 (13.8); 27	46.0 (11.8); 20	3.91	−2.78 to 10.60	0.252	4.79	−2.49 to 12.08	0.197

TABLE 54 Personal and Social Performance: BCSS

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Negative others								
9 months								
< 7.2	55.4 (14.3); 104	53.3 (13.7); 88	0.91	−2.43 to 4.26	0.592	1.30	−3.41 to 6.01	0.588
≥ 7.2	51.5 (14.7); 84	50.0 (13.7); 117	2.22	−1.09 to 5.52	0.189			
21 months								
< 7.2	54.4 (15.0); 99	52.5 (15.8); 84	0.66	−2.76 to 4.08	0.705	−2.32	−7.10 to 2.47	0.343
≥ 7.2	48.5 (15.4); 85	51.5 (14.2); 111	−1.66	−4.99 to 1.68	0.330			
Negative self								
9 months								
< 7.2	54.6 (14.8); 121	52.2 (14.7); 125	0.57	−2.36 to 3.50	0.702	2.85	−1.94 to 7.65	0.244
≥ 7.2	50.8 (13.0); 68	49.7 (12.0); 81	3.42	−0.36 to 7.21	0.076			
21 months								
< 7.2	54.6 (15.8); 116	53.2 (15.0); 121	0.02	−2.96 to 3.00	0.990	−0.57	−5.47 to 4.33	0.819
≥ 7.2	46.1 (13.1); 66	49.1 (14.2); 76	−0.55	−4.43 to 3.32	0.780			
Positive others								
9 months								
< 7.2	50.3 (15.6); 44	47.6 (13.3); 69	2.22	−2.19 to 6.62	0.324	−1.35	−6.54 to 3.84	0.611
≥ 7.2	54.1 (13.8); 144	53.3 (13.7); 136	0.87	−1.85 to 3.59	0.530			
21 months								
< 7.2	48.0 (15.7); 39	47.4 (14.5); 69	−0.27	−4.85 to 4.30	0.906	−1.17	−6.52 to 4.19	0.669
≥ 7.2	52.5 (15.4); 144	54.6 (14.4); 128	−1.44	−4.20 to 1.32	0.306			
continued								

TABLE 54 Personal and Social Performance: BCSS (continued)

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Positive self								
9 months								
< 7.2	49.6 (14.0); 81	49.4 (13.3); 96	−0.38	−3.86 to 3.10	0.831			
≥ 7.2	56.2 (14.3); 108	53.0 (14.1); 108	3.07	−0.06 to 6.20	0.054	3.45	−1.24 to 8.14	0.149
21 months								
< 7.2	48.8 (15.0); 76	50.2 (14.8); 92	−2.07	−5.65 to 1.51	0.257			
≥ 7.2	53.4 (15.7); 106	53.3 (14.8); 103	0.61	−2.57 to 3.79	0.705	2.69	−2.11 to 7.48	0.273

TABLE 55 Personal and Social Performance: psychosis

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
9 months								
Stress sensitivity	54.3 (14.3); 74	49.9 (14.6); 76	3.74	0.01 to 7.47	0.049			
Drug related	54.8 (14.0); 61	51.4 (12.6); 53	0.59	−3.70 to 4.89	0.786	−3.15	−8.83 to 2.53	0.277
Trauma	46.9 (17.4); 10	42.6 (14.4); 7	7.17	−4.09 to 18.44	0.212	3.43	−8.45 to 15.31	0.571
Anxiety	53.5 (14.9); 22	54.7 (15.3); 36	1.59	−4.61 to 7.78	0.616	−2.16	−9.39 to 5.07	0.559
Drug and trauma	44.3 (11.0); 3	54.5 (5.7); 4	−3.15	−21.04 to 14.74	0.730	−3.15	−21.04 to 14.74	0.730
21 months								
Stress sensitivity	53.8 (14.4); 72	51.9 (15.1); 75	1.24	−2.53 to 5.01	0.519			
Drug related	53.3 (16.3); 60	51.2 (13.7); 54	−0.48	−4.77 to 3.80	0.825	−1.72	−7.43 to 3.98	0.553
Trauma	41.8 (14.5); 8	45.6 (20.9); 7	−1.39	−13.23 to 10.45	0.818	−2.63	−15.07 to 9.81	0.678
Anxiety	51.9 (15.0); 24	52.7 (15.9); 35	2.86	−3.20 to 8.93	0.354	1.62	−5.51 to 8.76	0.655
Drug and trauma	32.7 (7.5); 3	53.0 (7.0); 4	−9.57	−27.06 to 7.92	0.284	−10.81	−28.71 to 7.09	0.236

TABLE 56 Psychotic Symptom Rating Scale – auditory hallucinations: age, age at onset and sex

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Age (years)								
9 months								
16–32	17.8 (13.5); 41	22.0 (13.8); 37	−1.66	−6.72 to 3.41	0.522	0.88	−5.02 to 6.78	0.770
33–49	17.5 (14.7); 102	23.0 (13.0); 105	−2.54	−5.59 to 0.52	0.104			
≥ 50	18.2 (14.2); 42	21.5 (14.1); 50	−3.43	−8.24 to 1.38	0.162	−0.90	−6.60 to 4.81	0.758
21 months								
16–32	16.8 (14.5); 98	20.0 (14.7); 105	−1.11	−4.22 to 2.01	0.485			
33–49	15.8 (12.8); 41	19.4 (13.4); 29	0.71	−4.73 to 6.15	0.798	1.82	−4.44 to 8.08	0.569
≥ 50	19.3 (14.6); 40	21.5 (14.4); 48	−3.46	−8.37 to 1.45	0.167	−2.35	−8.17 to 3.46	0.428
Age at onset (years)								
9 months								
≤ 35	17.4 (14.2); 157	22.7 (13.3); 163	−2.95	−5.46 to −0.44	0.021			
≥ 36	17.3 (14.0); 19	21.8 (14.8); 18	−3.16	−10.90 to 4.58	0.423	−0.21	−8.37 to 7.94	0.959
21 months								
≤ 35	17.0 (14.1); 153	20.7 (14.1); 153	−1.02	−3.60 to 1.56	0.438			
≥ 36	16.5 (14.9); 19	19.3 (14.9); 18	−5.56	−13.28 to 2.16	0.158	−4.54	−12.70 to 3.61	0.275
Sex								
9 months								
Female	19.1 (15.2); 54	25.4 (12.5); 54	−3.54	−7.69 to 0.61	0.095			
Male	17.2 (13.8); 131	21.3 (13.6); 138	−2.15	−4.89 to 0.60	0.125	1.39	−3.57 to 6.35	0.583
21 months								
Female	16.5 (15.6); 51	22.0 (14.0); 54	−3.87	−8.12 to 0.38	0.074			
Male	17.4 (13.6); 128	19.6 (14.5); 128	−0.28	−3.11 to 2.55	0.846	3.59	−1.51 to 8.68	0.167

TABLE 57 Psychotic Symptom Rating Scale – auditory hallucinations: DI, DUP and clozapine

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
<i>DI (years)</i>								
9 months								
0–15	19.1 (13.5); 79	20.2 (13.8); 65	1.08	–2.67 to 4.83	0.573			
16–30	15.2 (14.7); 80	25.3 (12.3); 90	–6.25	–9.70 to –2.80	< 0.001	–7.33	–12.41 to –2.25	0.005
≥ 31	19.9 (13.9); 17	19.8 (14.5); 26	–4.13	–10.77 to 2.51	0.223	–5.21	–12.84 to 2.42	0.181
21 months								
0–15	16.4 (13.8); 78	18.7 (13.9); 60	0.09	–3.75 to 3.94	0.962			
16–30	16.9 (14.8); 78	22.1 (13.9); 87	–1.99	–5.52 to 1.55	0.272	–2.08	–7.29 to 3.13	0.434
≥ 31	19.2 (13.1); 16	19.5 (15.4); 24	–4.56	–11.54 to 2.41	0.199	–4.66	–12.62 to 3.30	0.251
<i>DUP (years)</i>								
9 months								
0–2	18.7 (14.1); 97	22.1 (14.3); 86	–1.36	–4.62 to 1.89	0.412			
2–5	11.3 (12.1); 33	22.9 (12.9); 52	–7.06	–11.93 to –2.19	0.005	–5.69	–11.53 to 0.14	0.056
≥ 6	16.4 (14.6); 25	23.8 (13.1); 28	–8.17	–14.29 to –2.05	0.009	–6.81	–13.72 to 0.11	0.054
21 months								
0–2	16.7 (13.9); 95	21.0 (14.3); 78	–1.69	–5.05 to 1.67	0.325			
2–5	11.5 (13.4); 29	20.0 (14.2); 49	–6.20	–11.32 to –1.07	0.018	–4.51	–10.62 to 1.61	0.149
≥ 6	18.3 (14.4); 25	22.8 (13.8); 27	–3.27	–9.58 to 3.05	0.311	–1.58	–8.71 to 5.55	0.665
continued								

TABLE 57 Psychotic Symptom Rating Scale – auditory hallucinations: DI, DUP and clozapine (*continued*)

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
Number of antipsychotic drugs at baseline								
9 months								
One or less	15.8 (14.1); 109	21.4 (13.6); 114	−2.75	−5.74 to 0.24	0.071			
Two or more	20.6 (14.0); 76	23.9 (13.1); 78	−2.49	−6.01 to 1.04	0.167	0.26	−4.36 to 4.89	0.911
21 months								
One or less	15.1 (14.0); 108	18.8 (14.3); 113	−0.56	−3.59 to 2.47	0.718			
Two or more	20.1 (14.0); 71	22.8 (14.1); 69	−2.92	−6.65 to 0.82	0.126	−2.36	−7.17 to 2.46	0.338
Clozapine daily dose (mg)								
9 months								
None	19.1 (15.7); 15	23.3 (14.6); 21	−1.94	−9.37 to 5.50	0.610			
< 300	10.9 (13.8); 23	22.3 (13.4); 39	−6.92	−12.71 to −1.13	0.019	−4.98	−14.38 to 4.42	0.299
300–600	18.2 (14.1); 113	22.3 (13.2); 99	−3.03	−6.05 to −0.01	0.049	−1.10	−9.11 to 6.92	0.788
≥ 600	20.2 (13.6); 34	22.4 (13.8); 33	1.70	−3.82 to 7.23	0.546	3.64	−5.62 to 12.89	0.441
21 months								
None	20.3 (15.3); 16	23.5 (13.4); 20	−1.98	−9.40 to 5.44	0.601			
< 300	11.6 (11.9); 24	21.1 (13.9); 37	−4.81	−10.55 to 0.94	0.101	−2.83	−12.18 to 6.53	0.554
300–600	17.6 (14.5); 109	20.1 (14.5); 94	−1.05	−4.18 to 2.08	0.511	0.93	−7.11 to 8.98	0.820
≥ 600	18.2 (13.7); 30	18.1 (15.2); 31	1.19	−4.64 to 7.02	0.689	3.17	−6.27 to 12.61	0.510

TABLE 58 Psychotic Symptom Rating Scale – auditory hallucinations: difficulty with abstract thinking, conceptual disorganisation and LN

		Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
		CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Difficulty with abstract thinking (PANSS)									
9 months									
0–4	16.9 (14.5); 112	21.2 (13.5); 126	–2.38	–5.27 to 0.51	0.106	–0.39	–5.18 to 4.40	0.874	
≥ 4	19.1 (13.8); 73	24.7 (13.0); 66	–2.77	–6.60 to 1.06	0.156				
21 months									
0–4	16.5 (14.4); 109	19.8 (14.1); 120	–2.04	–4.99 to 0.92	0.177	2.03	–2.91 to 6.97	0.420	
≥ 4	18.1 (13.8); 70	21.4 (14.8); 62	–0.00	–3.97 to 3.96	0.998				
Conceptual disorganisation (PANSS)									
9 months									
0–4	18.2 (14.3); 160	22.6 (13.3); 160	–2.53	–5.02 to –0.03	0.047	–0.41	–6.87 to 6.05	0.901	
≥ 4	15.0 (14.1); 25	21.3 (13.9); 32	–2.94	–8.90 to 3.03	0.335				
21 months									
0–4	17.7 (14.3); 150	20.6 (14.3); 153	–1.43	–4.02 to 1.16	0.280	0.35	–6.03 to 6.73	0.914	
≥ 4	14.3 (13.4); 29	18.8 (15.0); 29	–1.08	–6.91 to 4.75	0.717				
LN									
9 months									
≤ 8	17.7 (13.1); 23	24.4 (14.0); 19	–1.01	–7.41 to 5.38	0.756	–3.79	–15.22 to 7.64	0.516	
≥ 9	17.8 (14.9); 16	22.4 (9.9); 9	–4.80	–14.43 to 4.83	0.328				
21 months									
≤ 8	19.5 (14.0); 21	21.5 (15.4); 17	3.51	–3.10 to 10.13	0.298	–6.55	–17.65 to 4.55	0.247	
≥ 9	20.1 (13.2); 16	23.3 (9.9); 9	–3.04	–12.08 to 6.00	0.510				

TABLE 59 Psychotic Symptom Rating Scale – auditory hallucinations: childhood trauma

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
Emotional abuse								
9 months								
≤ 9	17.2 (14.5); 79	23.5 (12.7); 75	−3.88	−7.39 to −0.37	0.030	2.39	−2.98 to 7.75	0.383
≥ 10	18.8 (14.6); 53	24.3 (12.2); 67	−1.49	−5.55 to 2.56	0.470			
21 months								
≤ 9	17.2 (13.7); 78	19.1 (14.3); 74	0.30	−3.25 to 3.84	0.870	−2.46	−7.90 to 2.98	0.376
≥ 10	19.2 (14.6); 52	23.4 (13.4); 64	−2.16	−6.28 to 1.96	0.304			
Emotional neglect								
9 months								
≤ 14	18.0 (14.7); 96	23.0 (12.5); 98	−3.60	−6.75 to −0.46	0.025	2.05	−3.86 to 7.97	0.497
≥ 15	16.1 (14.5); 36	25.6 (12.3); 43	−1.55	−6.59 to 3.49	0.546			
21 months								
≤ 14	17.7 (13.7); 97	19.8 (13.9); 95	−0.71	−3.88 to 2.46	0.660	−2.22	−8.33 to 3.89	0.476
≥ 15	16.5 (15.5); 32	24.7 (13.0); 42	−2.93	−8.17 to 2.30	0.273			
Physical abuse								
9 months								
≤ 7	16.8 (14.7); 87	23.4 (12.4); 93	−4.04	−7.36 to −0.72	0.017	1.96	−3.63 to 7.55	0.492
≥ 8	18.0 (15.0); 44	25.3 (12.7); 50	−2.08	−6.61 to 2.45	0.367			
21 months								
≤ 7	16.8 (14.0); 87	19.7 (14.0); 90	−0.69	−4.06 to 2.68	0.689	−2.22	−7.94 to 3.49	0.446
≥ 8	17.9 (14.8); 41	24.3 (13.2); 48	−2.91	−7.55 to 1.73	0.219			

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
Physical neglect								
9 months								
≤ 7	17.0 (15.1); 65	24.6 (12.0); 67	−5.13	−8.93 to −1.34	0.008	3.26	−2.04 to 8.55	0.228
≥ 8	17.5 (14.0); 65	23.9 (12.7); 76	−1.88	−5.61 to 1.86	0.325			
21 months								
≤ 7	17.5 (14.4); 66	21.0 (13.3); 67	−0.98	−4.80 to 2.83	0.613	−1.28	−6.66 to 4.09	0.640
≥ 8	17.2 (14.1); 61	21.8 (14.4); 73	−2.27	−6.08 to 1.55	0.244			
Sexual abuse								
9 months								
≤ 7	16.7 (14.3); 96	23.4 (12.7); 100	−3.85	−7.02 to −0.68	0.017	1.81	−4.16 to 7.79	0.552
≥ 8	19.7 (15.1); 32	25.3 (11.9); 43	−2.04	−7.12 to 3.05	0.433			
21 months								
≤ 7	16.8 (14.1); 97	19.4 (14.1); 99	−0.42	−3.61 to 2.76	0.795	−4.15	−10.43 to 2.12	0.194
≥ 8	18.9 (13.8); 29	26.0 (12.4); 39	−4.58	−10.00 to 0.84	0.098			

TABLE 60 Psychotic Symptom Rating Scale – auditory hallucinations: AUDIT, DAST and PAM-SR attachment avoidance

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
AUDIT								
9 months								
≤ 12	18.2 (14.4); 160	21.9 (13.6); 173	−1.88	−4.33 to 0.57	0.132			
≥ 13	16.2 (12.8); 18	31.4 (5.9); 12	−11.64	−19.93 to −3.35	0.006	−9.76	−18.40 to −1.12	0.027
21 months								
≤ 12	17.8 (14.2); 155	20.0 (14.3); 164	−0.75	−3.26 to 1.76	0.558			
≥ 13	15.2 (12.8); 16	26.8 (12.9); 12	−7.76	−16.34 to 0.82	0.076	−7.01	−15.95 to 1.92	0.124
DAST								
9 months								
1–2	17.5 (14.3); 161	23.0 (13.1); 171	−3.59	−6.03 to −1.16	0.004			
≥ 3	19.6 (10.6); 10	20.0 (15.7); 12	4.83	−4.73 to 14.39	0.322	8.42	−1.43 to 18.27	0.094
21 months								
1–2	17.3 (14.0); 156	21.0 (14.2); 160	−2.05	−4.55 to 0.44	0.107			
≥ 3	15.2 (12.5); 9	19.5 (16.1); 12	−0.77	−11.27 to 9.73	0.885	1.28	−9.50 to 12.06	0.816
PAM-SR attachment avoidance								
9 months								
< 9	14.9 (13.9); 114	21.5 (12.7); 108	−4.21	−7.19 to −1.23	0.006			
9–16	23.8 (13.0); 50	26.3 (12.3); 68	−0.97	−4.94 to 3.00	0.632	3.24	−1.72 to 8.21	0.201
17–24	19.0 (14.8); 21	12.4 (16.8); 16	4.35	−2.88 to 11.58	0.239	8.56	0.73 to 16.39	0.032
21 months								
< 9	15.3 (13.6); 114	19.6 (13.6); 104	−2.06	−5.08 to 0.96	0.181			
9–16	23.9 (13.7); 43	23.6 (14.4); 62	0.13	−4.15 to 4.42	0.951	2.20	−3.05 to 7.44	0.412
17–24	13.5 (14.2); 22	12.3 (16.0); 16	1.62	−5.59 to 8.83	0.660	3.68	−4.14 to 11.51	0.356

TABLE 61 Psychotic Symptom Rating Scale – auditory hallucinations: BCSS

	Trial arm, mean (SD); <i>n</i>							
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)	Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
Negative others								
9 months								
< 7.2	15.7 (14.0); 90	23.4 (12.0); 72	−4.55	−8.19 to −0.92	0.014			
≥ 7.2	20.5 (13.6); 75	23.1 (13.5); 104	−1.75	−5.15 to 1.66	0.314	2.80	−2.19 to 7.80	0.271
21 months								
< 7.2	16.6 (13.8); 89	21.9 (13.3); 69	−2.48	−6.17 to 1.20	0.186			
≥ 7.2	18.7 (14.4); 73	19.9 (14.7); 96	−0.91	−4.46 to 2.64	0.616	1.57	−3.55 to 6.70	0.547
Negative self								
9 months								
< 7.2	16.4 (13.9); 105	21.5 (12.8); 105	−1.47	−4.66 to 1.71	0.365			
≥ 7.2	20.0 (14.2); 60	25.3 (13.1); 74	−5.36	−9.16 to −1.57	0.006	−3.89	−8.86 to 1.07	0.125
21 months								
< 7.2	15.4 (13.4); 100	19.7 (13.7); 99	−1.34	−4.59 to 1.92	0.422			
≥ 7.2	20.8 (14.4); 59	22.7 (14.6); 68	−1.86	−5.80 to 2.08	0.355	−0.53	−5.65 to 4.59	0.840
Positive others								
9 months								
< 7.2	16.6 (14.9); 38	24.2 (13.2); 59	−1.97	−6.68 to 2.73	0.411			
≥ 7.2	18.4 (13.9); 127	22.5 (12.8); 118	−3.42	−6.31 to −0.52	0.021	−1.44	−6.96 to 4.07	0.608
21 months								
< 7.2	15.5 (13.9); 35	22.5 (14.9); 60	−3.28	−8.10 to 1.53	0.182			
≥ 7.2	18.2 (14.0); 125	19.7 (13.6); 108	−0.38	−3.38 to 2.62	0.804	2.90	−2.76 to 8.57	0.315
								continued

TABLE 61 Psychotic Symptom Rating Scale – auditory hallucinations: BCSS (*continued*)

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
Positive self								
9 months								
< 7.2	19.2 (15.1); 67	23.6 (13.5); 85	−3.06	−6.71 to 0.58	0.099	0.11	−4.80 to 5.02	0.965
≥ 7.2	17.1 (13.3); 98	22.3 (12.7); 92	−2.95	−6.25 to 0.34	0.079			
21 months								
< 7.2	18.7 (14.5); 71	21.5 (14.3); 81	−2.24	−5.89 to 1.41	0.229	1.80	−3.24 to 6.85	0.484
≥ 7.2	17.1 (13.7); 89	20.1 (13.9); 85	−0.44	−3.92 to 3.04	0.805			

TABLE 62 Psychotic Symptom Rating Scale – auditory hallucinations: psychosis

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
9 months								
Stress sensitivity	16.1 (14.2); 60	23.0 (13.3); 65	−4.17	−8.05 to −0.28	0.035			
Drug related	15.8 (13.2); 56	22.7 (13.5); 44	−4.05	−8.57 to 0.48	0.079	0.12	−5.82 to 6.06	0.969
Trauma	31.1 (2.7); 9	18.9 (18.2); 7	6.81	−3.62 to 17.23	0.201	10.98	−0.18 to 22.13	0.054
Anxiety	12.9 (14.4); 22	21.4 (13.6); 33	−5.20	−11.33 to 0.93	0.096	−1.03	−8.27 to 6.20	0.779
Drug and trauma	33.0 (1.4); 2	25.3 (12.3); 3	19.71	0.45 to 38.98	0.045	19.71	0.45 to 38.98	0.045
21 months								
Stress sensitivity	19.6 (13.8); 63	22.2 (14.4); 65	−0.56	−4.46 to 3.34	0.778			
Drug related	14.5 (12.6); 57	18.8 (13.5); 44	−2.02	−6.50 to 2.47	0.378	−1.46	−7.38 to 4.46	0.629
Trauma	21.3 (16.8); 7	22.1 (15.9); 7	−5.11	−16.18 to 5.95	0.365	−4.55	−16.32 to 7.21	0.448
Anxiety	8.9 (13.6); 22	20.4 (14.4); 30	−8.60	−14.79 to −2.41	0.006	−8.04	−15.33 to −0.75	0.031
Drug and trauma	34.3 (7.5); 3	9.3 (18.5); 4	31.39	13.46 to 49.31	0.001	31.95	13.62 to 50.28	0.001

TABLE 63 Sensitivity analysis of LN subgroup

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
PANSS total								
9 months								
≤ 8	75.8 (13.9); 29	82.5 (15.0); 27	−2.31	−7.82 to 3.20	0.412			
≥ 9	75.5 (17.0); 69	76.5 (14.2); 75	−2.34	−7.32 to 2.63	0.356	−0.04	−7.48 to 7.41	0.992
21 months								
≤ 8	76.8 (18.4); 26	78.9 (16.4); 27	−1.12	−6.73 to 4.49	0.696			
≥ 9	72.9 (18.2); 67	74.5 (14.7); 72	−2.37	−7.48 to 2.74	0.364	−1.25	−8.86 to 6.36	0.748
QPR								
9 months								
≤ 8	52.6 (11.7); 24	44.7 (13.7); 20	3.53	−0.76 to 7.81	0.107			
≥ 9	50.9 (11.5); 55	49.5 (9.9); 64	1.32	−2.26 to 4.90	0.469	−2.21	−7.79 to 3.38	0.439
21 months								
≤ 8	51.4 (8.7); 21	50.7 (8.8); 19	−0.04	−4.47 to 4.38	0.985			
≥ 9	52.4 (10.4); 50	49.8 (11.1); 62	0.45	−3.25 to 4.16	0.811	0.50	−5.28 to 6.27	0.866
PSP								
9 months								
≤ 8	51.2 (12.1); 26	45.2 (14.2); 26	7.08	1.93 to 12.22	0.007			
≥ 9	52.2 (15.2); 69	51.4 (14.4); 73	−1.90	−6.54 to 2.73	0.421	−8.98	−15.92 to −2.04	0.011
21 months								
≤ 8	48.0 (12.6); 25	51.4 (13.5); 27	−0.11	−5.32 to 5.10	0.967			
≥ 9	52.1 (15.6); 65	50.0 (15.6); 71	1.71	−3.02 to 6.44	0.479	1.82	−5.23 to 8.87	0.613

	Trial arm, mean (SD); <i>n</i>		Mean difference	95% CI	<i>p</i> -value	Interaction effect	95% CI	<i>p</i> -value
	CBT (<i>N</i> = 242)	TAU (<i>N</i> = 245)						
<i>PSYRATS – auditory hallucination</i>								
9 months								
≤ 8	16.9 (13.3); 24	23.8 (14.1); 22	−0.75	−5.71 to 4.22	0.768			
≥ 9	15.0 (13.9); 58	22.9 (12.7); 64	−4.10	−8.21 to 0.01	0.051	−3.35	−9.76 to 3.06	0.305
21 months								
≤ 8	18.6 (14.3); 22	20.2 (15.4); 19	2.84	−2.16 to 7.85	0.266			
≥ 9	15.1 (13.8); 57	22.1 (13.4); 61	−4.60	−8.90 to −0.30	0.036	−7.44	−14.02 to −0.86	0.027

TABLE 64 Participants responding 'quite a lot' or 'very much' to each of the items by whole trial and by treatment group

Item	Whole sample (<i>N</i> = 279), <i>n</i> (%)		Trial arm, <i>n</i> (%)				<i>p</i> -value
			CBT (<i>N</i> = 131)		TAU (<i>N</i> = 148)		
	Quite a lot	Very much	Quite a lot	Very much	Quite a lot	Very much	
1	50 (17.9)	20 (7.2)	23 (17.6)	8 (6.1)	27 (18.2)	12 (8.1)	0.61
2	0 (0.0)	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.4)	0.18
3	8 (2.9)	2 (0.7)	4 (3.1)	0 (0.0)	4 (2.7)	2 (1.4)	0.65
4	6 (2.2)	1 (0.4)	3 (2.3)	0 (0.0)	3 (2.0)	1 (0.7)	0.83
5	4 (1.4)	1 (0.4)	2 (1.5)	1 (0.8)	2 (1.4)	0 (0.0)	0.56
6	1 (0.4)	1 (0.4)	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.7)	0.93
7	9 (3.2)	5 (1.8)	4 (3.1)	5 (3.8)	5 (3.4)	0 (0.0)	0.18
8	20 (7.2)	12 (4.3)	10 (7.6)	8 (6.1)	10 (6.8)	4 (2.7)	0.26
9	4 (1.4)	0 (0.0)	2 (1.5)	0 (0.0)	2 (1.4)	0 (0.0)	0.90
10	7 (2.5)	1 (0.4)	3 (2.3)	0 (0.0)	4 (2.7)	1 (0.7)	0.59
11	9 (3.2)	0 (0.0)	5 (3.8)	0 (0.0)	4 (2.7)	0 (0.0)	0.60
12	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.4)	0 (0.0)	0.18
13	2 (0.7)	2 (0.7)	1 (0.8)	0 (0.0)	1 (0.7)	2 (1.4)	0.38
14	0 (0.0)	1 (0.4)	0 (0.0)	1 (0.8)	0 (0.0)	0 (0.0)	0.29
15	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.7)	0 (0.0)	0.35
16	3 (1.1)	0 (0.0)	2 (1.5)	0 (0.0)	1 (0.7)	0 (0.0)	0.49
17	2 (0.7)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.7)	0 (0.0)	0.93
18	3 (1.1)	2 (0.7)	1 (0.8)	0 (0.0)	2 (1.4)	2 (1.4)	0.22
19	18 (6.5)	2 (0.7)	7 (5.3)	0 (0.0)	11 (7.4)	2 (1.4)	0.23
20	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.7)	0 (0.0)	0.35
21	9 (3.2)	2 (0.7)	5 (3.8)	1 (0.8)	4 (2.7)	1 (0.7)	0.61
22	4 (1.4)	0 (0.0)	2 (1.5)	0 (0.0)	2 (1.4)	0 (0.0)	0.90
23	5 (1.8)	0 (0.0)	1 (0.8)	0 (0.0)	4 (2.7)	0 (0.0)	0.22
24	14 (5.0)	3 (1.1)	8 (6.1)	0 (0.0)	6 (4.1)	3 (2.0)	0.99
25	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.7)	0 (0.0)	0.35
26	2 (0.7)	1 (0.4)	1 (0.8)	1 (0.8)	1 (0.7)	0 (0.0)	0.49
27 ^a	15 (5.4)	5 (1.8)	12 (9.2)	1 (0.8)	3 (2.0)	4 (2.7)	0.09

^a A response of ‘Quite a lot’ or ‘Very much’ indicates an improvement.

Appendix 3 Economic analyses

TABLE 65 Baseline EQ-5D domain responses for participants with complete cost and QALY data

EQ-5D health states	Trial arm, <i>n</i> (%)	
	CBT (<i>N</i> = 76)	TAU (<i>N</i> = 93)
Mobility		
No problems	55 (72)	50 (54)
Slight problems	12 (16)	19 (20)
Moderate problems	5 (7)	15 (16)
Severe problems	4 (5)	8 (9)
Extreme problems	0 (0)	1 (1)
Self-care		
No problems	48 (63)	64 (69)
Slight problems	15 (20)	15 (16)
Moderate problems	10 (13)	11 (12)
Severe problems	3 (4)	3 (3)
Extreme problems	0	0
Usual activities		
No problems	27 (35)	32 (34)
Slight problems	19 (25)	22 (24)
Moderate problems	21 (28)	29 (31)
Severe problems	7 (9)	8 (9)
Extreme problems	2 (3)	2 (2)
Pain and distress		
No problems	43 (57)	38 (41)
Slight problems	17 (22)	21 (23)
Moderate problems	11 (15)	16 (17)
Severe problems	4 (5)	12 (13)
Extreme problems	1 (1)	6 (6)
Anxiety and depression		
No problems	9 (12)	12 (13)
Slight problems	25 (33)	20 (22)
Moderate problems	22 (29)	34 (36)
Severe problems	15 (20)	16 (17)
Extreme problems	5 (6)	11 (12)

TABLE 66 The EQ-5D domain responses at 9 months for participants with complete cost and QALY data

EQ-5D health states	Trial arm, <i>n</i> (%)	
	CBT (<i>N</i> = 76)	TAU (<i>N</i> = 93)
Mobility		
No problems	54 (71)	47 (50)
Slight problems	12 (16)	21 (23)
Moderate problems	5 (6.5)	14 (15)
Severe problems	5 (6.5)	11 (12)
Extreme problems	0 (0)	0 (0)
Self-care		
No problems	55 (72)	60 (65)
Slight problems	9 (12)	18 (19)
Moderate problems	10 (13)	10 (11)
Severe problems	2 (3)	5 (5)
Extreme problems	0 (0)	0 (0)
Usual activities		
No problems	41 (54)	40 (43)
Slight problems	12 (16)	17 (18)
Moderate problems	18 (24)	26 (28)
Severe problems	4 (5)	10 (11)
Extreme problems	1 (1)	0 (0)
Pain and distress		
No problems	47 (62)	42 (45)
Slight problems	12 (16)	20 (22)
Moderate problems	13 (17)	16 (17)
Severe problems	3 (4)	11 (12)
Extreme problems	1 (1)	4 (4)
Anxiety and depression		
No problems	17 (22)	11 (12)
Slight problems	20 (26)	28 (30)
Moderate problems	24 (32)	32 (34)
Severe problems	11 (15)	12 (13)
Extreme problems	4 (5)	10 (11)

TABLE 67 The EQ-5D domain responses at 21 months for participants with complete cost and QALY data

EQ-5D health states	Trial arm, <i>n</i> (%)	
	CBT (<i>N</i> = 76)	TAU (<i>N</i> = 93)
Mobility		
No problems	50 (66)	49 (53)
Slight problems	6 (8)	16 (17)
Moderate problems	14 (18)	16 (17)
Severe problems	6 (8)	10 (11)
Extreme problems	0 (0)	2 (2)
Self-care		
No problems	55 (72)	51 (55)
Slight problems	12 (16)	30 (32)
Moderate problems	7 (9)	6 (7)
Severe problems	2 (3)	4 (4)
Extreme problems	0 (0)	2 (2)
Usual activities		
No problems	38 (50)	36 (39)
Slight problems	22 (29)	20 (21)
Moderate problems	13 (17)	29 (31)
Severe problems	3 (4)	6 (7)
Extreme problems	0 (0)	2 (2)
Pain and distress		
No problems	47 (62)	38 (41)
Slight problems	13 (17)	20 (21.5)
Moderate problems	10 (13)	20 (21.5)
Severe problems	5 (7)	12 (13)
Extreme problems	1 (1)	3 (3)
Anxiety and depression		
No problems	17 (22)	15 (16)
Slight problems	23 (30)	18 (20)
Moderate problems	26 (34)	41 (44)
Severe problems	8 (11)	14 (15)
Extreme problems	2 (3)	5 (5)

TABLE 68 Unit costs of health and social care services

Service type	Unit costs (£)	Source
Inpatient costs		
Psychiatric ward	381.55	NHS Reference Costs ¹⁶¹
Emergency/crisis centre	414.06	NHS Reference Costs ¹⁶¹
General medical ward	538.63	NHS Reference Costs ¹⁶¹
Alcohol-treatment ward	334.28	NHS Reference Costs ¹⁶¹
Drug-treatment ward	334.28	NHS Reference Costs ¹⁶¹
Respite care	389.16	NHS Reference Costs ¹⁶¹
Maternity	919.45	NHS Reference Costs ¹⁶¹
Outpatient and day visits		
Psychiatric	105.08	NHS Reference Costs ¹⁶¹
Hospital alcohol service	101.46	NHS Reference Costs ¹⁶¹
Hospital substance use service	101.46	NHS Reference Costs ¹⁶¹
A&E	146.86	NHS Reference Costs ¹⁶¹
Day hospital	120.61	NHS Reference Costs ¹⁶¹
Psychotherapy	199.06	NHS Reference Costs ¹⁶¹
Clinical psychology/psychology	144.70	NHS Reference Costs ¹⁶¹
Colonoscopy	455.82	NHS Reference Costs ¹⁶¹
General diagnostic test	37.30	NHS Reference Costs ¹⁶¹
Eating disorders	52.92	NHS Reference Costs ¹⁶¹
Stroke	170.60	NHS Reference Costs ¹⁶¹
Maxillofacial	118.90	NHS Reference Costs ¹⁶¹
Neurosurgery	205.98	NHS Reference Costs ¹⁶¹
Hepatology	255.35	NHS Reference Costs ¹⁶¹
Clozapine clinic	3.37	NHS Reference Costs ¹⁶¹
Crisis team	148	NHS Reference Costs ¹⁶¹
Anticoagulant clinic	26.26	NHS Reference Costs ¹⁶¹
Oncology	151.12	NHS Reference Costs ¹⁶¹
Clinical oncology	126.60	NHS Reference Costs ¹⁶¹
Haematology	160.58	NHS Reference Costs ¹⁶¹
General surgery	130.06	NHS Reference Costs ¹⁶¹
Cataract	123.98	NHS Reference Costs ¹⁶¹
Spinal unit	280.03	NHS Reference Costs ¹⁶¹
Obstetrics	127.54	NHS Reference Costs ¹⁶¹
Plastic surgery	99.95	NHS Reference Costs ¹⁶¹
Ear, nose and throat	96.87	NHS Reference Costs ¹⁶¹

TABLE 68 Unit costs of health and social care services (*continued*)

Service type	Unit costs (£)	Source
Radiography	37.30	NHS Reference Costs ¹⁶¹
Neurology	175.60	NHS Reference Costs ¹⁶¹
Diabetic	159.31	NHS Reference Costs ¹⁶¹
Sexual health	84.11	NHS Reference Costs ¹⁶¹
Drug services	21.30	NHS Reference Costs ¹⁶¹
Endocrinology	157.74	NHS Reference Costs ¹⁶¹
Ophthalmology	90.64	NHS Reference Costs ¹⁶¹
Trauma and orthopaedics	117.01	NHS Reference Costs ¹⁶¹
Gynaecology	133.01	NHS Reference Costs ¹⁶¹
Gastroenterology	136.57	NHS Reference Costs ¹⁶¹
Mammogram	37.30	NHS Reference Costs ¹⁶¹
MRI	147.25	NHS Reference Costs ¹⁶¹
Occupational therapy	65.85	NHS Reference Costs ¹⁶¹
Orthotics	57.76	NHS Reference Costs ¹⁶¹
Radiology	84.52	NHS Reference Costs ¹⁶¹
Physiotherapist	48.33	NHS Reference Costs ¹⁶¹
CT scan	107.04	NHS Reference Costs ¹⁶¹
Ultrasound scan	52.55	NHS Reference Costs ¹⁶¹
Midwifery	75.15	NHS Reference Costs ¹⁶¹
Diagnostic biopsy	30.77	NHS Reference Costs ¹⁶¹
Urology	105.19	NHS Reference Costs ¹⁶¹
Audiology	58.33	NHS Reference Costs ¹⁶¹
Dermatologist	101.63	NHS Reference Costs ¹⁶¹
Dentist	124.14	NHS Reference Costs ¹⁶¹
Pain management	139.12	NHS Reference Costs ¹⁶¹
Nephrology	150.78	NHS Reference Costs ¹⁶¹
Respiratory	154.77	NHS Reference Costs ¹⁶¹
Dietitian	71.17	NHS Reference Costs ¹⁶¹
General	116.92	NHS Reference Costs ¹⁶¹
Podiatry	42.84	NHS Reference Costs ¹⁶¹
Electrocardiography	162.09	NHS Reference Costs ¹⁶¹
Endoscopy	259.73	NHS Reference Costs ¹⁶¹
Lung function	115.59	NHS Reference Costs ¹⁶¹
Knee surgery	130.06	NHS Reference Costs ¹⁶¹
Gastric-band management	157.75	NHS Reference Costs ¹⁶¹

continued

TABLE 68 Unit costs of health and social care services (*continued*)

Service type	Unit costs (£)	Source
Abscess draining	121.60	NHS Reference Costs ¹⁶¹
Simple blood test	3.37	NHS Reference Costs ¹⁶¹
Rheumatology	142.74	NHS Reference Costs ¹⁶¹
Gender reassignment	309.75	NHS Reference Costs ¹⁶¹
Orthopaedics	117.01	NHS Reference Costs ¹⁶¹
Fracture clinic	117.01	NHS Reference Costs ¹⁶¹
Gall bladder pre surgery	201.25	NHS Reference Costs ¹⁶¹
Cardiology	127.67	NHS Reference Costs ¹⁶¹
Clinical neurophysiology	215.59	NHS Reference Costs ¹⁶¹
Group therapy	46.72	NHS Reference Costs ¹⁶¹
Primary, community and social care		
GP, surgery visit	36.00	PSSRU 2016 ¹⁶⁴
GP, home visit	115.32	PSSRU 2014, ¹⁶² updated to 2016 prices ¹⁶⁴
GP (telephone call)	36.00	PSSRU 2016 ¹⁶⁴
Practice nurse (at surgery)	11.11	Estimated from average time per visit (PSSRU 2015 ¹⁶³) and cost per minute (PSSRU 2016 ¹⁶⁴)
Blood test/clozapine clinic	3.37	NHS Reference Costs ¹⁶¹
Psychiatrist	105.08	NHS Reference Costs ¹⁶¹
Psychologist	144.70	NHS Reference Costs ¹⁶¹
Alcohol or drug treatment or rehabilitation service	52.00 (per hour)	PSSRU ¹⁶⁴
District nurse	38	NHS Reference Costs ¹⁶¹
Community psychiatric nurse/case manager	77.24	NHS Reference Costs ¹⁶¹
Social worker	79.00 (per hour)	PSSRU ¹⁶⁴
Occupational therapist	Individual: 78.54 (per hour) Group: 46.72	NHS Reference Costs ¹⁶¹
Voluntary counsellor	32.00 (per hour)	PSSRU ¹⁶⁴
Home help/care worker	24.00 (per hour)	PSSRU ¹⁶⁴
Advocacy worker	58.00 (per hour)	PSSRU ¹⁶⁴
Anticoagulant clinic	26.26	NHS Reference Costs ¹⁶¹
Assertive outreach team	55.00	PSSRU ¹⁶⁴
Day care	32.00–34.00	PSSRU ¹⁶⁴
Community mental health team	38.00 (per hour)	PSSRU ¹⁶⁴
Community rehabilitation team	78.31	NHS Reference Costs ¹⁶¹
Crisis team	39.00 (per hour)	PSSRU ¹⁶⁴
Dentist	121.00	PSSRU ¹⁶⁴
Debt advice	270.00	PSSRU ¹⁶⁴

TABLE 68 Unit costs of health and social care services (*continued*)

Service type	Unit costs (£)	Source
Dermatologist	101.63	NHS Reference Costs ¹⁶¹
Dietitian	81.32	NHS Reference Costs ¹⁶¹
Diabetes mellitus clinic	70.59	NHS Reference Costs ¹⁶¹
Gender identity	309.75	NHS Reference Costs ¹⁶¹
Housing support – council	22.97	PSSRU ¹⁶⁴
Mindfulness	14.00	PSSRU ¹⁶⁴
One-to-one therapy	78.95	NHS Reference Costs ¹⁶¹
Podiatrist	42.39	NHS Reference Costs ¹⁶¹
Physiotherapy	48.94	NHS Reference Costs ¹⁶¹
Support group	17.00	PSSRU ¹⁶⁴
Sexual health	84.11	NHS Reference Costs ¹⁶¹
Support worker	21.94 (per hour)	PSSRU 2015, inflated ¹⁶³

A&E, accident and emergency; CT, computerised tomography; MRI, magnetic resonance imaging.

TABLE 69 Mean costs of health and social care for participants with complete cost and QALY data, by cost category and assessment

Service type	Trial arm, mean cost (£), SE (95% CI)	
	CBT (N = 76)	TAU (N = 93)
3 months prior to baseline		
Hospital inpatient admission (psychiatric)	63, 63 (0 to 187)	308, 264 (0 to 829)
Hospital inpatient admission (non-psychiatric)	0, 0 (0 to 0)	0, 0 (0 to 0)
Hospital outpatient, day and emergency care	45, 17 (11 to 78)	62, 22 (19 to 104)
General practice, community and social care	704, 89 (529 to 879)	616, 63 (491 to 741)
Baseline to 3 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	50, 50 (0 to 148)	23, 23 (0 to 69)
Hospital outpatient, day and emergency care	34, 9 (17 to 51)	69, 18 (33 to 106)
General practice, community and social care	604, 60 (486 to 723)	577, 67 (445 to 710)
3–6 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	99, 99 (0 to 297)	122, 59 (5 to 238)
Hospital outpatient, day and emergency care	31, 8 (14 to 48)	81, 23 (35 to 127)
General practice, community and social care	457, 54 (350 to 564)	558, 60 (438 to 677)

continued

TABLE 69 Mean costs of health and social care for participants with complete cost and QALY data, by cost category and assessment (*continued*)

Service type	Trial arm, mean cost (£), SE (95% CI)	
	CBT (N = 76)	TAU (N = 93)
6–9 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	85, 85 (0 to 254)	145, 65 (15 to 275)
Hospital outpatient, day and emergency care	60, 18 (23 to 97)	64, 16 (33 to 95)
General practice, community and social care	507, 53 (400 to 613)	764, 125 (515 to 1013)
9–13 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	21, 16 (0 to 53)	46, 29 (0 to 105)
Hospital outpatient, day and emergency care	59, 19 (22 to 96)	55, 14 (26 to 83)
General practice, community and social care	731, 120 (492 to 970)	970, 268 (438 to 1502)
13–17 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	0, 0 (0 to 0)	81, 59 (0 to 200)
Hospital outpatient, day and emergency care	50, 18 (14 to 86)	46, 9 (28 to 65)
General practice, community and social care	807, 106 (597 to 1017)	832, 143 (549 to 1116)
17–21 months		
Hospital inpatient admission (psychiatric)	No cases using inpatient care	No cases using inpatient care
Hospital inpatient admission (non-psychiatric)	269, 148 (0 to 564)	98, 56 (0 to 209)
Hospital outpatient, day and emergency care	71, 16 (39 to 104)	134 to 48 (38 to 230)
General practice, community and social care	867, 171 (526 to 1208)	802, 117 (569 to 1034)

TABLE 70 Total cost of health and social care at each follow-up assessment for participants with complete cost and QALY data

Assessment period	Trial arm, mean cost (£), SE (95% CI)	
	CBT (N = 76)	TAU (N = 93)
3 months prior to baseline	718, 100 (521 to 915)	661, 68 (527 to 795)
Baseline to 3 months	688, 83 (523 to 853)	670, 77 (517 to 823)
3–6 months	587, 116 (356 to 819)	761, 91 (581 to 941)
6–9 months	652, 113 (427 to 876)	973, 147 (681 to 1265)
9–13 months	811, 128 (557 to 1065)	1071, 275 (525 to 1616)
13–17 months	857, 108 (642 to 1072)	959, 165 (632 to 1287)
17–21 months	1208, 222 (765 to 1651)	1034, 136 (763 to 1305)
Baseline to 9-month follow-up	1927, 251 (1255 to 2184)	2404, 250 (1841 to 2827)
Baseline to 21-month follow-up	4635, 529 (3241 to 5204)	5277, 581 (4026 to 6417)

TABLE 71 Mean cost of health and social care, by cost category and assessment point: MI data

Service type	Trial arm, mean cost (£), SE (95% CI)	
	CBT (N = 242)	TAU (N = 245)
3 months prior to baseline (single imputation)		
Hospital inpatient admission (psychiatric)	2170, 515 (1158 to 3183)	2581, 553 (1494 to 3668)
Hospital inpatient admission (non-psychiatric)	48, 25 (0 to 97)	44, 24 (0 to 92)
Hospital outpatient care	95, 19 (57 to 133)	95, 21 (54 to 135)
General practice, community and social care	796, 65 (668 to 924)	830, 78 (677 to 981)
Baseline to 3 months		
Hospital inpatient admission (psychiatric)	2607, 588 (1451 to 3762)	2802, 627 (1569 to 4035)
Hospital inpatient admission (non-psychiatric)	57, 30 (0 to 117)	56, 39 (0 to 135)
Hospital outpatient care	56, 11 (34 to 77)	93, 19 (55 to 131)
General practice, community and social care	692, 68 (558 to 825)	715, 71 (575 to 855)
3–6 months		
Hospital inpatient admission (psychiatric)	2932, 615 (1724 to 4139)	2889, 630 (1651 to 4126)
Hospital inpatient admission (non-psychiatric)	44, 35 (0 to 113)	59, 30 (0 to 120)
Hospital outpatient care	59, 12 (36 to 83)	87, 19 (50 to 125)
General practice, community and social care	650, 71 (510 to 789)	593, 49 (497 to 689)
6–9 months		
Hospital inpatient admission (psychiatric)	3561, 834 (1921 to 5200)	2414, 591 (1253 to 3575)
Hospital inpatient admission (non-psychiatric)	81, 44 (0 to 169)	154, 60 (36 to 271)
Hospital outpatient care	63, 11 (41 to 85)	124, 21 (82 to 166)
General practice, community and social care	631, 73 (488 to 774)	881, 99 (686 to 1077)
9–13 months		
Hospital inpatient admission (psychiatric)	2391, 597 (1219 to 3564)	2345, 598 (1170 to 3519)
Hospital inpatient admission (non-psychiatric)	56, 29 (0 to 113)	86, 51 (0 to 186)
Hospital outpatient care	155, 52 (13 to 217)	92, 32 (30 to 154)
General practice, community and social care	1017, 142 (738 to 1295)	958, 128 (706 to 1210)
13–17 months		
Hospital inpatient admission (psychiatric)	2931, 693 (1569 to 4292)	2246, 587 (1094 to 3399)
Hospital inpatient admission (non-psychiatric)	131, 70 (0 to 269)	64, 39 (0 to 140)
Hospital outpatient care	95, 19 (57 to 133)	86, 20 (47 to 125)
General practice, community and social care	1093, 121 (854 to 1331)	969, 113 (743 to 1195)
17–21 months		
Hospital inpatient admission (psychiatric)	3706, 876 (1985 to 5427)	3348, 814 (1748 to 4948)
Hospital inpatient admission (non-psychiatric)	242, 97 (51 to 433)	176, 78 (20 to 331)
Hospital outpatient care	121, 22 (78 to 164)	141, 27 (87 to 195)
General practice, community and social care	977, 105 (770 to 1183)	901, 91 (722 to 1080)

TABLE 72 Net costs of CBT intervention, generalised linear regression, gamma (log) distribution: MI data, baseline to 21 months

Model details					
Number of imputations					10
Number of observations					487
Average RVI					0.02
Largest FMI					0.00
DF adjustment: large sample					
Minimum					7481.84
Average					121,678.36
Maximum					438,186.39
Model <i>F</i> -test					
Equal FMI					$F(6, 170,398.3) = 9.99$
Within-VCE type: OIM					Probability $> F = 0.0000$
Model results					
Net cost	Coefficient	SE	t-value	p-value	95% CI
CBT	0.22	0.18	1.21	0.226	−0.14 to 0.58
Baseline cost	0.00	0.00	1.25	0.213	0.00 to 0.00
DI	0.00	0.00	−0.31	0.758	0.00 to 0.00
Taking clozapine	0.09	0.32	0.29	0.775	−0.54 to 0.72
Baseline PSP score	−0.05	0.01	−7.11	0.000	−0.06 to −0.03
Baseline CDSS score	−0.04	0.02	−2.15	0.032	−0.07 to 0.00
Constant	12.04	0.49	24.65	0.000	11.08 to 13.00
DF, degrees of freedom; FMI, fraction of missing information; OIM, observed information matrix; RVI, relative variance increase; VCE, variance–covariance estimate. The regression model used a gamma (log) distribution to account for the skewed distribution. The Stata® <i>mimrgns</i> command was used to generate the predicted net cost for the CBT arm that is reported in Table 12.					

TABLE 73 Net QALYs of CBT intervention, linear regression: MI data, baseline to 21 months

Model details	
Number of imputations	10
Number of observations	487
Average RVI	0.08
Largest FMI	0.20
Complete DF	478
DF adjustment: small sample	
Minimum	151.20
Average	328.53
Maximum	439.92
Model <i>F</i> -test	$F(8, 455.1) = 20.88$
Equal FMI	0.0000
Within-VCE type: OLS	151.20

TABLE 73 Net QALYs of CBT intervention, linear regression: MI data, baseline to 21 months (*continued*)

Model details					
Model results					
<i>Net cost</i>	<i>Coefficient</i>	<i>SE</i>	<i>t-value</i>	<i>p-value</i>	<i>95% CI</i>
CBT	0.053	0.027	1.96	0.050	0.000 to 0.106
Age	−0.006	0.001	−4.58	0.000	−0.009 to −0.004
Taking clozapine	0.036	0.050	0.73	0.468	−0.062 to 0.133
Number of benzodiazepines	−0.036	0.038	−0.93	0.351	−0.111 to 0.040
Baseline CDSS score	−0.001	0.001	−0.81	0.420	−0.003 to 0.001
Baseline QPR score	−0.013	0.003	−3.980	0.000	−0.020 to −0.007
Baseline EQ VAS score	0.005	0.001	3.350	0.001	0.002 to 0.008
DF, degrees of freedom; FMI, fraction of missing information; OLS, ordinary least squares; RVI, relative variance increase; VCE, variance–covariance estimate.					

TABLE 74 Net costs and QALYs of CBT vs. TAU for participants with complete cost and QALY data

Complete case analysis	Net cost (£), SE (95% CI); <i>p</i> -value	Net QALYs, SE (95% CI)
Unadjusted for baseline covariates (N = 169)		
Baseline to 9 months	1793, 359 (1085 to 2501); <i>p</i> < 0.001	0.06, 0.03 (0.005 to 0.11); <i>p</i> = 0.031
Baseline to 21 months	1628, 800 (48 to 3208); <i>p</i> = 0.043	0.15, 0.05 (0.04 to 0.26); <i>p</i> = 0.006
Adjusted for baseline covariates (N = 169)		
Baseline to 9 months	3151, 562 (2050 to 4253); <i>p</i> < 0.001	0.05, 0.02 (0.01 to 0.10); <i>p</i> = 0.020
Baseline to 21 months	2872, 715 (1471 to 4274); <i>p</i> < 0.001	0.15, 0.05 (0.06 to 0.25); <i>p</i> = 0.002

A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and flow.

EME
HS&DR
HTA
PGfAR
PHR

Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk

This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care

Published by the NIHR Journals Library